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3 E-cigarettes 
Summary
E-cigarettes present an opportunity to significantly accelerate already declining 
smoking rates, and thereby tackle one of the largest causes of death in the UK today. 
They are substantially less harmful—by around 95%—than conventional cigarettes. 
They lack the tar and carbon monoxide of conventional cigarettes—the most dangerous 
components. It has also proven challenging to measure the risks from ‘second-hand’ 
e-cigarette vapour because it is negligible and substantially less than that of conventional 
cigarettes.
There are uncertainties, nevertheless, especially about any long-term health effects, 
because the products have not yet had a history of long use. Ultimately, however, any 
judgement of risks has to take account of the risk of not adopting e-cigarettes—that is, 
continuing to smoke conventional cigarettes, which are substantially more harmful. 
Existing smokers should be encouraged to give up, but if that is not possible they should 
switch to e-cigarettes as a considerably less harmful alternative.
To help fill remaining gaps in the evidence on the relative risks of e-cigarettes and heat-
not-burn products, the Government should maintain its planned annual ‘evidence 
review’ on e-cigarettes, and extend it to also cover ‘heat-not-burn’ products—a more 
recently introduced product which heats rather than combusts tobacco—and support 
a long-term research programme to be overseen by Public Health England and the 
Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment. 
The Government should report each year on the state of research in its Tobacco Control 
Plan, and establish an online hub for making the detailed evidence readily available to 
the public and to health professionals.
An estimated 2.9 million people in the UK are using e-cigarettes to stop smoking, and 
tens of thousands are using them to successfully quit smoking each year. Concerns about 
the risk of e-cigarettes potentially providing a ‘gateway’ into conventional smoking, or 
that the variety and type of flavours could attract young non-smokers in significant 
numbers, have not materialised.
A medically licensed e-cigarette could assist smoking cessation efforts by making it 
easier for medical professionals to discuss and recommend them as a stop smoking 
treatment with patients. The Government should review with the e-cigarette industry 
how its systems for approving stop smoking therapies could be streamlined to be able 
to respond appropriately should e-cigarette manufacturers put forward a product for 
licensing.
People with mental health issues smoke significantly more than the rest of the population, 
and could therefore benefit significantly by using e-cigarettes to stop smoking. By 
encouraging patients in mental health units who are smokers to switch to e-cigarettes 
as a way out of their cigarette addiction, they could continue to engage in treatment 
sessions within the facilities, without the interruption of smoking breaks. Some NHS 
mental health units are allowing unrestricted use of e-cigarettes but it is unacceptable 
that a third of the 50 English NHS trusts who responded to the Committee’s survey 
ban them. Three-quarters of NHS trusts were mistakenly concerned about ‘second-
 E-cigarettes 4
hand’ e-cigarette vapour, despite the negligible health risk. NHS England should set a 
policy of mental health facilities allowing e-cigarette use by patients unless trusts can 
demonstrate evidence-based reasons for not doing so.
Many businesses, public transport providers and other public places do not allow 
e-cigarettes in the same way that they prohibit conventional smoking. But, there is no 
public health (or indeed fire safety) rationale for treating use of the two products the 
same. There is now a need for a wider debate on how e-cigarettes are to be dealt with 
in our public places, to help arrive at a solution which at least starts from the evidence 
rather than misconceptions about their health impacts.
Some aspects of the regulatory system for e-cigarettes appear to be holding back their 
use as a stop smoking measure. The limit on the strength of refills makes some users 
have to puff harder to get the nicotine they seek and may put some heavy smokers off 
persisting with them. The restriction on tank size does not appear to be founded on 
scientific evidence, and should therefore urgently be reviewed. A prohibition on making 
claims for the relative health benefits of switching to e-cigarettes means that some who 
might switch are not getting that message. A ban on advertising ‘tobacco’ products has 
prevented manufacturers putting information in ‘pack inserts’. The Government should 
review these regulatory barriers to identify scope for change post-Brexit, including an 
evidence-based assessment of the case for discontinuing the ban on ‘snus’ oral tobacco.
There should be a shift to a more risk-proportionate regulatory environment; where 
regulations, advertising rules and tax duties reflect the evidence of the relative harms 
of the various e-cigarette and tobacco products available. While an evidence-based 
approach is important in its own right, it also would help bring forward the behaviours 
that we want as a society—less smoking, and greater use and acceptance of e-cigarettes 
and novel tobacco products if that serves to reduce smoking rates.
5 E-cigarettes 
1 Introduction
1. E-cigarettes and conventional cigarettes are substantially different products. A lit 
conventional cigarette contains tobacco and produces carbon monoxide, tar and smoke, 
whilst an e-cigarette does not contain tobacco and heats up its nicotine liquid rather 
than burning it. E-cigarettes were first introduced to the UK market in 2007 (see Box 
1). New rules for nicotine-containing e-cigarettes and refill containers were introduced 
in May 2016 by the Tobacco and Related Products Regulations 2016,1 implementing the 
EU Tobacco Products Directive.2 In 2016 it was estimated that 2 million consumers in 
England had used these products and completely stopped smoking and a further 470,000 
were using them as an aid to stop smoking.3
2. In 2016, the Royal College of Physicians concluded that:
Large-scale substitution of e-cigarettes, or other non-tobacco nicotine 
products, for tobacco smoking has the potential to prevent almost all 
the harm from smoking in society. Promoting e-cigarettes, [Nicotine 
Replacement Therapy] and other non-tobacco nicotine products as widely 
as possible, as a substitute for smoking, is therefore likely to generate 
significant health gains in the UK.4
The Government published its Tobacco Control Plan in July 2017, advising that e-cigarettes 
could be an aid for smokers attempting to give up conventional cigarettes, on the basis 
that “evidence is increasingly clear that e-cigarettes are significantly less harmful to health 
than smoking tobacco”.5 Public Health England has concluded that “vaping is at least 95% 
less harmful than smoking”.6
3. There have nevertheless been a number of organisations and commentators that have 
seen e-cigarettes as a health hazard in their own right. Concerns were raised by the US 
National Academies of Sciences, Engineering and Medicine earlier this year7 and by the 
US Surgeon General.8 Some have raised objections to e-cigarettes on the grounds of being 
exposed to unpleasant second-hand vapour.9 E-cigarettes are banned in many workplaces 
and in most enclosed public spaces and on public transport.
1 Tobacco and Related Products Regulations (2016)
2 EU Tobacco Products Directive (2014)
3 Towards a Smokefree Generation - A Tobacco Control Plan for England, Department of Health, 2017
4 Nicotine without smoke: Tobacco harm reduction, Royal College of Physicians, 2016
5 Towards a Smokefree Generation - A Tobacco Control Plan for England, Department of Health, 2017
6 Evidence Review of E-cigarettes and Heated Tobacco Products 2018, Public Health England, March 2018
7 The National Academies of Sciences, Engineering, and Medicine, A Consensus Study Report by the Committee 
on the Review of the Health Effects of Electronic Nicotine Delivery Systems (January 2018)
8 E-Cigarette Use Among Youth and Young Adults: A Report of the Surgeon General, The US Surgeon General, 
2016
9 Ian Bardrick (ECG0006); David Bareham and Professor Martin McKee (ECG0039)
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Our inquiry
4. Against a background of contradictory national policies towards e-cigarettes and 
disagreement and apparent uncertainty over the health risks, we decided to examine the 
evidence on the health impacts and on e-cigarettes’ role as a smoking cessation tool. We 
received over 100 pieces of written evidence, and held five oral evidence sessions between 
January and May 2018, hearing from 25 witnesses. We are grateful to all those who 
contributed.
Box 1: A brief overview of e-cigarettes
2007 E-cigarettes are introduced to the UK market
2014 EU Tobacco Products Directive (TPD) comes in to force, covering the bulk of 
ecigarette regulation in Europe
2016 Tobacco and Related Products Regulations transposes TPD in to UK law—
18.4% of adults (age 16+ years) surveyed in the ONS Opinions and Lifestyle Survey 
had tried an e-cigarette and 5.4% of adults considered themselves current e-cigarette 
users.
2017 The proportion of ex-smokers who regularly vape has risen from 1.1% in 2012 
to 9.5% in 2017
Both the youth and adult data shows smoking prevalence has continued to decline 
as e-cigarette use has grown. Smoking rates are currently at their lowest recorded 
levels—15.5% for adults in England, down from 19.9% in 2010, and 7% among 
15-year-olds in England, down from 12% in 2010.
Sources: Written evidence from Action on Smoking and Health and Public Health England and MHRA
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2 Reducing Harm
E-cigarettes’ comparative lower harm
5. Smoking prevalence amongst young people overall is decreasing in the UK, with 
almost an 8% decrease amongst 18 to 24-year olds since 2011.10 However, there is great 
disparity between various groups in society. A quarter of those in manual jobs smoke 
whilst the same number within managerial jobs is one in ten. Men are more likely to smoke 
compared to women, and those suffering from poor mental health are over represented 
in these statistics.11 Public Health England, the NHS, the Department of Health and 
Social Care and NICE are all encouraging smokers of conventional cigarettes to switch 
to e-cigarettes.12 Public Health England state that vaping presents a “small fraction 
of the risks of smoking” and that there are substantial health benefits from swapping 
permanently.13
6. NHS Scotland recently published a statement on e-cigarettes, co-signed by Action 
on Smoking & Health Scotland, the Royal College of Physicians of Edinburgh and others, 
stating that although the safety of e-cigarettes cannot be guaranteed due to lack of high 
quality and longitudinal research, e-cigarettes are “definitely less harmful” compared to 
cigarettes.14
7. The UK Centre for Tobacco and Alcohol studies assessed the risks of e-cigarettes in 
comparison to conventional cigarettes:
Sustained inhalation of the multiple components of [e-cigarette] vapour 
is likely to cause some harm to health, and potential harms include lung 
cancer, chronic obstructive pulmonary disease, interstitial lung disease 
and cardiovascular disease. However the concentrations of toxins and 
particulates in vapour are generally low, and much lower than in tobacco 
smoke, so the risk of e-cigarette use is likely to be small in relation to 
tobacco smoking, and may also be small in absolute terms. Recent evidence 
indicates that smokers who switch to e-cigarettes experience significant 
falls in exposure to tobacco carcinogens and other toxicants, consistent 
with a reduction in health risk.15
8. Public Health England report that e-cigarettes are 95% less harmful than conventional 
cigarettes, although Professor John Newton, Public Health England’s Director of Health 
Improvement, explained that the figure was not a precise one:
[The figure] originates from a review of the evidence by independent 
scientists, who were themselves quoting another figure. Our position on 
the figure is that it is the best available published estimate. It has value. We 
are trying to convey the extent to which e-cigarettes are likely to be much 
less harmful than smoking cigarettes. It is a useful figure, but it is not a 
precise scientific estimate. As the Committee will know very well, it is not 
10 Adult smoking habits in Great Britain, The Office for National Statistics, July 2018
11 Adult smoking habits in Great Britain, The Office for National Statistics, July 2018
12 The National Institute for Health and Care Excellence
13 E-cigarettes and heated tobacco products: evidence review, Public Health England, February 2018
14 Consensus statement on e-cigarettes, NHS Scotland, 2017
15 Written evidence submitted by the UK Centre for Tobacco and Alcohol Studies (ECG0031)
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the sort of issue you can put a single number on. We are trying to convey 
the extent to which e-cigarettes are likely to be much less harmful than 
smoking cigarettes.16
9. NHS Smokefree’s campaign material highlights that e-cigarette vapour lacks tar and 
carbon monoxide—two of the most harmful compounds in tobacco smoke—and carries 
“a small fraction of the risk of smoking, and can help you quit”.17 The Department of 
Health and Social Care argued that:
The best thing a smoker can do for their health is to quit smoking. However, 
the evidence is increasingly clear that e-cigarettes are significantly less 
harmful to health than smoking tobacco. The government will seek to 
support consumers in stopping smoking and adopting the use of less 
harmful nicotine products.18
10. The National Institute for Care and Excellence’s (NICE’s) most recent guidance 
on e-cigarettes similarly states that although not completely risk free, e-cigarettes are 
comparatively less harmful than conventional cigarettes.19 Our written evidence likewise 
emphasised the harm-reducing potential of smokers swapping to e-cigarettes. Action on 
Smoking and Health stated:
E-cigarettes are substantially less harmful than smoking and the regulatory 
system now in place is likely to reduce the risks still further. E-cigarettes 
are now the most popular aid for smokers trying to stop smoking, and are 
proving effective in helping many smokers to stop smoking.20
The Cochrane Tobacco Addiction Review Group summarised the evidence it had reviewed:
Our findings from independently reviewing the best available evidence 
on the topic suggest that for existing smokers of conventional cigarettes, 
switching to electronic cigarettes is likely to lead to significant improvements 
in health. These findings are based in studies of people who smoked 
conventional cigarettes, but findings are consonant with findings from 
the Royal College of Physicians which were based on comparisons of the 
composition of carcinogens and toxicants in tobacco smoke and vapour 
from electronic cigarettes.21
11. The Committee on Toxicity of Chemicals in Food, Consumer Products and the 
Environment is currently examining e-cigarettes, and has recently finished work on ‘heat-
not-burn’ tobacco products (which heat tobacco without combustion (see paragraph 1)). 
Professor Harrison from the Committee on Toxicity told us that the main health dangers 
in a conventional cigarette lie in the combustion of the tobacco:
16 Oral evidence taken on 24 April 2018, HC (2017–19) 505, Q359 [Professor Newton]
17 NHS Stop Smoking Campaign Stop-tober, October 2017
18 Towards a Smokefree Generation - A Tobacco Control Plan for England, Department of Health, 2017
19 Stop smoking interventions and services, NICE guideline [NG92], March 2018
20 Written Evidence submitted by Action on Smoking and Health (ECG0071)
21 Written evidence submitted by the Cochrane Tobacco Addiction Review Group (ECG0041)
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Combustion is extremely important. We reviewed that at length, and we 
found that, overall, there was a 90% to 95% reduction in cancer-causing 
chemicals. Some disappeared altogether, and some were reduced by only a 
half.22
Public Health England and the MHRA23 explained that:
Levels of carcinogenic chemicals (including polycyclic aromatic 
hydrocarbons, tobacco-specific N-nitrosamines, heavy metals and volatile 
organic compounds are substantially lower in e-cigarettes’ aerosol compared 
with tobacco smoke. Biomarkers of carcinogen exposures (chemicals 
detected in the blood or urine of users) are also substantially decreased 
in current e-cigarette-only users compared with cigarette smokers, and 
decrease when smokers switch to e-cigarettes.24
12. Professor Newton from Public Health England told us:
We avoid using the word “safe,” because that is a very difficult word to 
use, but there is no doubt that using an e-cigarette regularly is much less 
harmful than smoking cigarettes. It is important to get that message across, 
particularly to smokers.25
The New Zealand Ministry of Health similarly encourages smokers who want to use 
e-cigarettes to quit smoking to seek the support of local stop smoking services:
Expert opinion is that e-cigarettes are significantly less harmful than 
smoking tobacco but not completely harmless. A range of toxicants have 
been found in e-cigarette vapour including some cancer causing agents 
but, in general, at levels much lower than found in cigarette smoke or at 
levels that are unlikely to cause harm. Smokers switching to e-cigarettes are 
highly likely to reduce their health risks and for those around them.26
In Canada e-cigarettes have been legal since 2016, when the Canadian Government 
amended the Tobacco Act and the Non-smokers’ Health Act to establish a new legislative 
framework for regulating vaping products in order to address the risks and potential 
benefits of these products.27
22 Oral evidence taken on 27 February 2018, HC (2017–19) 505, Q185 [Professor Harrison]
23 Medicines and Healthcare Products Regulatory Agency
24 Written evidence submitted by Public Health England and the Medicines and Healthcare products Regulatory 
Agency (ECG0081)
25 Oral evidence taken on 24 April 2018, HC (2017–19) 505, Q378 [Professor Newton]
26 Vaping, smokeless, including heated tobacco, New Zeeland Ministry of Health, October 2017
27 Parliament of Canada, Bill S-5, an Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make 
consequential amendments to other Acts
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13. We asked Professor David Harrison from the UK Committee on Carcinogenicity of 
Chemicals in Food, Consumer Products and the Environment about any ‘second-hand’ 
harm from vaping: He told us:
With e-cigarettes or with heat-not-burn, there is a similar issue. Everything 
is reduced compared with cigarette smoke, but bystander effects are 
something to be aware of. One would expect, however, that the dose would 
be commensurately less than for cigarettes.28
Professor Aveyard from the Cochrane Tobacco Addiction Group also thought that the 
harm of second-hand vaping was negligible.29 Professor Ricardo Polosa explained that:
It is very well known historically that combustible cigarette smoke is a big 
cause of diseases, mainly because of side-stream smoke and the smoke that 
is generated between puffs. An electronic cigarette does not operate on the 
same principle. It does not have the deadly side-stream smoke and does 
not generate any smoke or aerosol between operating cycles. Aerosols are 
emitted by these products only when you exhale. That sets the principle 
that, on common sense, you will immediately identify that there is less risk 
just because of that. If you then consider that, as Public Health England 
and the Royal College of Physicians have already emphasised in their 
comprehensive reviews, these aerosols are 95% less harmful than common 
tobacco, you will immediately realise that, from a percentage point of view, 
the risks will be minuscule.30
Heat-not-burn tobacco products
14. ‘Heat-not-burn’ products contain tobacco which is heated rather than combusted, 
and is therefore likely to be less harmful compared to conventional cigarettes. The Centre 
for Tobacco and Alcohol Studies state that the only available data on emissions and safety 
of heat-not-burn products arises primarily from one of the major tobacco companies, 
Philip Morris. This research, they argue, therefore needs to be independently validated 
before it is used to inform policy, but nevertheless pointed to an early evaluation of likely 
cancer risk which assessed heat-not-burn products to have about 10% of the harm of 
conventional cigarettes.31
15. The Royal Society for Public Health believed that the lack of independent, high 
quality research into the “harm profile” of heated tobacco products warrants a regulatory 
model structured in line with their relative risk as evidence emerges.32 The Department of 
Health and Social Care similarly stated that there was currently not enough evidence on 
heat-not-burn products and their relative harmfulness, and that a pragmatic approach to 
their regulatory framework was appropriate for now.33 Cancer Research UK told us:
28 Oral evidence taken on 27 February 2018, HC (2017–19) 505, Q192 [Professor Harrison]
29 Oral evidence taken on 9 January 2018, HC (2017–19) 505, Q107 [Professor Aveyard]
30 Oral evidence taken on 9 January 2018, HC (2017–19) 505, Q7 [Professor Polosa]
31 Written evidence submitted by the UK Centre for Tobacco and Alcohol Studies (ECG0031)
32 Written evidence submitted by the Royal Society for Public Health (ECG0049)
33 Written evidence submitted by the Department of Health (England) (ECG0030)
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Unlike e-cigarettes, [‘heat-not-burn’] tobacco products are a largely 
unknown entity, and all of these products are owned by the tobacco industry. 
There is currently no independent evidence of their safety. We need more 
evidence, independent from tobacco industry funding or involvement, to 
determine the level of harm these products may cause, as well as the extent 
of any potential benefits compared to continued use of tobacco cigarettes.34
The Committee on Toxicity of Chemicals in Food, Consumer Products and the 
Environment highlighted the current uncertainties about any health risks from heat-not-
burn products:
The risks associated with use of heat-not-burn tobacco products cannot 
be quantified due to gaps in the information available and uncertainties 
in the dose-response relationship of the chemicals and potential adverse 
health outcomes. In addition, the levels of the different compounds in the 
aerosol vary compared to the levels in smoke from conventional cigarettes 
and therefore it is not possible to extrapolate from epidemiological data on 
smoking risks, particularly given the complexity of the interactions that 
occur between these compounds in producing adverse health effects.35
Flavourings
16. Some of our evidence expressed a concern about possible risks from e-cigarette liquid 
flavourings.36 Finland, for example, does not permit flavourings in e-cigarettes at all.37 
The British Medical Association believed that flavoured liquids did not cause any acute 
harm to users, but wanted a long-term assessment to monitor their safety:
Many flavourings used in e-liquid are ‘food safe’, being considered safe 
when ingested orally, but their safety after heating and inhalation is not 
established. Given the large numbers of people using flavoured e-liquid 
without reporting problems, it is unlikely they are having a significant acute 
impact on the health of users.38
Action on Smoking and Health emphasised the importance of flavourings as part of the 
appeal of e-cigarettes and possibly also what stopped users from going back to smoking.39 
The Cochrane Tobacco Addiction review group called for more research data to be 
collected from more realistic settings, taking factors such as individual preferences for 
strength, flavours and devices into account.40
Uncertainty about long-term effects
17. Some have doubts about the long-term safety of e-cigarettes. The US Surgeon 
General, citing a lack of long-term evidence, could not rule out possible harm from 
34 Written evidence submitted by Cancer Research UK (ECG0057)
35 Written evidence submitted by the Committee on Toxicity of Chemicals in Food, Consumer Products and the 
Environment (ECG0082)
36 Written evidence from the Royal Society for Public Health (ECG0049),
37 Written evidence submitted by Cancer Research UK (ECG0057)
38 Written evidence submitted by the British Medical Association (ECG0037)
39 Written Evidence submitted by Action on Smoking and Health (ECG0071)
40 Written evidence submitted Cochrane Tobacco Addiction Review Group (ECG0041)
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e-cigarette ultra-fine particles, flavourings or heavy metals.41 The US National Academies 
of Sciences, Engineering, and Medicine explained that in the USA “because the efficacy 
of e-cigarettes to actually reduce harm remains unclear, some have raised concerns about 
using e-cigarettes for tobacco harm reduction”.42
18. Australia prohibits the sale of nicotine e-cigarettes unless approved as an aid to 
help people quit smoking and, so far, no e-cigarette has been approved for this purpose.43 
The Australian Health, Sport and Aged Care Committee in the Australian House of 
Representatives concluded that there were two ways of viewing e-cigarette regulation—to 
take a precautionary approach or a harm-reducing approach. Those arguing for easier 
access to e-cigarettes, it said, were following a harm-reducing approach, whereas the 
Committee favoured a continued ban on the basis of the precautionary approach (like 
the US Surgeon General) until long-term research is able to rule out any long term health 
consequences.44
19. The Chair of the Australian Committee dissented from his Committee’s report, 
however, stating that:
In order to assist the millions of smokers struggling to quit tobacco smoking 
and improve their quality of life, nicotine e-cigarettes should be made 
available as consumer products. At the same time, regulatory restrictions 
should be imposed to limit the appeal of e-cigarettes to young people and 
non-smokers.45
Professor Newton from Public Health England, when giving evidence to the same 
Committee, told them:
There is this general problem that many of the people who are opposed to 
e-cigarettes are starting from a position that any smoking is bad and we 
need to have a firm line. […] We [in the UK] think that, rather than waiting 
20 years to get definitive evidence, we have to make the best decision on the 
evidence that’s available now, and that points us towards cautious use of 
e-cigarettes.46
And he explained to us:
The Australian situation was different. They had lower smoking rates to 
begin with when e-cigarettes first appeared. The feeling there was that they 
41 E-cigarette Use Among Youth and Young People, United States Surgeon General, U.S. Department of Health 
and Human Services
42 Consensus Study Report: Public Health Consequences of E-cigarettes, The National Academies of Sciences, 
Engineering and Medicine, 2018
43 Report on the Inquiry into the Use and Marketing of Electronic Cigarettes and Personal Vaporisers in Australia, 
The Standing Committee on Health, Aged Care and Sport, The Australian House of Representatives, March 2018
44 Report on the Inquiry into the Use and Marketing of Electronic Cigarettes and Personal Vaporisers in Australia, 
The Standing Committee on Health, Aged Care and Sport, The Australian House of Representatives, March 2018
45 Chair’s Foreword, Report on the Inquiry into the Use and Marketing of Electronic Cigarettes and Personal 
Vaporisers in Australia, The Standing Committee on Health, Aged Care and Sport, The Australian House of 
Representatives, March 2018
46 Oral Evidence taken 18 October 2017, The Standing Committee on Health, Aged Care and Sport, The Australian 
House of Representatives, Inquiry into the Use and Marketing of Electronic Cigarettes and Personal Vaporisers 
in Australia
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could continue to control and drive down smoking prevalence without 
using e-cigarettes. Therefore, in the absence of clear evidence of safety, it 
was wise to ban them.47
20. Some of those who submitted evidence to our inquiry also highlighted a lack of long-
term evidence on the potential harm, if any, from e-cigarette use.48 Some noted that there 
were very few current vapers who had not previously smoked conventional cigarettes, 
making comparative studies between vapers and non-vapers difficult to assess.49
21. The Tobacco and Alcohol Research Group at University College London argued, on the 
other hand, that some research reports have “over-claimed” findings on the harmfulness 
of e-cigarettes because they have “little or no relevance to prediction of serious illnesses in 
e-cigarette users”.50 Dr Lion Shahab and Dr Jamie Brown from the UCL Research Group 
explained that:
A lot of the papers, while written quite correctly, in the press release 
overstate what has been found. This may be partly because often the papers 
look at acute and not at chronic effects, and effects that are not very well 
linked to long-term health outcomes. One of them is arterial stiffness on 
which a paper was published recently. That was then linked to the fact that 
ecigarettes cause heart disease. The very same authors also published a paper 
that showed that, for instance, exercise increased arterial stiffness, so it is 
very difficult to link that particular marker to long-term health outcomes. 
That is one of the problems. Another is that often people use unrealistic use 
conditions. A study looked at the formation of formaldehyde, which is very 
toxic. […] It is an acrid taste called dry puffing, which is unlikely to occur in 
real-life conditions. Lastly, often the models used to investigate the effects 
of ecigarettes are not really relevant to humans—for example, mice models. 
One big problem is that mice are much more sensitive to nicotine than 
humans, and often the effects observed in animal studies may just reflect 
nicotine poisoning rather than the effects of any of the other potentially 
harmful substances.51
22. Professor Peter Hajek, Professor of Clinical Psychology, Queen Mary University of 
London, did not believe the uncertainty about any long-term effects would be significant:
We have two ways of looking at it; there is logic and there is data. The logic 
tells you that most of the chemicals that are dangerous to smokers are 
absent, or present in very small amounts, in e-cigarettes. As far as we know, 
none of the chemicals that are specific to e-cigarettes and are not present 
in smoking poses major health harm. Basically, the data back that up. 
Recently, there was a detailed paper about kinds of carcinogens, comparing 
the risk of cancer from smoking and from vaping. That paper took at face 
value some of the studies on e-cigarettes that actually fry the e-liquid and 
therefore produce aldehydes, which could be carcinogenic, but even taking 
47 Oral evidence taken on 24 April 2018, HC (2017–19) 505, Q361 [Professor Newton]
48 See for example Written evidence submitted by Pfizer UK (ECG0023),
49 Written evidence submitted by the British Lung Foundation (ECG0042)
50 Written evidence submitted by University College London, Tobacco and Alcohol Research Group (UTARG) 
(ECG0047)
51 Oral evidence taken on 9 January 2018, HC (2017–19) 505, Q86 [Professor Shahab]
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into account those studies, which do not reflect what vapers are taking in, 
the conclusion was that the cancer risk is less than 0.5% of the cancer risk 
from smoking.52
23. Ultimately, whatever any long-term risks there may be from e-cigarettes, not 
switching from conventional cigarettes also presents its own (very certain) risks in terms 
of continued conventional smoking-related diseases. Dr Jamie Brown from UCL was clear 
about how such a balance of risks should be weighed:
Any perceived risk associated with offering reassurance before we have the 
long-term data [on e-cigarettes] must be balanced against the risk associated 
with the opportunity cost of failing to inform the millions of people who 
are currently smoking uniquely dangerous products that e-cigarettes are 
safer when they believe they are not.53
Research
24. Although the evidence we received has been overwhelmingly that e-cigarettes are 
much less harmful than conventional cigarettes, new products are constantly being 
developed; both e-cigarettes and heat-not-burn devices. Research needs to keep abreast 
of these developments in order to continue to reassure consumers of their relative 
safety. The Cochrane Tobacco Addiction Review Group told us that more randomized 
controlled trials were needed, which would compare electronic cigarettes with “alternative 
pharmacological and behavioural treatments”.54 They stated:
As electronic cigarettes have been used for only a few years, there is little 
evidence on their safety when used as a long-term or permanent replacement 
for smoking. As almost all regular use of electronic cigarettes occurs in 
former or current smokers, interpreting future epidemiological data will be 
difficult. In the meantime, findings from short- to medium- term studies, 
studies of biomarkers, and studies of toxicants all suggest electronic 
cigarettes are significantly less harmful than conventional cigarettes.55
25. The Committee on Toxicity of Chemicals in Food, Consumer Products and the 
Environment noted that the settings, such as voltage and temperature, on some e-cigarette 
devices can be modified by the user which, they told us, will result in variations in the 
composition of the vapour. They explained that the settings on devices used in studies are 
often not reported in the literature, and that as a result “it will be difficult to establish a 
worst-case scenario that is representative of human exposure”.56 Professor Aveyard from 
the Cochrane Review emphasised that “the majority of dangerous compounds present in 
cigarettes are not there in e-cigarettes”, but:
52 Oral evidence taken on 9 January 2018, HC (2017–19) 505, Q5 [Professor Hajek]
53 Oral evidence taken on 9 January 2018, HC (2017–19) 505, Q90 [Dr Brown]
54 Written evidence submitted by Cochrane Tobacco Addiction Review Group (ECG0041)
55 Written evidence submitted by Cochrane Tobacco Addiction Review Group (ECG0041)
56 Written evidence submitted by the Committee on Toxicity of Chemicals in Food, Consumer Products and the 
Environment (ECG0082)
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what we do not have is a cohort of people who have been using ecigarettes 
for a long time, in order to realise whether there is a true risk in humans. 
Everything we say is either extrapolation or speculation. There is not a 
technological fix around that problem; we just do not have people who have 
used them for 30 or 40 years.57
26. The Department of Health and Social Care told us that to support further independent 
research and collaboration, the UK E-Cigarette Research Forum, an initiative developed 
by Cancer Research UK in partnership with PHE and the UK Centre for Tobacco and 
Alcohol Studies, is “bringing together policy-makers, researchers, practitioners and 
the NGO community to discuss the emerging evidence and knowledge gaps about 
e-cigarettes”. The Department pointed out that the group has asked it “to contribute 
suggestions for further areas of e-cigarette research to help develop improvements in 
policy to achieve the Tobacco Control Plan aims”.58 The Department is also running an 
annual evidence review on e-cigarettes, through Public Health England, which will look 
at the latest evidence on “adult and youth prevalence, safety, effectiveness for quitting 
and perceptions of harmfulness, addictiveness of nicotine and a section on heat-not-burn 
tobacco products”.59
27. There is clear evidence that e-cigarettes are substantially less harmful than 
conventional cigarettes. Public Health England estimate e-cigarettes as 95% less 
harmful, although the evidence available does not currently allow a precise figure to be 
determined. E-cigarettes lack the tar and carbon monoxide of conventional cigarettes—
the most dangerous components of conventional cigarettes—which are produced by 
combustion. Some potentially harmful components are present in both products, 
such as heavy metals, but at substantially lower levels in e-cigarettes. Researchers have 
found it almost impossible to measure the risks from ‘second-hand’ e-cigarette vapour 
because any potentially harmful compounds released into the surrounding area are so 
negligible.
28. More recently introduced ‘heat-not-burn’ products—producing nicotine from 
tobacco but without the combustion—have been estimated to be around 90% less 
harmful than conventional cigarettes, although there is a lack of independent research 
to validate this claim.
29. There are uncertainties, nevertheless, especially about any long-term health 
effects of e-cigarettes, because the products have not yet had a history of long use. 
The studies needed to guarantee the safety of e-cigarettes are inevitably frustrated by 
the absence of a population of e-cigarette users who have never smoked conventional 
cigarettes before taking up vaping. Ultimately, however, any judgement of risks has 
to take account of the risk of not adopting e-cigarettes—that is, continuing to smoke 
conventional cigarettes, which are substantially more harmful than e-cigarettes. 
Existing smokers should always be encouraged to give up all types of smoking, but if 
that is not possible they should switch to e-cigarettes as a considerably less harmful 
alternative.
57 Oral evidence taken on 9 January 2018, HC (2017–19) 505, Q87 [Professor Aveyard]
58 Written evidence submitted by the Department of Health (England) (ECG0030)
59 Written evidence submitted by the Department of Health (England) (ECG0030)
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30. To help fill remaining gaps in the evidence on the relative risks of e-cigarettes 
and heat-not-burn products, the Government should maintain its planned annual 
‘evidence review’ on e-cigarettes and extend it to also cover heat-not-burn products. 
It should support a long-term research programme, to be overseen by Public Health 
England and the Committee on Toxicity of Chemicals in Food, Consumer Products and 
the Environment, to ensure that health-related evidence is not dependent solely on the 
tobacco industry or the manufacturers of e-cigarettes. That PHE/COT research should 
include examining health risks arising from the flavourings added to e-cigarettes. The 
Government should report each year on the state of research in its Tobacco Control 
Plan, and establish an online hub for making the detailed evidence readily available to 
the public and to health professionals.
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3 E-cigarettes and smoking cessation
The evidence on smoking cessation
31. The Tobacco Control Plan reported that in 2016 there were 470,000 people using 
e-cigarettes as a way to stop smoking conventional cigarettes.60 The Department of Health 
and Social Care estimates that e-cigarettes contribute to between 16,000 and 22,000 people 
successfully quitting smoking each year who would not otherwise have done so had they 
used nicotine replacement therapies or willpower alone.61 Professor Paul Aveyard from the 
Cochrane Review highlighted that e-cigarettes are a popular alternative to other smoking 
cessation tools.62 Professor John Newton from Public Health England similarly told us:
E-cigarettes are the most popular quitting aid among smokers. Whatever 
we think of the evidence on their effectiveness, smokers are choosing to use 
e-cigarettes much more widely than other available forms, such as nicotine 
patches and nicotine-containing gums. There is no doubt that they are 
popular among smokers. The first step to being an effective aid is that they 
have to be used by smokers. That is very much in their favour. We have 
recognised that by introducing references to e-cigarettes in our campaigns.
32. Professor Newton recognised gaps in the evidence on the effectiveness of e-cigarettes 
as a smoking cessation tool, but said that this should not detract from their already 
apparent usefulness:
There is a lack of hard, randomised control-trial evidence of their 
effectiveness in cessation, but the evidence from observational studies, 
which are quite convincing, is that many smokers have used e-cigarettes to 
quit—and to quit completely, not just for dual use. We need to continue to 
build the evidence base. At the same time, we need to be clear that this is 
for smokers, particularly those who have tried to quit before. If they have 
not tried an e-cigarette, they should try an e-cigarette, because that might 
be their route out of smoking.63
Action on Smoking and Health similarly highlighted both the benefits of e-cigarettes as a 
stop smoking route and the need for further research on their effectiveness as a cessation 
aid.64 The Royal Society for Public Health noted that although e-cigarettes appear to be 
successful as a cessation tool, especially when combined with behavioural support, more 
“high quality research” is needed.65
33. One of the difficulties in undertaking research to assess their effectiveness is that 
some people continue to smoke conventional cigarettes, albeit fewer, at the same time—
cutting down rather than giving up completely.66 This means that some studies which 
have claimed that e-cigarettes hamper smoking cessation have been based on observations 
60 Towards a Smokefree Generation - A Tobacco Control Plan for England, Department of Health, 2017
61 Written evidence submitted by the Department of Health (England) (ECG0030)
62 Oral evidence taken on 9 January 2018, HC (2017–19) 505, Q92 [Professor Aveyard]
63 Oral evidence taken on 24 April 2018, HC (2017–19) 505, Q394 [Professor Newton]
64 Written Evidence submitted by Action on Smoking and Health (ECG0071)
65 Written evidence submitted by the Royal Society for Public Health (ECG0049)
66 Written evidence submitted by Pfizer UK (ECG0023)Written evidence submitted by ASH Scotland (ECG0011)
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that e-cigarette users still describe themselves as “smokers”.67 The UCL Research Group 
also argued that claims that e-cigarettes could reduce smoking cessation rates did not tally 
with the significant increases seen in the number of conventional smokers quitting in the 
UK and the US.68
The British Medical Association concluded:
Although the data in favour of the effectiveness of e-cigarettes as a cessation 
aid is not conclusive, given the quality of the studies, the overall picture—
at present—is that they do play a helpful role in helping people to stop 
smoking.69
The UK Centre for Tobacco and Alcohol Studies argued that e-cigarettes, as an 
alternative consumer product to tobacco rather than a medical therapy like other nicotine 
replacements products, had allowed them to reach more people. They believed, in that 
context, that this gave e-cigarettes a better result overall: “A low efficacy treatment used by 
large numbers of smokers will generate more quitters than a high efficacy treatment used 
by a small minority”.70
34. Heat-not-burn products, the Centre for Tobacco and Alcohol Studies suggested, may 
also have a role in helping those smokers to quit who do not find e-cigarettes a solution:
The role of heat-not-burn products is, thus, far from clear: if more toxic 
than e-cigarettes and no more effective and acceptable to smokers as 
smoking substitutes, then their role is likely to be limited. If more effective 
however, or (for example) as a result of being more similar in taste and 
experience to tobacco cigarettes, heat-not-burn products are able to appeal 
to sectors of the smoking population who find e-cigarettes ineffective or 
otherwise unacceptable, then they may offer a public health benefit despite 
their relative hazard.71
Young people and a potential gateway to conventional smoking
35. One of the concerns that has been raised about e-cigarettes has been a fear that 
they could appeal to young people and potentially act as a ‘gateway’ to conventional 
smoking. The evidence we received, however, has not shown this to be the case. Research 
undertaken by the Association for Young People’s Health found that the proportion of 
young people ‘experimenting’ with e-cigarettes ranged between an eighth and a quarter 
of young people, but that regular use by secondary school children was limited to about 
1%, and those children generally engaged in smoking behaviour.72
36. Professor Peter Hajek of Queen Mary University nevertheless cautioned:
67 Oral evidence taken on 24 April 2018, HC (2017–19) 505, Q394 [Professor Newton]
68 Written evidence submitted by University College London, Tobacco and Alcohol Research Group (UTARG) 
(ECG0047)
69 Written evidence submitted by the British Medical Association (ECG0037)
70 Written evidence submitted by the UK Centre for Tobacco and Alcohol Studies (ECG0031)
71 Written evidence submitted by the UK Centre for Tobacco and Alcohol Studies (ECG0031)
72 Key Data on Young People 2017, Association for Young People’s Health 2017, 2017. See also Written evidence 
submitted by The Association for Young People’s Health (AYPH), The Royal College of General Practitioners’ 
(RCGP) Adolescent Health Group, The Royal College of Paediatrics and Child Health (RCPCH), The Royal 
Pharmaceutical Society (RPS), and The Young People’s Health Special Interest Group of the RCPCH (YPHSIG) 
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We need to keep an eye on it, because somebody will figure out what you 
need to add to e-cigarettes to make them more addictive to non-smokers. 
At the moment, non-smokers do not progress to daily vaping; it is really 
difficult. If they do, they often vape nicotine-free, just for some kind of 
flavour and behaviour. There would be a very legitimate concern if we saw 
large numbers of young people who have never smoked becoming daily 
vapers, but you would be hard pushed to find anybody.73
Public Health England and the MHRA similarly concluded:
British youth experiment with e-cigarettes but regular use is rare and 
very largely confined to young people who have smoked. There is some 
evidence that young people who have vaped but never smoked are more 
likely subsequently to smoke but there is no evidence that this relationship 
is causal. The UK has good data on this issue from surveys.74
37. There remain some gaps in the evidence about how effective e-cigarettes are as a 
stop smoking tool in comparison to other nicotine replacement therapies. Nevertheless, 
an estimated 2.9 million people in the UK are using e-cigarettes, and tens of thousands 
are using them to successfully quit smoking each year. Concerns about the risk of 
e-cigarettes potentially providing a ‘gateway’ into conventional smoking have not 
materialised to any significant degree. Similarly, the risk of the variety and type of 
flavours being attractive to young non-smokers, who would be drawn into e-cigarette 
use, also appears to be negligible.
E-cigarettes as a medically licensed product
38. While many conventional smokers have taken up vaping, some of our witnesses 
believed that more would do so if an e-cigarette was approved for medical use, and 
thereby able to be prescribed by a doctor. They saw advantages in two ways. Firstly, a 
medically licensed product would enable health professionals to feel able to recommend 
e-cigarettes as a smoking cessation tool, knowing that the device and liquid had been 
tested and approved by the Medicines and Healthcare products Regulatory Agency 
(MHRA). Professor Newton from Public Health England told us:
We would like to see a medicinally licensed product because […] it would 
send a stronger message about relative safety, and it would also provide 
another avenue and help smoking cessation services to use e-cigarettes 
more. We think there would be considerable advantages if there was a 
medically licensed product.75
39. Deborah Arnott from Action on Smoking and Health similarly told us:
We have doctors saying to us all the time, “If we had products that we could 
prescribe and that were licensed, we would feel much more comfortable.” 
They would be effective on prescription and highly cost-effective. There have 
73 Oral evidence taken on 9 January 2018, HC (2017–19) 505, Q29 [Professor Hajek]
74 Written evidence submitted by Public Health England and the Medicines and Healthcare products Regulatory 
Agency (ECG0081)
75 Oral evidence taken on 24 April 2018, HC (2017–19) 505, Q426 [Professor Newton]
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been criticisms, with people asking why they should be on prescription. 
These are cheap products that are highly effective in helping smokers to quit. 
It would be reassuring to consumers, as well as to the medical profession.76
The Royal Society for Public Health stressed the importance of smoking cessation advisors 
being able to provide information, with assurance, to smokers:
Research has shown that perceptions of harm can indeed inhibit the use 
of e-cigarettes among smokers, and this barrier will only be exacerbated if 
the concerns of the public go unaddressed. Responsible messaging could 
help to counteract this threat, for example highlighting that smoking 
cessation services are advised to support smokers who choose to quit using 
e-cigarettes.77
40. A licensed product could also provide the basis for a doctor-patient relationship 
that could extend over the period needed to give up smoking, and help overcome some 
smokers’ reluctance to swap to e-cigarettes because of cost considerations. Several studies 
show that smokers receiving specialised cessation assistance through their GP are more 
likely to stop successfully.78 The initial start-up cost of e-cigarettes, Hazel Cheeseman 
from Action on Smoking and Health explained, may stop some people from swapping to 
vaping:
Although for most people using an electronic cigarette is cheaper than 
continuing to smoke, there is a group of people, particularly people with 
mental health conditions, for whom there is a barrier to entry—an initial 
cost that you have to meet. For somebody on a low income, that is quite a 
risk to take, potentially, if you are not sure that the product will work for 
you. Having something on prescription can help to ease that risk for people. 
It will also lock people into a relationship with medical professionals and 
quit services, which we know can significantly improve people’s chances of 
quitting successfully. Having something on prescription would be a benefit 
for both of those reasons. For groups that are vulnerable, have high levels of 
addiction and face lots of barriers to quitting, a prescription product could 
be really valuable.79
41. As we discuss in Chapter 4, the regulation of e-cigarettes currently prohibits claims 
being made for their harm-reduction properties. Dr Ian Hudson from MHRA noted that 
medicines’ licensing would allow such health claims to be made:
Gum, patches and so on have smoking cessation or harm-reduction claims, 
and those can be promoted as such. The advertising restrictions would be 
different. They would be able to promote a bit more in relation to the claims 
for medicines available on prescription […] if these were authorised as 
‘medicines’.80
76 Oral evidence taken on 27 March 2018, HC (2017–19) 505, Q299 [Deborah Arnott]
77 Written evidence submitted by the Royal Society for Public Health (ECG0049)
78 Towards a Smokefree Generation - A Tobacco Control Plan for England, Department of Health, 2017
79 Oral evidence taken on 27 March 2018, HC (2017–19) 505, Q300 [Hazel Cheeseman]
80 Oral evidence taken on 24 April 2018, HC (2017–19) 505, Q422 [Dr Hudson]
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We heard, however, that the MHRA medical authorisation process was itself a barrier. Dr 
Ian Jones from Japan Tobacco International told us:
The concern that we have, other than the cost, is mainly about the time. 
These products are innovating and changing so fast—if you run for a 
medicinal licence approval, you essentially freeze the product at the start, 
and you have to have the same product at the end. By that time, particularly 
in today’s environment, the other products have evolved so fast that your 
product is out of date by the time you reach the other end.81
MHRA highlighted that as a “relatively new” product, it would take longer to go through 
the generation of the evidence for a ‘medicine’ and through the review process.82
42. Action on Smoking and Health argued for a shorter licensing period to make it a 
more attractive route for e-cigarette producers to take, and to ensure there were more 
medically licensed e-cigarettes on the market:
There are precedents for adopting a less restrictive approach, in particular 
in the area of nicotine regulation. Until nicotine replacement therapy 
was liberalised in 2005, NRT products were licensed for a maximum of 
12 weeks. In 2005 this was extended for some products to a year, and in 
2009 the MHRA approved a ‘harm reduction’ extension to the license of 
the nicorette inhalator without a limit to duration of use. This was on the 
basis that, “it had become widely accepted that there were no circumstances 
in which it was safer to smoke than to use NRT.” The Commission went on to 
say that there was a need for further research and data collection to assess 
long term safety and agreed that the holder of the market authorization 
“should be asked to provide a robust risk management plan that would 
satisfactorily address the outstanding issues”.83
‘Leicester partnership’
43. Leicester City Council’s “e-cigarette friendly” smoking cessation service was 
highlighted in our inquiry as a model for others to follow. They actively encourage those 
interacting with patients to recommend e-cigarettes as a stop smoking tool, provide online 
resources describing experiences of individual smokers who have switched to e-cigarettes, 
and in some cases supply a free e-cigarette ‘start-up’ kit. The Council emphasises the 
importance of also providing behavioural support to increase the chances of quitting 
permanently.84 Leicester City Council told us:
Our advice to those stopping smoking with e-cigarettes is that it is their 
choice whether they continue to vape—the nicotine they get from their 
vaporiser could be exactly what stops them relapsing to smoking, and it’s 
the smoke that kills. The key difference that we see among service users 
who have switched to vaping though is their increased confidence in their 
determination never to smoke again. Most have tried many, many times 
81 Oral evidence taken on 27 February 2018, HC (2017–19) 505, Q176 [Dr Jones]
82 Oral evidence taken on 24 April 2018, HC (2017–19) 505, Q423 [Dr Hudson]
83 Written evidence submitted by Action on Smoking and Health ECG0071.
84 Stop Smoking Leicester website
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before, with medicinal products, or by willpower alone, and have relapsed 
to smoking. Vaping has made a difference that has taken them (and often 
their families) by surprise.85
44. Leicester City Council told us about their experience of allowing them in mental 
health facilities (which we discuss below):
Even highly dependent smokers such as those with poor mental health, 
and homeless people, are doing really well with vaping. Nursing staff in the 
mental health wards who were initially sceptical about vaping have been 
pleasantly surprised at how much easier it has been for their patients who 
have started using a vaporiser to manage their nicotine needs.86
45. The Minister called the public health team running the Council initiative “a 
trailblazing group” who were “achieving good things”.87
46. A medically licensed e-cigarette could assist smoking cessation efforts by making 
it easier for medical professionals to discuss and recommend them as a stop smoking 
treatment with patients. It would also make it easier for claims to be explicitly made 
about their harm-reduction relative to conventional smoking, which regulations 
currently prevent (Chapter 4). The Government should review with MHRA and the 
e-cigarette industry how its systems for approving stop smoking therapies could be 
streamlined; to be able to respond appropriately should manufacturers put forward a 
product for licensing.
E-cigarettes in mental health facilities
47. The Government’s Tobacco Control Plan highlights the need to tackle the much 
higher rate of smoking among those with mental illness. It reports that 40% of adults 
with mental illness smoke,88 compared with 16% of the general population.89 The Mental 
Health and Smoking Partnership told us that:
While people with a mental health condition are as motivated to quit 
smoking as other smokers they are less likely to be successful. As a 
consequence, while the rates of smoking in the general population have 
fallen steadily over the last few decades, the same rate of progress is not 
apparent for people with a mental health condition, with almost no decline 
recorded.90
The Tobacco Control Plan states that “Smoking causes premature death, disability and 
poverty and if we do not reduce smoking prevalence among this group [with mental 
illness], we will have failed to reduce inequalities”.91
85 Written evidence submitted by Leicester City Council (ECG0022)
86 Written evidence submitted by Leicester City Council (ECG0022)
87 Oral evidence taken on 24 April 2018, HC (2017–19) 505, Q441 [Steve Brine MP]
88 Towards a Smokefree Generation - A Tobacco Control Plan for England, Department of Health, 2017
89 Adult smoking habits in the UK: 2016, Office for National Statistics, 2017
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48. The Plan sets out the Government’s goal for all sites providing mental health inpatient 
services to be smoke-free by 2018. The document states that:
People with mental health conditions have an equal right to be asked whether 
they smoke. They need to be offered effective methods to quit smoking or 
reduce harm as part of their care plan and there is an urgent clinical need 
to improve the support they receive. In some instances, healthcare staff will 
escort patients on and away from hospital grounds to smoke. This practice 
is outdated. It reduces the resources available to deliver clinical care and 
causes direct harm to patients.92
The Mental Health and Smoking Partnership told us that e-cigarettes could play a role in 
reducing smoking in this group because some evidence indicated that e-cigarettes are seen 
as more acceptable to people with mental health conditions than other forms of support. 
They concluded, however, that:
There are barriers to access of e-cigarettes for people with a mental health 
condition and this includes the policies in NHS settings, attitudes and 
understanding of health care professionals, false perceptions of harm 
among smokers with a mental health condition and barriers to entry such 
as cost of devices.93
49. Heather Thomson from Nottinghamshire Healthcare NHS Foundation Trust told 
us that restricting patients to specific areas within facilities where they can vape may be 
counter-productive:
We do not want to make patients become more isolated than they were. 
If one e-cigarette lasts as long as 30 cigarettes and somebody who is a 
40-a-day smoker usually can use it only in their room, we may find that 
they have even less interaction. We want to encourage them to be a part 
of activities that are going on. If vaping during an activity enables them 
to remain focused and within that activity, that is part of their therapeutic 
recovery and is a good thing.94
While the Care Quality Commission’s (CQC) guidance for its inspectors asks them not 
to challenge smoke-free policies, it does emphasise how such policies can be mitigated for 
patients affected:
CQC inspections should not challenge smoke-free policies, including bans 
on tobacco smoking in mental health inpatient services (for example, by 
raising such policies as an unwarranted ‘blanket restriction’). Instead, focus 
should be paid on whether such a ban is mitigated by adequate advice and 
support for smokers to stop or temporarily abstain from smoking with the 
assistance of behavioural support, and a range of stop smoking medicines 
and/or e-cigarettes. Inspections should also consider whether alternative 
activities are in place and promoted, including regular access to outside 
areas.95
92 Towards a Smokefree Generation - A Tobacco Control Plan for England, Department of Health, 2017
93 Written Evidence submitted by Mental Health and Smoking Partnership (ECG0060)
94 Oral evidence given 16 April 2018 HC (2017–19) 505 Q280 [Heather Thomson]
95 Brief guide: Smokefree policies in mental health inpatient services, Care Quality Commission, 2017.
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Encouragingly, it states that a ban on e-cigarettes without “cogent justification” can be 
criticised as effectively being an unwarranted ‘blanket restrictions’.96
50. We decided to directly survey all English NHS mental health trusts (see Appendix 1), 
and found that a third of the 50 NHS trusts that responded banned e-cigarettes within their 
facilities (three failed to respond—Cumbria Partnership NHS Foundation Trust, Greater 
Manchester West Mental Health NHS Foundation Trust, and Hertfordshire Partnership 
University NHS Foundation Trust). Some of these NHS trusts stated that e-cigarette use 
was allowed in designated shelters outside, along with conventional smoking, whilst others 
designated the facility’s entire estate as smoke-free including for e-cigarettes. Amongst the 
NHS trusts which allowed e-cigarettes indoors, this was generally in designated areas, 
to make sure that those patients, staff and visitors who did not wish to be exposed to the 
vapour could avoid it. Three-quarters of NHS trusts were concerned about ‘second-hand’ 
e-cigarette vapour despite evidence that it presents negligible, if any, health risks (Chapter 
2), and some NHS trusts reported that staff had complained about the smell. Some NHS 
trusts allowed only certain types of e-cigarettes, usually ‘tamper proof’ models, which had 
been approved by the NHS trust. Heather Thomson, Smokefree Lead, Nottinghamshire 
Healthcare NHS Foundation Trust, emphasised possible difficulties caused by not having 
a consistent approach across NHS trusts, which could mean that e-cigarettes approved 
by one site were not permitted in another, or that e-cigarettes were stocked in some retail 
outlets but not others.97
51. Hazel Cheeseman from Action on Smoking Health emphasised a need for “some 
central guidance and policy in relation to ecigarettes and smoke-free policies, and greater 
investment in the training of mental health staff”.98 Professor Newton from Public Health 
England highlighted the importance of evidence-based local decision-making in this area:
We have provided guidance to NHS trusts, including mental health trusts, 
and to employers on the basis on which they should produce their own 
policies. We think that there is value in individual organisations developing 
their own policies, based on a general understanding of the evidence, because 
they are more likely to know what their particular circumstances are. I 
agree with you that it seems unlikely that an overall ban [on e-cigarettes] is 
the right approach, given the evidence.99
52. Heather Thomson believed that a central policy from NHS England would, 
nevertheless, be beneficial:
It would be very useful to have some central guidance, because there is an 
anxiety about bringing in something that, in years to come, may prove to 
have been harmful. However, we need to balance that against the fact that 
we absolutely know the harms that are associated with smoking. Anything 
that allays those fears and lays the foundations will be useful.100
96 Brief guide: Smokefree policies in mental health inpatient services, Care Quality Commission, 2017.
97 Oral evidence taken on 27 March 2018, HC (2017–19) 505, Q284 [Heather Thomson]
98 Oral evidence taken on 27 March 2018, HC (2017–19) 505, Q334 [Hazel Cheeseman]
99 Oral evidence taken on 24 April 2018, HC (2017–19) 505, Q373 [Professor Newton]
100 Oral evidence taken on 27 March 2018, HC (2017–19) 505, Q262 [Heather Thomson]
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NHS Providers recognised “the potential value of national guidance from NHS England to 
support NHS mental health services in permitting the use of e-cigarettes”, but cautioned 
that:
[A policy would] need to be sufficiently flexible and allow trusts to incorporate 
the guidance in an individually tailored way as part of personalised care 
planning, as well as to manage their permissions as to where e-cigarettes 
can be used on the trust’s premises. We would also maintain that the cost of 
using e-cigarettes services remains with the service user and not the trust, 
unless such a time comes that e-cigarettes are prescribed by the NHS.101
E-cigarettes in prisons
53. In the prison estate, like mental health NHS trusts, a conventional smoking ban is 
being rolled out across England. The difference however is that e-cigarettes and vaping 
devices are made available for purchase within the entire prison estate whilst only in some 
mental health facilities. E-cigarettes had been brought into some prisons on a trial basis 
in 2014. In 2015 the then Minister for Prisons and Probation told the Justice Committee:
Our steps to date [towards a smoke-free prison service] include the recent 
and highly successful roll out of electronic cigarettes to all prisons. These 
are available in every prison shop and offer a comparable alternative to 
traditional tobacco products in cost terms.102
54. Michelle Jarman-Howe, Executive Director of Public Sector Prisons South, told us 
that the policy was working well:
At the point at which the [prison] service introduced no smoking, offenders 
could access disposable e-cigarettes through the offender canteen system 
on closed sites in the public sector. Later, in October 2017, we also enabled 
offenders to access rechargeable vaping facilities. That proved to be far more 
popular.103
55. Smoking cessation is a particular challenge in mental health. People with 
mental health issues smoke significantly more than the rest of the population and, 
as the Government warns, if we do not reduce smoking prevalence among this group, 
“we will have failed to reduce inequalities”. Patients in mental health units who are 
smokers would benefit from using e-cigarettes to help them stop smoking conventional 
cigarettes whilst also encouraging them to engage with treatments within the facilities, 
because they can continue to engage in treatment sessions, when as smokers they 
would have to leave. Some NHS mental health units are allowing unrestricted use of 
e-cigarettes—Nottinghamshire Healthcare NHS Foundation Trust is an exemplar—
but it is unacceptable that a third of mental health NHS trusts still ban e-cigarettes 
within their facilities. Three-quarters of NHS trusts are mistakenly concerned about 
‘second-hand’ e-cigarette vapour, despite evidence that it presents a negligible health 
risk.
101 Written evidence submitted by NHS Providers (ECG0109)
102 Letter from Prisons Minister Andrew Selous to Robert Neill MP, Chairman of the Justice Select Committee 
regarding smoking in prisons, 29 September 2015.
103 Oral evidence taken on 27 March 2018, HC (2017–19) 505, Q233 [Michelle Jarman-Howe]
 E-cigarettes 26
56. We are concerned that NHS England declined our invitation to give evidence on 
how it was working to encourage innovative solutions, such as e-cigarettes, to battle 
the worryingly high numbers of smokers amongst those with poor mental health. 
NHS England stated that it was unable to provide a representative to put in front of the 
Committee. NHS England explained that there was no one responsible centrally with 
“oversight” of e-cigarette policies amongst NHS mental health trusts, nor did NHS 
England do anything centrally to enforce any type of policy approach. NHS England 
should take a strong leadership role in ensuring that everything is done to reduce the 
numbers of smokers amongst those with poor mental health, as smoking is the single 
largest cause of premature mortality within this group. We also find it very concerning 
that there is not a dedicated person within NHS England responsible for implementing 
the Government’s Tobacco Control Plan. NHS England should as a matter of urgency 
ensure that such a position is created.
57. NHS England should set a clear central NHS policy on e-cigarettes in mental health 
facilities which establishes a default of allowing e-cigarette use by patients unless an 
NHS trust can show reasons for not doing so which are demonstrably evidence-based. 
NHS England should issue e-cigarette guidance to all NHS mental health trusts to 
ensure that they understand the physical and mental health benefits for their patients.
E-cigarettes in public places
58. Although e-cigarettes are significantly less harmful than conventional cigarettes, 
and are helping people to stop smoking, they are generally prohibited in closed spaces 
including workplaces, restaurants and on public transport. Vapers are typically shown to 
outside ‘smoking areas’ to vape next to a conventional smoker, which could be counter-
productive for those attempting to stay away from cigarettes while trying to quit smoking. 
John Dunne from the UK Vaping Industry Association compared making vapers stand 
with smokers as “putting an alcoholic in a bar: It just does not make sense”.104
59. Smoking has been banned in closed public spaces and many workplaces to protect 
non-smokers from the effects of second-hand smoke, and in some cases to reduce fire-risk, 
but it appears that the same logic is being used to prevent e-cigarette vaping. Yet, as we 
discussed in Chapter 2, second-hand vapour does not cause harm. Professor Newton from 
Public Health England pointed to another more basic factor potentially involved, noting 
that while “there is no evidence that exposure to the vapour of e-cigarettes is harmful, […] 
some people do not necessarily like it”.105
60. Many businesses, public transport providers and owners of other public places do 
not allow e-cigarettes in the same way that they prohibit conventional smoking. There 
is some hostility towards the use of e-cigarettes in public areas, if only because some 
bystanders find its vapour unpleasant. As we have described in this Report, there is no 
public health rationale for treating use of the two products the same. Indeed, forcing 
vapers to use the same ‘smoking shelters’ as conventional smokers could undermine 
their efforts to quit. There is now a need for a wider debate on how e-cigarettes are to 
be dealt with in our public spaces, to help arrive at a solution which at least starts from 
the evidence rather than misconceptions about their health impacts. A liberalisation of 
104 Oral evidence taken on 9 May 2018, HC (2017–19) 505, Q554 [John Dunne]
105 Oral evidence taken on 24 April 2018, HC (2017–19) 505, Q401 [Professor Newton]
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restrictions on e-cigarettes, which provide a popular route for people to stop smoking, 
would result in non-vapers having to accommodate vapers (for a relatively short period 
of time).
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4 Regulation
61. E-cigarettes are regulated under the UK Tobacco and Related Products Regulations 
2016 (TRP Regulation),106 which implemented the EU’s Tobacco Products Directive.107 
Because the regulations are connected with trade, it is largely a reserved matter and the 
Department of Health and Social Care transposed the regulations on behalf of Northern 
Ireland, Scotland and Wales. The EU Directive:
• Sets minimum standards for the safety and quality of all e-cigarettes and liquid 
refill containers;
• Requires that information is provided to consumers so that they can make 
informed choices; and
• Requires that children are protected from starting to use ‘tobacco’ products.108
It leaves national governments to stipulate and control:
• smoke-free environments;
• domestic advertising;
• domestic sales;
• age restrictions;
• nicotine-free cigarettes; and
• flavourings of e-cigarettes.109
62. E-cigarettes and e-liquids are subject to a notification scheme, for which the Medicines 
and Healthcare products Regulatory Agency (MHRA) is the competent authority in the 
UK. This system is intended to ensure standards that:
• require child-resistant and tamper-evident packaging;
• provide protection against breakage and leakage;
• ban certain ingredients (including certain colourings, caffeine and taurine);
• require that devices deliver a consistent dose of nicotine under normal conditions; 
and
• limit liquid tank and cartridges to no more than 2ml in volume and 20mg/ml in 
nicotine strengths.110
106 The Tobacco and Related Products Regulations 2016
107 The Tobacco Products Directive (2014/40/EU)
108 The Tobacco Products Directive (2014/40/EU)
109 The Tobacco Products Directive (2014/40/EU)
110 The Tobacco and Related Products Regulations 2016
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63. The Department of Health and Social Care regarded the e-cigarette regulatory 
framework as “proportionate”. The EU and national regulations, they told us, have enabled 
them:
[…] to introduce measures to regulate e-cigarettes to reduce the risk of harm 
to children and protect against any risk of re-normalisation of tobacco use, 
provide assurance on relative safety for users, and provide legal certainty for 
businesses. This has enabled the UK to implement standards and consistency. 
There are a few exceptions in terms of UK domestic law and it is right for 
each UK country to decide on those matters. For example, in Scotland there 
are powers to introduce domestic legislation banning domestic advertising 
of e-cigarettes. This is a matter for the Scottish Parliament.111
64. The Scottish Government has made provision, through the Health (Tobacco, Nicotine 
etc. and Care) (Scotland) Act 2016, to restrict the advertising of vapour products through 
secondary legislation, though this is not yet in place. This would require retailers selling 
‘nicotine vapour product’, or e-cigarettes, to register on a tobacco retailer register. It would 
also restrict domestic advertising and promotions and bans staff under the age of 18 from 
selling tobacco and ‘nicotine vapour products’.112 In 2015–16, the Welsh Government 
attempted to go further and introduce stricter controls on the use of e-cigarettes in public 
places and, like Scotland, introduce a national register for tobacco and nicotine retailers.113 
Its Bill was defeated in the Welsh Assembly.
65. Many of our witnesses identified problems with the regulatory system in four main 
areas: the 20mg/ml maximum nicotine refill limit, a size restriction on the tank, a block 
on advertising e-cigarettes’ relative harm-reduction potential, and the notification scheme 
for e-cigarette ingredients, as we discuss below.
The refill strength limit
66. The Centre for Addictive Behaviours Research at London South Bank University told 
us that the 20 mg/ml nicotine limit for e-cigarette refills was not evidence-based and was 
actually counter-productive:
Vapers using higher nicotine e-liquid concentrations have been compelled 
to switch to lower nicotine concentrations since the introduction of the 
[EU Directive]. This upper limit is arbitrary and is not based on empirical 
evidence. In fact, it may increase harm if smokers cannot achieve the 
nicotine delivery they need to supress cravings for tobacco, which in turn 
may dis-incentivise switching to electronic cigarettes and expose high 
nicotine-dependent smokers, willing to switch to e-cigarettes, to greater 
risks of relapse.114
111 Written evidence submitted by the Department of Health (England) (ECG0030)
112 Health (Tobacco, Nicotine etc. and Care) (Scotland) Act 2016
113 First minister dismisses e-cigs ban plan in health bill, BBC News, 22 May 2015
114 Written evidence submitted by London Southbank University and the University of East London (ECG0018)
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Sarah Jakes from the New Nicotine Alliance similarly told us, in regard to the size of the 
tank size restriction, that:
There is no scientific basis at all for the 2 ml tank limit and 10 ml bottle 
limit. Speaking for consumers, they make things fiddlier and the bottles 
are easier to lose. It is generally inconvenient and there is no possible gain 
from it.115
Regulation of health claims
67. Under the current EU tobacco regulations, there are restrictions on how e-cigarettes
and tobacco products can be advertised and where. The detailed rules are determined by
the Committee on Advertising Practice for non-broadcast media and by the UK Code of
Broadcast Advertising for broadcast media. The Advertising Standards Authority, who
regulate and monitor advertisements, told us:
The [Department of Health and Social Care] took a minimal approach to 
implementing the advertising prohibitions in the [EU tobacco directive]. The 
legal prohibitions emanating from the Directive and the TRP Regulation 
apply only to ads which promote (directly or indirectly) certain types of 
products (those which are unlicensed and which contain nicotine) and only 
in some media channels. In general terms the prohibited media channels 
are those which have a cross-EU-border effect. The result is that a nicotine-
containing e-cigarette may be lawfully advertised on an outdoor poster, 
in a leaflet and in the cinema. However, the same ad would be illegal on 
television and radio and in magazines and newspapers.116
68. Health claims in advertising can only be made about a product which has a medical 
licence from the MHRA,117 but the Advertising Standards Authority is reviewing whether 
health claims should be allowed when promoting e-cigarettes.118 We were told that 27 
representations made to the consultation had been in favour of allowing health claims for 
e-cigarette advertising, and six for the retention of the current legislation.119
69. The UK Centre for T obacco and Alcohol Studies argued that due to currently 
restrictive advertising rules, there is a lack of clear guidance on the relative harms of 
e-cigarettes and conventional cigarettes. This, they believed, contributes to a common 
misconception among smokers who have never used an e-cigarette that they are no less 
harmful.120 Fraser Cropper from the Independent British Vape Trade Association 
explained that e-cigarette manufacturers wanted to make claims only about the products’ 
relatively lower harm compared with conventional cigarettes:
To tie a hand behind our back and not allow us to be able to promote our 
products, to seize even more of those smokers out of the hands of the 
tobacco businesses, does not make sense. We are in a regulated space; we 
115 Oral evidence taken on 9 May 2018, HC (2017–19) 505, Q504 [Sarah Jakes]
116 Written evidence submitted by the Advertising Standards Authority (ECG0015)
117 Written evidence submitted by the Advertising Standards Authority (ECG0015)
118 Oral evidence taken on 24 April 2018, HC (2017–19) 505, Q387 [Mr Morrison]
119 E-cigarette advertising consultation, the Advertising Standards Authority, September 2017
120 Written evidence submitted by the UK Centre for Tobacco and Alcohol Studies (ECG0031)
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are protecting our consumers because of that. It should, therefore, also 
allow for confidence that we can continue to deliver those products and 
services in an ethical and responsible way.121
Vaping does not make anybody better per se; it significantly reduces the 
risk of what a smoker is exposed to. It is a relative health claim. It is not a 
health claim in the singular sense that it makes somebody better.122
70. One way of targeting information about the relative harm reduction of e-cigarettes 
at existing smokers, rather than more broadly, would be through ‘pack inserts’ placed in 
conventional cigarette cartons. Dr Moira Gilchrist from Philip Morris International told 
us that:
We are very interested in ensuring we have the opportunity to have targeted 
communications to smokers. We are not interested in broad communication 
opportunities; we are interested in attracting the right users—smokers who 
would otherwise continue to use cigarettes. Pack inserts in conventional 
cigarette packs are one example of that. Unfortunately, we cannot do that 
here in the United Kingdom, because of the laws that exist. We believe that 
that would be a tremendous opportunity to talk only to smokers, to tell 
them about the existence of new smoke-free products. That would be a very 
simple thing to do here in the United Kingdom that would allow marketing 
to exactly the right audience and not to the wrong audience.123
71. Dr Tim Baxter from the Department of Health and Social Care told us that, in 
relation to ‘pack inserts’ in conventional cigarette packs, “there is not a single UK phone 
number for helping people to stop smoking, so that is an issue. We cannot use inserts. We 
do effectively use the pack to give various messages, with graphic health warnings.”124
Regulation of e-cigarette ingredients
72. Whilst the MHRA includes all nicotine containing e-cigarette products in its 
notification scheme for obtaining product approval, non-nicotine containing products 
such as nicotine-free vaping liquids fall outside of the approval process.125 Dr Grant 
O’Connell from Fontem Ventures noted that there is a blacklist of ingredients which are 
not allowed, and took issue with the less rigorous approach of the notification process for 
products which do not contain nicotine:
The issue regarding whether some liquids already contain these chemicals 
is that in the absence of product standards, particularly around testing 
methods, you are comparing apples with pears. There is not one standard 
method. One lab will use method A and one will use method B, so you 
might not detect the chemical. We agree that strict enforcement of product 
standards is absolutely essential. We believe that that would form the basis 
of a bespoke regulatory framework for these products.126
121 Oral evidence taken on 9 May 2018, HC (2017–19) 505, Q547 [Mr Cropper]
122 Oral evidence taken on 9 May 2018, HC (2017–19) 505, Q544 [Mr Cropper]
123 Oral evidence taken on 27 February 2018, HC (2017–19) 505, Q152 [Dr Gilchrist]
124 Oral evidence taken on 24 April 2018, HC (2017–19) 505, Q491 [Dr Baxter]
125 Oral evidence taken on 24 April 2018, HC (2017–19) 505, Q405 [Dr Hudson]
126 Oral evidence taken on 27 February 2018, HC (2017–19) 505, Q164 [Dr O’Connell]
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Dr Ian Jones from Japan Tobacco International wanted non-nicotine containing liquids to 
be tested in the same way as nicotine containing liquids:
Consumers are still inhaling the vapour from these liquids. We are also 
seeing—I believe, in the UK—what are called ‘short fills’, where consumers 
buy a small bottle of nicotine-containing liquid and add it to an unregulated 
bottle of zero-nicotine flavoured liquid. For me, as a scientist, that is a 
concern, because we do not know what is in that zero-nicotine flavoured 
liquid combination. Based on the principles of consumer protection, I think 
that zero-nicotine liquids should be regulated in the same way.127
73. Dr Ian Hudson, Chief Executive of the MHRA, wrote to us:
The [MHRA] is aware of concern in the industry that products that do not 
contain nicotine when sold could potentially include harmful ingredients 
as they do not fall under scope TRP Regulation. MHRA is collaborating 
with the Department of Health and Public Health England, who are 
carrying out research into the safety of e-cigarette products. Together with 
the compliance work undertaken by Trading Standards and trade bodies, 
this research will provide clearer view of the risks of these products.128
When subsequently he gave evidence to us, he elaborated:
We are doing a number of things. One of them is to work with the Chartered 
Trading Standards Institute in relation to the sampling of products, such 
that they can be tested, and to confirm that they comply with the regulations 
and notifications—and also to ensure that there are no banned substances 
in there.129 […] We cannot test directly, but we are working with trading 
standards to do a pilot of testing, to ensure compliance.130
Regulation of novel tobacco products
74. The regulatory system is also being applied to new products in two areas: ‘heat-not-
burn’ products (Chapter 2) and ‘snus’. ‘Snus’, a Scandinavian non-combustible tobacco 
product inserted under the user’s lip, is currently illegal in the UK under the EU Tobacco 
Products Directive. The same directive does however make an exception for the product 
to be produced and sold in Sweden:
Given the general prohibition of the sale of tobacco for oral use in the 
Union, the responsibility for regulating the ingredients of tobacco for oral 
use, which requires in-depth knowledge of the specific characteristics of 
this product and of its patterns of consumption, should, in accordance 
with the principle of subsidiarity, remain with Sweden, where the sale of 
this product is permitted pursuant to Article 151 of the Act of Accession of 
Austria, Finland and Sweden.131
127 Oral evidence taken on 27 February 2018, HC (2017–19) 505, Q156 [Dr Jones]
128 Letter from Dr Ian Hudson, Medicines and Healthcare products Regulatory Agency (ECG0103)
129 Oral evidence taken on 24 April 2018, HC (2017–19) 505, Q408 [Dr Hudson]
130 Oral evidence taken on 24 April 2018, HC (2017–19) 505, Q409 [Dr Hudson]
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Swedish Match, a company which develops, manufactures and sells tobacco alternatives 
including Snus, recently challenged the ban on the product in British courts, arguing that 
new scientific data had shown it to be less harmful than cigarettes. The Advocate General 
of the European Courts of Justice has judged that the ban outside Sweden remains valid, 
and the Court will make a ruling in the coming months.132
75. Professor Peter Hajek of Queen Mary University told us that snus’ use in Scandinavia 
provided useful data on the health impact of nicotine from long-term users of nicotine 
replacement treatments:
It is not a huge sample, but it is very reassuring. We have a huge population of 
data from Sweden and Norway on people who use snus, which is a nicotine-
containing tobacco product. There is no sign of an increase in cancer that 
is linked to nicotine. There are some pancreatic cancer concerns, but there 
are nitrosamines in those products; the concerns are not nicotine linked. 
Smoking-linked lung cancer is gone. The same applies to heart disease. […] 
I do not think we have any evidence of nicotine being that harmful.133
76. We wrote to the then Health Secretary, Jeremy Hunt MP, about the UK Government’s 
position on the Swedish Match case at the European Court of Justice including its support 
for maintaining the ban on snus. In response, he set out the grounds of the Government’s 
continued support for the ban:
It is worth noting that there are strongly diverging views in terms of the 
evidence on the health risks of snus—with significant concerns in Norway 
and Sweden about the impact of the use of snus, particularly by young people 
and pregnant women. Where such controversy exists, our view is that a ban 
constitutes a proportionate response. However, the primary objective of the 
UK government was not to secure the continued prohibition of snus, but to 
seek to protect the principle of proportionality on which it is based.134
When we subsequently asked the Health Minister, Steve Brine MP, whether he could see 
a case for an end to the ban on snus in the UK post-Brexit, he replied: “No—but I have an 
open mind”.135
Risk-based regulation and taxation
77. The University of Otago, New Zealand, has argued for a differentiated risk-
proportionate regulatory framework for e-cigarettes, heat-not-burn products and 
conventional cigarettes “to ensure the least harmful products are the most affordable, 
accessible and appealing to smokers, while the most harmful smoked tobacco products 
are the least affordable, accessible and appealing to both smokers and young people at 
risk of starting to smoke”.136 Their framework would involve abolishing excise duty and 
taxation of e-cigarettes, except potentially for a level deemed to be required to deter young 
people from starting.
132 Written evidence submitted by the UK Centre for Tobacco and Alcohol Studies (ECG0031)
133 Oral evidence taken on 9 January 2018, HC (2017–19) 505, Q25 [Professor Hajek]
134 Letter from the Secretary of State, Department of Health and Social Care (ECG0095)
135 Oral evidence taken on 24 April 2018, HC (2017–19) 505, Q477 [Steve Brine MP]
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78. The Government’s Tobacco Control Plan states that, once the UK has left the EU, 
tobacco regulation will have to “reflect the new environment in which tobacco control will 
be delivered”.137 The current regulations will be reviewed and the legislation will be re-
assessed, including the regulatory framework around e-cigarettes.138 ASH recommended 
a review of the various regulations post-Brexit.139 Health Minister Steve Brine MP told us:
On the question of post-Brexit and whether Brexit gives us more room for 
manoeuvre, unquestionably yes. That is a bit of “take back control” that I do 
not remember seeing on any buses, but it is a fact that we would have more 
room for manoeuvre.140
79. Some of our witnesses nevertheless raised a concern about needing to ensure 
that vaping products were only advertised to adults, and preferably only to existing 
conventional cigarette smokers. Although currently the proportion of young people using 
e-cigarettes is very small (Chapter 3), the Association for Young People’s Health believed 
that e-cigarettes are marketed to young people, and were concerned that “young people, 
who are early adopters of all new technologies may be attracted to use e-cigarettes whether 
or not they already smoke”.141
80. Currently, e-cigarettes are not subject to excise duty in the UK, unlike conventional 
cigarettes, heat-not-burn and other tobacco-containing products.142 Dr Lion Shahab from 
UCL believed that taxation could play an important part in encouraging smokers to switch 
from conventional smoking to less harmful alternatives including e-cigarettes.143
81. Some aspects of the regulatory system for e-cigarettes appear to be holding 
back their use as a stop smoking measure. The limit on the strength of refills means 
that some users have to puff harder to get the nicotine they seek and may put some 
heavy smokers off persisting with e-cigarettes. The tank size restriction does not 
seem to be founded on any scientific rationale. A prohibition on making claims for 
the relative health benefits of switching to e-cigarettes from conventional cigarettes 
means that some who might switch are not getting that message. A ban on advertising 
‘tobacco’ products, has prevented manufacturers putting ‘pack insert’ information 
about e-cigarettes in cigarette cartons. The Government, together with the ASA and 
the MHRA, should review all these regulatory anomalies and, to the extent that EU 
directives do not present barriers, publish a plan for addressing these in the next annual 
Tobacco Control Plan.
82. The level of taxation on smoking-related products should directly correspond to the 
health risks that they present, to encourage less harmful consumption. Applying that 
logic, e-cigarettes should remain the least-taxed and conventional cigarettes the most, 
with heat-not-burn products falling between the two.
83. The Government should conduct a review of regulations on e-cigarettes and novel 
tobacco products which are currently applied under EU legislation, to identify scope for 
change post-Brexit, including an evidence-based review of the case for discontinuing 
137 Towards a Smokefree Generation - A Tobacco Control Plan for England, Department of Health, 2017
138 Towards a Smokefree Generation - A Tobacco Control Plan for England, Department of Health, 2017
139 Action on Smoking and Health (ECG0071)
140 Oral evidence taken on 24 April 2018, HC (2017–19) 505, Q481 [Steve Brine MP]
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142 Tax on shopping and services, HMRC
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the ban on ‘snus’ oral tobacco. This should be part of a wider shift to a more risk-
proportionate regulatory environment; where regulations, advertising rules and tax/
duties reflect the evidence on the relative harms of the various e-cigarette and tobacco 
products available. While an evidence-based approach is important in its own right, it 
also may help bring forward the behaviours that we want as a society—less smoking, 
and greater use and acceptance of e-cigarettes and novel tobacco products if that serves 
to reduce smoking rates.
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Conclusions and recommendations
Reducing Harm
1. There is clear evidence that e-cigarettes are substantially less harmful than 
conventional cigarettes. Public Health England estimate e-cigarettes as 95% less 
harmful, although the evidence available does not currently allow a precise figure 
to be determined. E-cigarettes lack the tar and carbon monoxide of conventional 
cigarettes—the most dangerous components of conventional cigarettes—which 
are produced by combustion. Some potentially harmful components are present in 
both products, such as heavy metals, but at substantially lower levels in e-cigarettes. 
Researchers have found it almost impossible to measure the risks from ‘second-
hand’ e-cigarette vapour because any potentially harmful compounds released into 
the surrounding area are so negligible. (Paragraph 27)
2. More recently introduced ‘heat-not-burn’ products—producing nicotine from 
tobacco but without the combustion—have been estimated to be around 90% less 
harmful than conventional cigarettes, although there is a lack of independent 
research to validate this claim. (Paragraph 28)
3. There are uncertainties, nevertheless, especially about any long-term health effects 
of e-cigarettes, because the products have not yet had a history of long use. The 
studies needed to guarantee the safety of e-cigarettes are inevitably frustrated by the 
absence of a population of e-cigarette users who have never smoked conventional 
cigarettes before taking up vaping. Ultimately, however, any judgement of risks has 
to take account of the risk of not adopting e-cigarettes—that is, continuing to smoke 
conventional cigarettes, which are substantially more harmful than e-cigarettes. 
Existing smokers should always be encouraged to give up all types of smoking, but if 
that is not possible they should switch to e-cigarettes as a considerably less harmful 
alternative. (Paragraph 29)
4. To help fill remaining gaps in the evidence on the relative risks of e-cigarettes and heat-
not-burn products, the Government should maintain its planned annual ‘evidence 
review’ on e-cigarettes and extend it to also cover heat-not-burn products. It should 
support a long-term research programme, to be overseen by Public Health England 
and the Committee on Toxicity of Chemicals in Food, Consumer Products and the 
Environment, to ensure that health-related evidence is not dependent solely on the 
tobacco industry or the manufacturers of e-cigarettes. That PHE/COT research should 
include examining health risks arising from the flavourings added to e-cigarettes. The 
Government should report each year on the state of research in its Tobacco Control 
Plan, and establish an online hub for making the detailed evidence readily available 
to the public and to health professionals. (Paragraph 30)
E-cigarettes and smoking cessation
5. There remain some gaps in the evidence about how effective e-cigarettes are as a stop 
smoking tool in comparison to other nicotine replacement therapies. Nevertheless, 
an estimated 2.9 million people in the UK are using e-cigarettes, and tens of 
thousands are using them to successfully quit smoking each year. Concerns about 
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the risk of e-cigarettes potentially providing a ‘gateway’ into conventional smoking 
have not materialised to any significant degree. Similarly, the risk of the variety and 
type of flavours being attractive to young non-smokers, who would be drawn into 
e-cigarette use, also appears to be negligible. (Paragraph 37)
6. A medically licensed e-cigarette could assist smoking cessation efforts by making it 
easier for medical professionals to discuss and recommend them as a stop smoking 
treatment with patients. It would also make it easier for claims to be explicitly made 
about their harm-reduction relative to conventional smoking, which regulations 
currently prevent (Chapter 4). The Government should review with MHRA and the 
e-cigarette industry how its systems for approving stop smoking therapies could be 
streamlined; to be able to respond appropriately should manufacturers put forward a 
product for licensing. (Paragraph 46)
7. Smoking cessation is a particular challenge in mental health. People with mental 
health issues smoke significantly more than the rest of the population and, as the 
Government warns, if we do not reduce smoking prevalence among this group, 
“we will have failed to reduce inequalities”. Patients in mental health units who 
are smokers would benefit from using e-cigarettes to help them stop smoking 
conventional cigarettes whilst also encouraging them to engage with treatments 
within the facilities, because they can continue to engage in treatment sessions, when 
as smokers they would have to leave. Some NHS mental health units are allowing 
unrestricted use of e-cigarettes—Nottinghamshire Healthcare NHS Foundation 
Trust is an exemplar—but it is unacceptable that a third of mental health NHS 
trusts still ban e-cigarettes within their facilities. Three-quarters of NHS trusts are 
mistakenly concerned about ‘second-hand’ e-cigarette vapour, despite evidence that 
it presents a negligible health risk. (Paragraph 55)
8. We are concerned that NHS England declined our invitation to give evidence on 
how it was working to encourage innovative solutions, such as e-cigarettes, to battle 
the worryingly high numbers of smokers amongst those with poor mental health. 
NHS England stated that it was unable to provide a representative to put in front of 
the Committee. NHS England explained that there was no one responsible centrally 
with “oversight” of e-cigarette policies amongst NHS mental health trusts, nor did 
NHS England do anything centrally to enforce any type of policy approach. NHS 
England should take a strong leadership role in ensuring that everything is done to 
reduce the numbers of smokers amongst those with poor mental health, as smoking 
is the single largest cause of premature mortality within this group. We also find it 
very concerning that there is not a dedicated person within NHS England responsible 
for implementing the Government’s Tobacco Control Plan. NHS England should as 
a matter of urgency ensure that such a position is created. (Paragraph 56)
9. NHS England should set a clear central NHS policy on e-cigarettes in mental health 
facilities which establishes a default of allowing e-cigarette use by patients unless an 
NHS trust can show reasons for not doing so which are demonstrably evidence-based. 
NHS England should issue e-cigarette guidance to all NHS mental health trusts to 
ensure that they understand the physical and mental health benefits for their patients. 
(Paragraph 57)
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10. Many businesses, public transport providers and owners of other public places do 
not allow e-cigarettes in the same way that they prohibit conventional smoking. 
There is some hostility towards the use of e-cigarettes in public areas, if only because 
some bystanders find its vapour unpleasant. As we have described in this Report, 
there is no public health rationale for treating use of the two products the same. 
Indeed, forcing vapers to use the same ‘smoking shelters’ as conventional smokers 
could undermine their efforts to quit. There is now a need for a wider debate on 
how e-cigarettes are to be dealt with in our public spaces, to help arrive at a solution 
which at least starts from the evidence rather than misconceptions about their 
health impacts. A liberalisation of restrictions on e-cigarettes, which provide a 
popular route for people to stop smoking, would result in non-vapers having to 
accommodate vapers (for a relatively short period of time). (Paragraph 60)
Regulation
11. Some aspects of the regulatory system for e-cigarettes appear to be holding back 
their use as a stop smoking measure. The limit on the strength of refills means that 
some users have to puff harder to get the nicotine they seek and may put some heavy 
smokers off persisting with e-cigarettes. The tank size restriction does not seem to be 
founded on any scientific rationale. A prohibition on making claims for the relative 
health benefits of switching to e-cigarettes from conventional cigarettes means 
that some who might switch are not getting that message. A ban on advertising 
‘tobacco’ products, has prevented manufacturers putting ‘pack insert’ information 
about e-cigarettes in cigarette cartons. The Government, together with the ASA and 
the MHRA, should review all these regulatory anomalies and, to the extent that EU 
directives do not present barriers, publish a plan for addressing these in the next 
annual Tobacco Control Plan. (Paragraph 81)
12. The level of taxation on smoking-related products should directly correspond to the 
health risks that they present, to encourage less harmful consumption. Applying that 
logic, e-cigarettes should remain the least-taxed and conventional cigarettes the most, 
with heat-not-burn products falling between the two (Paragraph 82)
13. The Government should conduct a review of regulations on e-cigarettes and novel 
tobacco products which are currently applied under EU legislation, to identify scope for 
change post-Brexit, including an evidence-based review of the case for discontinuing 
the ban on ‘snus’ oral tobacco. This should be part of a wider shift to a more risk-
proportionate regulatory environment; where regulations, advertising rules and tax/
duties reflect the evidence on the relative harms of the various e-cigarette and tobacco 
products available. While an evidence-based approach is important in its own right, 
it also may help bring forward the behaviours that we want as a society—less smoking, 
and greater use and acceptance of e-cigarettes and novel tobacco products if that serves 
to reduce smoking rates. (Paragraph 83)
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/ s
to
p
p
in
g
 s
m
o
ki
n
g
. T
h
er
e 
h
as
 a
ls
o
 b
ee
n
 c
o
n
si
d
er
ab
le
 d
eb
at
e 
o
f 
th
e 
d
if
fe
re
n
t 
ty
p
es
 o
f 
el
ec
tr
o
n
ic
 c
ig
ar
et
te
s,
 t
h
es
e 
b
ei
n
g
 p
re
 fi
lle
d
, d
is
p
o
sa
b
le
 o
r 
th
e 
ta
n
k 
ty
p
e 
ci
g
ar
et
te
s,
 c
o
n
ce
rn
s 
h
av
e 
b
ee
n
 h
ig
h
lig
h
te
d
 
ar
o
u
n
d
 t
h
e 
u
se
 o
f 
ill
eg
al
 s
u
b
st
an
ce
s 
in
 t
h
e 
re
fi
lla
b
le
 e
le
ct
ro
n
ic
 c
ig
ar
et
te
 t
yp
es
.
Th
er
e 
ar
e 
co
n
ce
rn
s 
ex
p
re
ss
ed
 b
y 
so
m
e 
g
ro
u
p
s 
re
g
ar
d
in
g
 a
n
y 
p
o
te
n
ti
al
 h
ar
m
 
fr
o
m
 s
ec
o
n
d
 h
an
d
 v
ap
o
u
r.
 T
h
er
e 
co
n
ti
n
u
es
 t
o
 b
e 
re
vi
ew
s 
in
to
 t
h
e 
p
o
te
n
ti
al
 
h
ar
m
 o
f 
th
is
. T
h
e 
tr
u
st
 d
o
es
 a
ck
n
o
w
le
d
g
e 
th
at
 t
h
er
e 
ar
e 
so
m
e 
co
n
ce
rn
s 
an
d
 t
h
is
 
h
as
 s
u
p
p
o
rt
ed
 t
h
e 
id
ea
 o
f 
el
ec
tr
o
n
ic
 
ci
g
ar
et
te
s 
o
n
ly
 b
ei
n
g
 u
se
d
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 o
u
ts
id
e 
sp
ac
es
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at
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en
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w
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se
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d
is
p
o
sa
b
le
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-c
ig
ar
et
te
s 
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se
rv
ic
e 
u
se
rs
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n
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-p
at
ie
n
t 
w
ar
d
s 
su
b
je
ct
 t
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 a
 r
is
k 
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se
ss
m
en
t.
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h
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 b
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au
se
 a
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h
o
u
g
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ic
o
ti
n
e 
re
p
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ce
m
en
t 
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er
ap
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(N
R
T
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va
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b
le
 
an
d
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ct
iv
el
y 
p
ro
m
o
te
d
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e 
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co
g
n
is
e 
th
at
 
fo
r 
so
m
e 
p
eo
p
le
 e
-c
ig
ar
et
te
s 
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e 
h
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p
fu
l 
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ag
in
g
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h
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n
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o
ti
n
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d
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o
n
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n
d
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o
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p
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g
 s
m
o
ki
n
g
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n
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h
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p
o
sa
b
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-c
ig
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et
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u
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k
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efi
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e
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ig
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et
te
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n
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h
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 r
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p
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ig
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et
te
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 b
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 b
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se
 w
e 
d
o
 n
o
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 r
e
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n
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b
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 p
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et
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u
b
lic
 a
re
as
 w
o
u
ld
 
al
so
 m
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e 
it
 h
ar
d
er
 t
o
 im
p
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m
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 d
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o
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n
g
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o
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g
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et
te
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-c
ig
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et
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d
 t
o
 m
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d
h
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h
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p
o
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y 
an
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b
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n
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 c
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m
o
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n
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n
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p
u
b
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p
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o
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 d
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 p
ro
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w
 e
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ig
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et
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se
 b
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p
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n
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e 
u
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rs
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u
b
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 r
is
k 
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se
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m
en
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 t
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o
llo
w
in
g
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u
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f 
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d
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vi
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 u
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o
f 
e
-c
ig
ar
et
te
 
u
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w
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f 
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e 
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u
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n
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h
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u
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 c
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n
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e
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 b
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H
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 d
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b
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 r
is
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p
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 f
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 b
u
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 b
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 p
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 r
is
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b
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n
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u
se
d
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n
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h
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u
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b
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d
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 f
re
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u
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g
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u
n
d
er
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w
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g
h
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o
f 
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d
 t
h
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vi
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 f
ro
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u
b
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 H
ea
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n
g
la
n
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Th
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 is
 p
ar
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o
f 
th
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o
ve
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o
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m
o
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 f
re
e 
Tr
u
st
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 is
 p
ar
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o
f 
th
e 
m
o
ve
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o
 a
 s
m
o
ke
 f
re
e 
Tr
u
st
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an
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N
H
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u
n
d
at
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Tr
u
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 o
u
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p
at
ie
n
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o
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 o
u
r 
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m
m
u
n
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es
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W
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h
is
 p
o
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o
n
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ev
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es
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an
d
 c
o
n
st
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ew
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rm
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n
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el
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in
g
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-c
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ar
et
te
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n
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V
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N
H
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u
n
d
at
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ru
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Th
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Tr
u
st
 d
ev
el
o
p
ed
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m
o
ke
fr
ee
 N
ic
o
ti
n
e 
M
an
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em
en
t 
Po
lic
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at
ed
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ar
ch
 2
01
6)
 
in
 p
re
p
ar
at
io
n
 t
o
 g
o
 f
u
lly
 s
m
o
ke
fr
ee
 o
n
 9
 
M
ar
ch
 2
01
6.
 T
h
is
 p
o
lic
y 
is
 c
u
rr
en
tl
y 
u
n
d
er
 
re
vi
ew
 b
u
t 
th
e 
o
ri
g
in
al
 v
er
si
o
n
 is
 a
tt
ac
h
ed
 
(a
p
p
en
d
ix
 1
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TE
W
V
 f
u
lly
 s
u
p
p
o
rt
 t
h
e 
u
se
 o
f 
al
l m
o
d
el
s 
o
f 
e
-c
ig
ar
et
te
s/
V
ap
es
 T
ru
st
 w
id
e 
ex
ce
p
t 
w
it
h
in
 
th
e 
Fo
re
n
si
c 
se
rv
ic
e 
w
h
er
e 
th
e 
d
ec
is
io
n
 w
as
 
ta
ke
n
 n
o
t 
to
 a
llo
w
 t
h
es
e 
d
u
e 
to
 t
h
e 
p
o
te
n
ti
al
 
ri
sk
s 
fo
r 
th
ei
r 
in
d
iv
id
u
al
 s
er
vi
ce
 u
se
rs
. I
n
 t
h
e 
o
ri
g
in
al
 P
o
lic
y 
(M
ar
ch
 2
01
6)
 b
o
th
 fi
rs
t 
an
d
 
se
co
n
d
 g
en
er
at
io
n
 e
-c
ig
s/
va
p
es
 w
er
e 
al
lo
w
ed
 
fo
r 
u
se
 b
u
t 
fo
llo
w
in
g
 c
o
n
su
lt
at
io
n
 t
h
e 
th
ir
d
 
g
en
er
at
io
n
 t
an
k 
m
o
d
el
s 
w
er
e 
al
so
 a
llo
w
ed
 
fo
r 
u
se
. A
ll 
re
ch
ar
g
ea
b
le
 m
o
d
el
s 
ar
e 
al
lo
w
ed
 
fo
llo
w
in
g
 in
d
iv
id
u
al
 r
is
k 
as
se
ss
m
en
ts
. T
h
e 
re
vi
se
d
 P
o
lic
y 
w
ill
 r
efl
ec
t 
th
is
 in
fo
rm
at
io
n
. I
n
 
ad
d
it
io
n
 w
e 
h
av
e 
p
ro
vi
d
ed
 e
-c
ig
ar
et
te
/v
ap
es
 
g
u
id
an
ce
 f
o
r 
TE
W
V
 s
ta
ff
 (
ap
p
en
d
ix
 2
).
Th
e 
Tr
u
st
 h
as
 a
ls
o
 m
ad
e 
av
ai
la
b
le
 f
re
e 
d
is
p
o
sa
b
le
 e
-c
ig
ar
et
te
s 
to
 a
ll 
in
p
at
ie
n
ts
 o
ve
r 
th
e 
ag
e 
o
f 
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n
d
 t
h
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C
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s 
te
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Su
it
e 
st
af
f 
ca
n
 a
ls
o
 a
cc
es
s 
th
es
e 
fo
r 
se
rv
ic
e 
u
se
rs
 a
t 
th
e 
ea
rl
ie
st
 o
p
p
o
rt
u
n
it
y 
to
 h
el
p
 
al
le
vi
at
e 
n
ic
o
ti
n
e 
w
it
h
d
ra
w
al
. T
h
es
e 
h
av
e 
b
ee
n
 w
el
l r
ec
ei
ve
d
 a
n
d
 a
re
 r
ea
d
ily
 a
va
ila
b
le
 
(o
th
er
 t
h
an
 F
o
re
n
si
c 
se
rv
ic
e)
 T
ru
st
 w
id
e.
TE
W
V
 c
u
rr
en
tl
y 
h
as
 n
o
 r
es
tr
ic
ti
o
n
s 
o
th
er
 
th
an
 in
 t
h
e 
Fo
re
n
si
c 
se
rv
ic
e.
 T
h
e 
Tr
u
st
 
o
ri
g
in
al
ly
 a
llo
w
ed
 t
h
e 
d
is
p
o
sa
b
le
 a
n
d
 
re
ch
ar
g
ea
b
le
 m
o
d
el
s 
to
 b
e 
u
se
d
 b
u
t 
in
 
O
ct
o
b
er
 2
01
7 
ta
n
k
/r
es
er
vo
ir
 m
o
d
el
s 
w
er
e 
al
so
 a
p
p
ro
ve
d
 f
o
r 
u
se
. R
is
k 
as
se
ss
m
en
ts
 a
re
 
ca
rr
ie
d
 o
u
t 
fo
r 
th
e 
re
ch
ar
g
ea
b
le
 m
o
d
el
s.
 T
h
e 
Tr
u
st
 o
ff
er
 f
re
e 
d
is
p
o
sa
b
le
 e
-c
ig
ar
et
te
s 
o
n
 
ad
m
is
si
o
n
 a
n
d
 w
o
rk
 is
 o
n
g
o
in
g
 t
o
 lo
o
k 
at
 
th
e 
p
o
ss
ib
ili
ty
 t
o
 p
ro
vi
d
e 
fr
ee
 r
ec
h
ar
g
ea
b
le
 
m
o
d
el
s 
in
 t
h
e 
n
ea
r 
fu
tu
re
 f
o
llo
w
in
g
 
d
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n
 d
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n
g
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h
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o
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n
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n
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 c
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 t
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ru
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 t
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 p
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er
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n
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f 
a 
n
u
m
b
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u
id
an
ce
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h
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h
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u
p
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o
rt
ed
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h
e 
Tr
u
st
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n
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n
 u
se
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e
-c
ig
ar
et
te
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Pr
io
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 g
o
in
g
 s
m
o
ke
fr
ee
 s
o
m
e 
w
ar
d
 
st
af
f 
w
er
e 
co
n
ce
rn
ed
 a
b
o
u
t 
th
e 
si
d
e 
ef
fe
ct
s 
fr
o
m
 t
h
e 
va
p
e 
in
 b
ed
ro
o
m
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 T
h
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N
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o
ti
n
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an
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em
en
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n
ke
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it
h
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n
d
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at
io
n
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 b
o
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ie
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 p
ro
vi
d
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y 
ev
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en
ce
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o
r 
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af
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o
n
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n
y 
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n
ce
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 t
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g
 
im
p
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m
en
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o
n
 o
f 
th
e 
Po
lic
y 
an
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-c
ig
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u
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n
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b
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n
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u
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 b
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n
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u
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 c
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h
e 
ta
n
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o
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re
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u
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p
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n
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at
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, d
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 d
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 m
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 t
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at
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o
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u
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h
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h
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o
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 d
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p
o
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b
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w
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o
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o
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n
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o
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th
e 
b
at
te
ri
es
 
to
 b
e 
in
g
es
te
d
. W
it
h
 ‘
ta
n
k’
 e
-c
ig
ar
et
te
s 
th
er
e 
is
 t
h
e 
p
o
te
n
ti
al
 f
o
r 
o
th
er
 s
u
b
st
an
ce
s 
to
 b
e 
sm
o
ke
d
.
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N
H
S 
Tr
u
st
Q
u
es
ti
o
n
 1
Q
u
es
ti
o
n
 2
Q
u
es
ti
o
n
 3
Q
u
es
ti
o
n
 4
Su
ss
ex
 P
ar
tn
er
sh
ip
 
N
H
S 
Fo
u
n
d
at
io
n
 
Tr
u
st
N
o
, w
e 
h
av
e 
n
o
t 
b
an
n
ed
 t
h
e 
u
se
 o
f 
el
ec
tr
o
n
ic
 c
ig
ar
et
te
s 
in
 o
u
r 
fa
ci
lit
ie
s.
 W
e 
cu
rr
en
tl
y 
al
lo
w
 fi
rs
t 
g
en
er
at
io
n
 d
is
p
o
sa
b
le
 
m
o
d
el
s.
W
e 
ar
e 
cu
rr
en
tl
y 
re
vi
ew
in
g
 t
h
is
 a
n
d
 
th
e 
p
o
ss
ib
ili
ty
 t
o
 e
xp
an
d
 t
h
e 
ra
n
g
e 
o
f 
e
-c
ig
ar
et
te
s 
to
 s
ec
o
n
d
 g
en
er
at
io
n
 a
n
d
 
ex
p
lo
ri
n
g
 t
h
e 
u
se
 o
f 
re
ch
ar
g
ea
b
le
 o
n
es
, 
w
h
ils
t 
re
co
g
n
is
in
g
 t
h
e 
n
at
io
n
al
 a
le
rt
.
Y
es
 w
e 
d
id
 c
o
n
si
d
er
 t
h
e 
h
ar
m
 r
ed
u
ci
n
g
 
p
o
te
n
ti
al
 o
f 
e
-c
ig
ar
et
te
s 
to
 c
o
n
ve
n
ti
o
n
al
 
ci
g
ar
et
te
s 
in
 o
u
r 
d
ec
is
io
n
 m
ak
in
g
.
W
e 
h
av
e 
n
o
 e
vi
d
en
ce
 t
o
 s
u
p
p
o
rt
 t
h
is
 a
t 
p
re
se
n
t 
b
u
t 
w
e 
re
m
ai
n
 o
p
en
 a
n
d
 c
o
n
ti
n
u
e 
to
 m
o
n
it
o
r 
th
is
 e
vi
d
en
ce
 a
n
d
 g
u
id
an
ce
 
fr
o
m
 p
u
b
lic
 h
ea
lt
h
.
D
ev
o
n
 P
ar
tn
er
sh
ip
 
N
H
S 
Fo
u
n
d
at
io
n
 
Tr
u
st
N
o
, a
n
 a
g
re
ed
 b
ra
n
d
 is
 a
llo
w
ed
 in
 o
u
ts
id
e 
ar
ea
s 
an
d
 b
ed
ro
o
m
s.
N
/A
Y
es
So
m
e 
st
af
f 
h
av
e 
ra
is
ed
 t
h
is
, s
ta
ti
n
g
 
th
at
 a
s 
re
se
ar
ch
 h
as
 n
o
t 
ye
t 
b
ee
n
 d
o
n
e,
 
w
e 
ca
n
n
o
t 
kn
o
w
 if
 t
h
er
e 
is
 a
 r
is
k 
o
f 
‘s
ec
o
n
d
ar
y 
va
p
in
g
.’ 
Th
e 
e 
ci
g
ar
et
te
s 
w
e 
w
ill
 a
llo
w
 p
ro
d
u
ce
 v
er
y 
lit
tl
e 
va
p
o
u
r.
D
er
b
ys
h
ir
e 
H
ea
lt
h
ca
re
 N
H
S 
Fo
u
n
d
at
io
n
 T
ru
st
E-
ci
g
ar
et
te
s 
h
av
e 
b
ee
n
 b
an
n
ed
 f
o
r 
u
se
 b
y 
p
at
ie
n
ts
 a
n
d
 a
ls
o
 b
y 
vi
si
to
rs
 o
n
 o
u
r 
g
ro
u
n
d
s.
 
Th
e 
in
it
ia
l d
ec
is
io
n
 w
as
 t
ak
en
 o
w
in
g
 t
o
 
la
ck
 o
f 
ev
id
en
ce
 r
eg
ar
d
in
g
 t
h
e 
lo
n
g
er
 t
er
m
 
ef
fe
ct
s 
an
d
 m
o
re
 im
p
o
rt
an
tl
y 
th
e 
p
o
te
n
ti
al
 
ri
sk
 t
o
 m
en
ta
l h
ea
lt
h
 p
at
ie
n
ts
. T
h
e 
la
tt
er
 
is
 o
w
in
g
 t
o
 t
h
e 
p
o
te
n
ti
al
 a
lt
er
n
at
iv
e 
u
se
s 
o
f 
th
e 
fl
u
id
s 
o
r 
in
d
ee
d
 t
h
e 
p
ro
d
u
ct
 it
se
lf
 
re
g
ar
d
in
g
 s
el
f-
h
ar
m
 o
r 
h
ar
m
 t
o
 o
th
er
 p
eo
p
le
. 
H
o
w
ev
er
, f
o
llo
w
in
g
 e
xt
en
si
ve
 b
en
ch
m
ar
ki
n
g
 
an
d
 f
ee
d
b
ac
k 
fr
o
m
 p
at
ie
n
ts
 a
n
d
 s
ta
ff
 w
e 
h
av
e 
re
ce
n
tl
y 
co
m
m
en
ce
d
 a
 t
ri
al
 o
f 
e
-b
u
rn
er
s 
w
h
ic
h
 a
re
 s
in
g
le
 u
se
 e
-c
ig
ar
et
te
s 
w
h
ic
h
 d
o
 
n
o
t 
h
av
e 
to
 b
e 
re
ch
ar
g
ed
 a
n
d
 h
av
e 
p
ro
ve
d
 
le
ss
 o
f 
a 
ri
sk
 t
o
 M
H
 p
at
ie
n
ts
. T
h
es
e 
h
av
e 
su
cc
es
sf
u
lly
 b
ee
n
 in
tr
o
d
u
ce
d
 in
 a
 n
u
m
b
er
 o
f 
M
H
 H
o
sp
it
al
s 
an
d
 s
ec
u
re
 u
n
it
s.
 A
s 
th
e 
tr
ia
l 
o
n
ly
 c
o
m
m
en
ce
d
 a
ft
er
 C
h
ri
st
m
as
 it
 is
 t
o
o
 
ea
rl
y 
to
 a
ss
es
s 
th
e 
su
cc
es
s 
o
r 
o
th
er
w
is
e.
E-
b
u
rn
er
s 
ar
e 
cl
as
se
d
 a
s 
n
ic
o
ti
n
e 
re
p
la
ce
m
en
t 
b
y 
PH
 a
n
d
 t
h
is
 w
as
 p
ar
t 
o
f 
th
e 
d
ec
is
io
n
 t
o
 
in
tr
o
d
u
ce
 t
h
em
.
Y
es
–m
ai
n
ly
 h
ar
m
 t
o
 s
ta
ff
 f
ro
m
 a
g
it
at
ed
 
p
at
ie
n
ts
. A
ls
o
 f
ee
d
b
ac
k 
fr
o
m
 s
ta
ff
 a
n
d
 
p
at
ie
n
ts
.
To
o
 e
ar
ly
 t
o
 r
ev
ie
w
. W
e 
ar
e 
o
n
ly
 a
llo
w
in
g
 
th
e 
e
-b
u
rn
er
s 
to
 b
e 
u
se
d
 o
u
ts
id
e 
an
d
 N
O
T 
o
n
 w
ar
d
s 
o
r 
o
th
er
 e
n
cl
o
se
d
 s
p
ac
es
.
N
o
rf
o
lk
 a
n
d
 
Su
ff
o
lk
 N
H
S 
Fo
u
n
d
at
io
n
 T
ru
st
N
o
, w
e 
ar
e 
en
co
u
ra
g
in
g
 t
h
e 
u
se
 o
f 
e
-c
ig
ar
et
te
s 
as
 a
n
 a
lt
er
n
at
iv
e 
to
 b
u
rn
t 
to
b
ac
co
 o
n
 t
h
e 
p
re
m
is
es
 b
u
t 
o
u
td
o
o
rs
W
e 
u
n
d
er
st
an
d
 a
n
d
 s
u
p
p
o
rt
 P
H
E 
p
o
si
ti
o
n
 
th
at
 e
-c
ig
ar
et
te
s 
ar
e 
95
%
 s
af
er
 t
h
an
 b
u
rn
t 
to
b
ac
co
W
e 
d
o
, t
h
at
’s
 w
h
y 
w
e 
su
p
p
o
rt
 u
se
 o
f 
e
-c
ig
ar
et
te
s
W
e 
ar
e 
n
o
t 
al
lo
w
in
g
 u
se
 o
f 
e
-c
ig
ar
et
te
s 
in
d
o
o
rs
 f
o
r 
th
is
 r
ea
so
n
, u
n
ti
l t
h
e 
h
ea
lt
h
 
ri
sk
s 
ar
e 
b
et
te
r 
u
n
d
er
st
o
o
d
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N
H
S 
Tr
u
st
Q
u
es
ti
o
n
 1
Q
u
es
ti
o
n
 2
Q
u
es
ti
o
n
 3
Q
u
es
ti
o
n
 4
C
o
ve
n
tr
y 
an
d
 
W
ar
w
ic
k
sh
ir
e 
Pa
rt
n
er
sh
ip
 N
H
S 
Fo
u
n
d
at
io
n
 T
ru
st
Sm
o
ki
n
g
 t
o
b
ac
co
 is
 n
o
t 
p
er
m
it
te
d
 in
 a
n
y 
p
ar
t 
o
f 
an
y 
Tr
u
st
 p
ro
p
er
ty
. A
s 
th
e 
Tr
u
st
 is
 a
 n
o
 
sm
o
ki
n
g
 o
rg
an
is
at
io
n
 s
ta
ff
 a
re
 n
o
t 
al
lo
w
ed
 
to
 s
m
o
ke
 o
r 
va
p
e 
e
-c
ig
ar
et
te
s 
d
u
ri
n
g
 p
ai
d
 
w
o
rk
in
g
 t
im
e.
 T
h
er
ef
o
re
 s
ta
ff
 a
re
 n
o
t 
p
er
m
it
te
d
 t
o
 v
ap
e 
e
-c
ig
ar
et
te
s 
o
n
 T
ru
st
 
p
ro
p
er
ty
 (
in
si
d
e 
o
r 
o
u
ts
id
e 
in
 o
u
r 
g
ro
u
n
d
s)
. 
Th
is
 r
es
tr
ic
ti
o
n
 a
ls
o
 a
p
p
lie
s 
to
 o
u
t-
p
at
ie
n
ts
 
an
d
 v
is
it
o
rs
.
W
e 
d
o
 a
llo
w
 e
-c
ig
ar
et
te
s 
fo
r 
in
-p
at
ie
n
ts
 
w
h
o
 a
re
 r
es
is
ta
n
t 
to
 “
Q
u
it
” 
o
r 
n
ic
o
ti
n
e 
re
p
la
ce
m
en
t 
th
er
ap
y 
[N
R
T
] 
p
ro
d
u
ct
s,
 in
 
lin
e 
w
it
h
 t
h
e 
Tr
u
st
’s
 N
R
T 
g
u
id
an
ce
. T
h
e 
u
se
 
o
f 
e
-c
ig
ar
et
te
s 
is
 p
er
m
it
te
d
 f
o
r 
o
u
r 
m
en
ta
l 
h
ea
lt
h
 in
-p
at
ie
n
ts
 in
 t
h
e 
g
ar
d
en
s 
/ f
re
sh
 a
ir
 
ar
ea
s,
 a
n
d
, f
o
llo
w
in
g
 c
lin
ic
al
 r
is
k 
as
se
ss
m
en
t 
an
d
 c
ar
e 
p
la
n
, t
h
e 
p
at
ie
n
t’
s 
o
w
n
 b
ed
ro
o
m
. 
A
p
p
ro
p
ri
at
e 
ar
ea
s 
ar
e 
id
en
ti
fi
ed
 lo
ca
lly
.
W
e 
h
av
e 
n
o
 p
la
n
s 
to
 r
ev
ie
w
 s
ta
ff
 u
se
 o
f 
e
-c
ig
ar
et
te
s 
w
it
h
in
 t
ru
st
 p
ro
p
er
ti
es
 (
ei
th
er
 
in
si
d
e 
o
r 
o
u
ts
id
e)
. W
e 
h
av
e 
re
ce
n
tl
y 
re
vi
ew
ed
 
an
d
 r
e
-c
o
n
fi
rm
ed
 o
u
r 
st
an
ce
 o
n
 b
an
n
in
g
 
re
fi
lla
b
le
 r
e
-u
sa
b
le
 e
-c
ig
ar
et
te
’s
 b
y 
in
-
p
at
ie
n
ts
.
Y
es
. T
h
er
e 
w
er
e 
in
it
ia
l e
th
ic
al
 a
n
d
 s
af
et
y 
co
n
ce
rn
s 
ab
o
u
t 
al
lo
w
in
g
 p
at
ie
n
ts
 a
cc
es
s 
to
 a
n
d
 t
h
e 
u
se
 o
f 
e
-c
ig
ar
et
te
s 
w
it
h
in
 o
u
r 
se
rv
ic
es
. T
h
es
e 
w
er
e 
d
eb
at
ed
 a
s 
p
ar
t 
o
f 
ag
re
ei
n
g
 o
u
r 
ab
o
ve
 p
o
si
ti
o
n
. W
e 
co
n
si
d
er
ed
 
th
e 
h
ar
m
 r
ed
u
ct
io
n
 p
o
te
n
ti
al
 t
o
 o
u
t-
w
ei
g
h
 
an
y 
p
o
te
n
ti
al
 h
ar
m
.
Y
es
. D
u
e 
to
 c
o
n
ce
rn
s 
ab
o
u
t 
“s
ec
o
n
d
 
h
an
d
” 
e
-c
ig
ar
et
te
 v
ap
o
u
r 
an
d
 a
ls
o
 b
ei
n
g
 
se
en
 t
o
 n
o
rm
al
is
e 
th
e 
sm
o
ki
n
g
 o
f 
to
b
ac
co
, 
u
se
 o
f 
e
-c
ig
ar
et
te
’s
 w
as
 r
es
tr
ic
te
d
 t
o
 
o
u
ts
id
e 
o
p
en
 d
efi
n
ed
 s
p
ac
es
 o
r 
a 
p
at
ie
n
t’
s 
o
w
n
-b
ed
ro
o
m
 (
al
l o
u
r 
b
ed
ro
o
m
s 
ar
e 
si
n
g
le
 o
cc
u
p
an
cy
).
N
o
rt
h
am
p
to
n
sh
ir
e 
H
ea
lt
h
ca
re
 N
H
S 
Fo
u
n
d
at
io
n
 T
ru
st
N
o
. T
h
e 
Tr
u
st
 d
ec
is
io
n
 w
as
 t
o
 p
er
m
it
 t
h
e 
u
se
 
o
f 
E-
ci
g
ar
et
te
s 
an
d
 v
ap
es
, s
u
b
je
ct
 t
o
 a
 r
is
k 
as
se
ss
m
en
t.
 V
ap
es
 a
n
d
 E
-c
ig
ar
et
te
s 
ar
e 
o
n
ly
 
p
er
m
it
te
d
 in
 t
h
e 
g
ar
d
en
 a
re
as
. W
e 
h
av
e 
a 
su
p
p
ly
 o
f 
d
is
p
o
sa
b
le
 E
-c
ig
ar
et
te
s 
o
n
 e
ac
h
 
w
ar
d
 a
va
ila
b
le
 t
o
 p
at
ie
n
ts
 f
o
r 
th
e 
fi
rs
t 
4
8 
h
o
u
rs
 o
f 
ad
m
is
si
o
n
. P
at
ie
n
ts
 c
an
 b
ri
n
g
 in
 
th
ei
r 
o
w
n
 E
-c
ig
ar
et
te
s 
o
r 
va
p
es
.
W
e 
h
av
e 
n
o
t 
b
an
n
ed
 t
h
em
, b
u
t 
o
u
r 
d
ec
is
io
n
 
to
 p
er
m
it
 t
h
ei
r 
u
se
 w
ill
 b
e 
re
vi
ew
ed
 
p
er
io
d
ic
al
ly
.
Y
es
 w
e 
d
id
, a
d
d
it
io
n
al
ly
 w
e 
co
n
si
d
er
ed
 t
h
e 
fa
ct
 t
h
at
 t
h
ey
 a
re
 “
th
e 
n
ex
t 
b
es
t 
th
in
g
” 
an
d
 
w
o
u
ld
 h
el
p
 p
at
ie
n
t 
w
h
o
 a
re
 s
tr
u
g
g
lin
g
 w
it
h
 
n
ic
o
ti
n
e 
w
it
h
d
ra
w
al
.
Th
e 
p
o
te
n
ti
al
 f
o
r 
se
co
n
d
-h
an
d
 h
ar
m
 
h
as
 b
ee
n
 c
o
n
si
d
er
ed
, t
h
e 
Tr
u
st
 t
o
o
k 
th
e 
d
ec
is
io
n
 t
o
 a
llo
w
 t
h
ei
r 
u
se
 o
n
 t
h
e 
b
as
is
 
th
at
 if
 e
vi
d
en
ce
 is
 r
el
ea
se
d
 t
h
at
 s
u
g
g
es
ts
 
d
et
ri
m
en
ta
l s
ec
o
n
d
-h
an
d
 h
ar
m
 t
h
e 
d
ec
is
io
n
 w
ill
 b
e 
re
vi
ew
ed
.
So
u
th
 
St
af
fo
rd
sh
ir
e 
an
d
 S
h
ro
p
sh
ir
e 
H
ea
lt
h
ca
re
 N
H
S 
Fo
u
n
d
at
io
n
 T
ru
st
Y
es
, u
n
ti
l D
ec
em
b
er
 2
01
7–
n
o
w
 p
er
m
it
te
d
 in
 
d
es
ig
n
at
ed
 a
re
as
 o
n
ly
Po
si
ti
o
n
 r
ev
ie
w
ed
 in
 2
01
7,
 f
o
llo
w
in
g
 P
H
E 
p
o
si
ti
o
n
 c
h
an
g
e
Y
es
N
o
–a
p
ar
t 
fr
o
m
 s
ta
ff
/p
at
ie
n
ts
 p
re
fe
re
n
ce
 
an
d
 im
p
ac
t 
o
n
 s
m
el
l o
f 
p
ro
d
u
ct
s
2g
et
h
er
 N
H
S 
Fo
u
n
d
at
io
n
 T
ru
st
N
o
. E
-c
ig
ar
et
te
s 
ca
n
 b
e 
u
se
d
 in
 o
u
ts
id
e 
sp
ac
es
 o
n
ly
; h
o
w
ev
er
, w
e 
m
ay
 c
o
n
si
d
er
 
ch
an
g
in
g
 t
h
e 
p
o
lic
y 
in
 d
u
e 
co
u
rs
e.
W
e 
d
o
 n
o
t 
b
an
 t
h
e 
u
se
 o
f 
e
-c
ig
ar
et
te
s;
 
h
o
w
ev
er
, o
u
r 
p
o
lic
y 
is
 u
n
d
er
 c
o
n
st
an
t 
re
vi
ew
Y
es
 w
e 
d
id
, u
si
n
g
 w
h
at
 in
fo
rm
at
io
n
 t
h
er
e 
w
as
 a
va
ila
b
le
 a
t 
th
e 
ti
m
e.
W
e 
ar
e 
aw
ar
e 
th
at
 e
-c
ig
ar
et
te
s 
d
el
iv
er
 
a 
h
ig
h
er
 le
ve
l o
f 
n
ic
o
ti
n
e 
co
m
p
ar
ed
 t
o
 
co
n
ve
n
ti
o
n
al
 N
R
T 
p
ro
d
u
ct
s,
 a
n
d
 t
h
is
 f
av
o
u
rs
 
o
u
r 
cl
ie
n
t 
g
ro
u
p
 d
u
e 
to
 t
h
ei
r 
h
ea
vy
 s
m
o
ki
n
g
 
le
ve
ls
.
W
e 
w
o
u
ld
 c
o
n
si
d
er
 a
n
y 
ad
vi
ce
 f
ro
m
 
Pu
b
lic
 H
ea
lt
h
 E
n
g
la
n
d
. C
u
rr
en
tl
y 
w
e 
ad
vo
ca
te
 t
h
e 
u
se
 d
u
e 
to
 t
h
e 
d
ra
m
at
ic
al
ly
 
re
d
u
ce
d
 r
is
k 
o
f 
e
-c
ig
ar
et
te
s 
co
m
p
ar
ed
 t
o
 
co
n
ve
n
ti
o
n
al
 c
ig
ar
et
te
s.
Th
e 
si
tu
at
io
n
 is
 b
ei
n
g
 c
o
n
st
an
tl
y 
re
vi
ew
ed
.
So
u
th
 W
es
t 
Y
o
rk
sh
ir
e 
Pa
rt
n
er
sh
ip
 N
H
S 
Fo
u
n
d
at
io
n
 T
ru
st
O
u
r 
cu
rr
en
t 
p
o
lic
y 
fo
r 
a 
sm
o
ke
-f
re
e 
en
vi
ro
n
m
en
t 
d
o
es
 in
cl
u
d
e 
a 
b
an
 o
n
 t
h
e 
u
se
 
o
f 
el
ec
tr
o
n
ic
 c
ig
ar
et
te
s 
in
 o
u
r 
fa
ci
lit
ie
s.
Th
e 
p
o
lic
y 
is
 c
u
rr
en
tl
y 
u
n
d
er
 r
ev
ie
w
 a
n
d
 
d
u
e 
to
 b
e 
am
en
d
ed
 b
y 
Ju
n
e 
20
18
. T
h
is
 w
ill
 
sp
ec
ifi
ca
lly
 t
ak
e 
in
to
 a
cc
o
u
n
t 
th
e 
ad
vi
ce
 f
ro
m
 
Pu
b
lic
 h
ea
lt
h
 E
n
g
la
n
d
W
e 
w
ill
 b
e 
co
n
si
d
er
in
g
 t
h
e 
h
ar
m
 r
ed
u
ct
io
n
 
p
o
te
n
ti
al
 o
f 
e
-c
ig
ar
et
te
s 
in
 t
h
e 
fo
rm
u
la
ti
o
n
 
o
f 
o
u
r 
u
p
d
at
ed
 p
o
lic
y.
Th
er
e 
ar
e 
co
n
si
d
er
ab
le
 c
o
n
ce
rn
s 
ab
o
u
t 
th
e 
p
o
te
n
ti
al
 f
o
r 
se
co
n
d
-h
an
d
 h
ar
m
 
ca
u
se
d
 b
y 
e
-c
ig
ar
et
te
s 
an
d
 t
h
es
e 
w
ill
 
n
ee
d
 t
o
 b
e 
m
it
ig
at
ed
 a
g
ai
n
st
 w
it
h
in
 o
u
r 
u
p
d
at
ed
 p
o
lic
y.
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N
H
S 
Tr
u
st
Q
u
es
ti
o
n
 1
Q
u
es
ti
o
n
 2
Q
u
es
ti
o
n
 3
Q
u
es
ti
o
n
 4
Le
ic
es
te
rs
h
ir
e 
Pa
rt
n
er
sh
ip
 N
H
S 
Tr
u
st
W
e 
al
lo
w
 t
h
e 
u
se
 o
f 
el
ec
tr
o
n
ic
 c
ig
ar
et
te
s 
w
it
h
in
 d
es
ig
n
at
ed
 a
re
as
 b
o
th
 in
si
d
e 
an
d
 
o
u
ts
id
e 
fa
ci
lit
ie
s.
W
e 
ar
e 
co
n
ti
n
u
al
ly
 r
ev
ie
w
in
g
 t
h
e 
u
se
 o
f 
e
-c
ig
ar
et
te
s 
w
it
h
in
 o
u
r 
fa
ci
lit
ie
s
Y
es
N
o
–c
u
rr
en
t 
ev
id
en
ce
 d
o
es
 n
o
t 
su
g
g
es
t 
th
at
 t
h
er
e 
is
 a
n
y 
se
co
n
d
 h
an
d
 h
ar
m
.
Le
ed
s 
an
d
 Y
o
rk
 
Pa
rt
n
er
sh
ip
 N
H
S 
Fo
u
n
d
at
io
n
 T
ru
st
C
u
rr
en
tl
y 
e
-c
ig
ar
et
te
s 
ar
e 
n
o
t 
b
an
n
ed
 b
u
t 
th
er
e 
is
 d
es
ig
n
at
ed
 o
u
ts
id
e 
ar
ea
s 
fo
r 
p
at
ie
n
ts
 
an
d
 t
h
e 
u
se
 o
f 
e
-c
ig
ar
et
te
s.
 T
h
is
 is
 w
it
h
in
 t
h
e 
co
n
te
xt
 o
f 
h
ea
lt
h
 p
ro
m
o
ti
o
n
al
 a
d
vi
ce
 a
n
d
 
th
e 
o
ff
er
 o
f 
n
ic
o
ti
n
e 
re
p
la
ce
m
en
t 
th
er
ap
y.
Th
e 
ap
p
ro
ac
h
 t
o
 im
p
ro
vi
n
g
 p
h
ys
ic
al
 h
ea
lt
h
 
o
f 
m
en
ta
l h
ea
lt
h
 p
at
ie
n
ts
 is
 u
n
d
er
 c
o
n
st
an
t 
re
vi
ew
 a
n
d
 t
h
e 
u
se
 o
f 
e
-c
ig
ar
et
te
s 
w
ill
 b
e 
p
ar
t 
o
f 
th
at
; s
ee
 r
es
p
o
n
se
 t
o
 q
u
es
ti
o
n
 1
–w
e 
d
o
 n
o
t 
cu
rr
en
tl
y 
b
an
.
Y
es
Th
is
 w
ill
 b
e 
ke
p
t 
u
n
d
er
 r
ev
ie
w
 a
s 
fu
rt
h
er
 
ev
id
en
ce
 b
ec
o
m
es
 a
va
ila
b
le
 o
n
 s
ec
o
n
d
-
h
an
d
 h
ar
m
 b
u
t 
is
 m
it
ig
at
ed
 b
y 
th
e 
d
es
ig
n
at
ed
 s
m
o
ki
n
g
 a
re
as
 b
ei
n
g
 o
u
ts
id
e 
at
 p
re
se
n
t.
 E-cigarettes 46
N
H
S 
Tr
u
st
Q
u
es
ti
o
n
 1
Q
u
es
ti
o
n
 2
Q
u
es
ti
o
n
 3
Q
u
es
ti
o
n
 4
C
en
tr
al
 a
n
d
 N
o
rt
h
 
W
es
t 
Lo
n
d
o
n
 N
H
S 
Fo
u
n
d
at
io
n
 T
ru
st
N
o
, w
e 
h
av
e 
n
o
t 
b
an
n
ed
 t
h
em
. S
er
vi
ce
 u
se
rs
 
ar
e 
ab
le
 t
o
 u
se
 e
-c
ig
ar
et
te
s 
th
at
 a
re
 o
f 
th
e 
d
is
p
o
sa
b
le
, n
o
n
-r
ec
h
ar
g
ea
b
le
 v
ar
ie
ty
 in
 t
h
ei
r 
ro
o
m
s 
an
d
 o
u
ts
id
e.
 H
o
w
ev
er
, w
e 
d
o
 r
es
tr
ic
t 
th
ei
r 
u
se
–w
e 
as
k 
th
at
 t
h
ey
 a
re
 n
o
t 
u
se
d
 in
 
co
m
m
u
n
al
 a
re
as
 a
s 
so
m
e 
se
rv
ic
e 
u
se
rs
 a
n
d
 
st
af
f 
h
av
e 
o
b
je
ct
ed
 t
o
 p
as
si
ve
 in
h
al
at
io
n
 o
f 
va
p
o
u
r.
W
e 
h
av
e 
re
ce
n
tl
y 
re
vi
ew
ed
 t
h
e 
Tr
u
st
’s
 
p
o
si
ti
o
n
 a
n
d
 h
av
e 
ag
re
ed
 t
h
at
 e
-c
ig
ar
et
te
 
ve
n
d
in
g
 m
ac
h
in
es
 a
re
 t
o
 b
e 
p
ro
vi
d
ed
 in
 in
-
p
at
ie
n
t 
fa
ci
lit
ie
s.
 S
er
vi
ce
 u
se
rs
 w
ill
 b
e 
ab
le
 
to
 p
u
rc
h
as
e 
e
-c
ig
ar
et
te
s 
if
 t
h
ey
 s
o
 c
h
o
o
se
. 
Th
e 
re
vi
ew
 o
f 
th
e 
u
se
 o
f 
e
-c
ig
ar
et
te
s 
h
as
 
b
ee
n
 o
n
g
o
in
g
 o
ve
r 
a 
co
n
si
d
er
ab
le
 p
er
io
d
 o
f 
ti
m
e,
 a
s 
ev
id
en
ce
 h
as
 b
ee
n
 m
ad
e 
av
ai
la
b
le
. 
Th
e 
Pu
b
lic
 H
ea
lt
h
 E
n
g
la
n
d
 g
u
id
an
ce
 w
as
 
p
ar
t 
o
f 
th
at
 e
vi
d
en
ce
, b
u
t 
w
e 
w
er
e 
al
re
ad
y 
re
vi
ew
in
g
 t
h
e 
Tr
u
st
 p
o
si
ti
o
n
 p
ri
o
r 
to
 it
s 
p
u
b
lic
at
io
n
.
A
lt
h
o
u
g
h
 e
-c
ig
ar
et
te
s 
ar
e 
p
u
b
lic
is
ed
 a
s 
le
ss
 
h
ar
m
fu
l t
h
an
 c
ig
ar
et
te
s,
 t
h
er
e 
ar
e 
g
ap
s 
in
 
th
e 
ev
id
en
ce
 b
as
e 
ar
o
u
n
d
 lo
n
g
-t
er
m
 b
en
efi
ts
 
an
d
 h
ar
m
s 
w
h
ic
h
 s
h
o
u
ld
 b
e 
ad
d
re
ss
ed
 w
h
en
 
en
co
u
ra
g
in
g
 t
h
ei
r 
u
se
 w
it
h
 t
h
e 
g
en
er
al
 
p
u
b
lic
.
In
 li
n
e 
w
it
h
 N
IC
E 
g
u
id
an
ce
, t
h
at
 li
ce
n
se
d
 
n
ic
o
ti
n
e 
co
n
ta
in
in
g
 p
ro
d
u
ct
s 
sh
o
u
ld
 b
e 
u
se
d
 
p
ri
m
ar
ily
 f
o
r 
th
o
se
 w
is
h
in
g
 t
o
 s
to
p
 s
m
o
ki
n
g
, 
e
-c
ig
ar
et
te
s 
sh
o
u
ld
 n
o
t 
b
e 
re
co
m
m
en
d
ed
 a
s 
th
es
e 
ar
e 
n
o
t 
ye
t 
lic
en
se
d
 w
it
h
 t
h
e 
M
ed
ic
in
es
 
an
d
 H
ea
lt
h
ca
re
 p
ro
d
u
ct
s 
R
eg
u
la
to
ry
 A
g
en
cy
. 
Th
is
 is
 a
 s
it
u
at
io
n
 t
h
at
 w
ill
 c
h
an
g
e 
th
is
 
ye
ar
 a
n
d
 t
h
e 
Tr
u
st
 w
ill
 f
u
lly
 r
ev
ie
w
 t
h
e 
u
se
 
o
f 
e
-c
ig
ar
et
te
s 
o
n
ce
 a
 li
ce
n
se
d
 p
ro
d
u
ct
 is
 
av
ai
la
b
le
.
It
 is
 r
ec
o
g
n
is
ed
 t
h
at
 p
at
ie
n
ts
 w
it
h
 m
en
ta
l 
h
ea
lt
h
 p
ro
b
le
m
s 
su
ff
er
 d
is
p
ro
p
o
rt
io
n
at
el
y 
h
ig
h
 le
ve
ls
 o
f 
h
ar
m
 f
ro
m
 s
m
o
ki
n
g
 a
n
d
 h
av
e 
lo
w
 q
u
it
 r
at
es
 o
n
 s
ta
n
d
ar
d
 s
m
o
ki
n
g
 c
es
sa
ti
o
n
 
ap
p
ro
ac
h
es
. T
ra
n
si
ti
o
n
 t
o
 e
-c
ig
ar
et
te
s 
m
ay
 
b
e 
o
f 
b
en
efi
t 
fo
r 
th
is
 g
ro
u
p
, a
n
d
 s
h
o
u
ld
 b
e 
ac
ti
ve
ly
 e
n
co
u
ra
g
ed
 a
s 
o
n
e 
p
ar
t 
o
f 
a 
h
ar
m
 
re
d
u
ct
io
n
 a
p
p
ro
ac
h
. T
h
is
 s
h
o
u
ld
 b
e 
ai
m
ed
 
p
ar
ti
cu
la
rl
y 
at
 t
h
o
se
 w
h
o
 h
av
e 
tr
ie
d
 a
n
d
 
fa
ile
d
 e
xi
st
in
g
 a
p
p
ro
ac
h
es
 in
cl
u
d
in
g
 N
R
T 
an
d
 
o
th
er
 s
m
o
ki
n
g
 c
es
sa
ti
o
n
 m
ed
ic
at
io
n
s,
 o
r 
ar
e 
u
n
w
ill
in
g
 t
o
 t
ry
 t
h
em
.
W
e 
ad
vi
se
 t
h
at
 p
re
sc
ri
p
ti
o
n
 o
f 
N
ic
o
ti
n
e 
R
ep
la
ce
m
en
t 
Th
er
ap
y 
(N
R
T
) 
o
r 
m
ed
ic
at
io
n
 
su
ch
 a
s 
V
ar
en
ic
lin
e,
 p
lu
s 
p
sy
ch
o
lo
g
ic
al
 
su
p
p
o
rt
, i
s 
th
e 
p
re
fe
rr
ed
 fi
rs
t 
ch
o
ic
e 
o
f 
tr
ea
tm
en
t 
fo
r 
n
ic
o
ti
n
e 
ad
d
ic
ti
o
n
/s
u
p
p
o
rt
in
g
 
sm
o
ke
rs
 in
 a
 s
m
o
ke
-f
re
e 
en
vi
ro
n
m
en
t.
H
o
w
ev
er
, w
e 
re
co
g
n
is
e 
th
at
 m
an
y 
fi
n
d
 
e
-c
ig
ar
et
te
s 
h
el
p
fu
l a
n
d
 u
n
d
er
st
an
d
 t
h
at
, i
f 
p
eo
p
le
 c
h
o
o
se
 t
o
 u
se
 t
h
em
, t
h
ey
 a
re
 li
ke
ly
 t
o
 
b
e 
le
ss
 h
ar
m
fu
l t
h
an
 c
o
n
ve
n
ti
o
n
al
 c
ig
ar
et
te
s 
(t
h
e 
sm
o
ke
 f
ro
m
 w
h
ic
h
 c
o
n
ta
in
s 
ta
r 
an
d
 
m
an
y 
to
xi
n
s)
.
St
ro
n
g
 v
ie
w
s 
ar
e 
h
el
d
 b
y 
b
o
th
 s
ta
ff
 a
n
d
 
se
rv
ic
e 
u
se
rs
. W
h
ils
t 
sm
o
ke
rs
 fi
n
d
 t
h
em
 
a 
u
se
fu
l o
p
ti
o
n
, o
th
er
s 
h
av
e 
ex
p
re
ss
ed
 
co
n
ce
rn
s 
ab
o
u
t 
th
e 
ri
sk
s 
o
f 
p
as
si
ve
 
in
h
al
at
io
n
 a
n
d
 a
d
ve
rs
e 
p
u
b
lic
it
y 
- 
th
er
e 
h
av
e 
b
ee
n
 m
an
y 
co
n
fl
ic
ti
n
g
 a
rt
ic
le
s 
in
 t
h
e 
m
ed
ia
 a
b
o
u
t 
co
n
d
it
io
n
s 
sa
id
 t
o
 p
o
ss
ib
ly
 
b
e 
ca
u
se
d
 o
r 
ex
ac
er
b
at
ed
 b
y 
e
-c
ig
ar
et
te
 
va
p
o
u
r 
(e
g
 ‘p
o
p
co
rn
 lu
n
g
’)
. T
h
is
 r
es
u
lt
s 
in
 c
o
n
fu
si
o
n
. I
n
 o
u
r 
o
p
in
io
n
 t
h
e 
m
ai
n
 
co
n
ce
rn
 is
 t
h
e 
ef
fe
ct
s 
o
f 
u
si
n
g
 o
f 
fo
o
d
 
fl
av
o
u
ri
n
g
s 
in
 v
ap
o
ri
se
d
 f
o
rm
 t
o
 e
n
te
r 
th
e 
lu
n
g
. T
h
is
 is
 s
o
m
et
h
in
g
 w
h
ic
h
 li
tt
le
 is
 
kn
o
w
n
 a
b
o
u
t 
an
d
 r
ep
re
se
n
ts
 t
h
e 
la
rg
es
t 
p
o
te
n
ti
al
 r
is
k 
fr
o
m
 ‘p
as
si
ve
 v
ap
in
g
’ i
n
 o
u
r 
o
p
in
io
n
.
Th
e 
Tr
u
st
 s
ta
n
ce
 is
 t
h
at
 if
 a
 s
er
vi
ce
 u
se
r 
ch
o
o
se
s 
to
 u
se
 e
-c
ig
ar
et
te
s 
to
 q
u
it
/
ab
st
ai
n
 f
ro
m
 t
h
ei
r 
sm
o
ki
n
g
 h
ab
it
, t
h
ey
 
sh
o
u
ld
 b
e 
en
co
u
ra
g
ed
 t
o
 u
se
 t
h
em
 a
s 
a 
to
o
l, 
ra
th
er
 t
h
an
 m
er
el
y 
as
 a
 r
ep
la
ce
m
en
t,
 
an
d
 b
e 
su
p
p
o
rt
ed
 t
o
 g
ra
d
u
al
ly
 w
ea
n
 
th
em
se
lv
es
 o
ff
 e
-c
ig
ar
et
te
s.
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N
H
S 
Tr
u
st
Q
u
es
ti
o
n
 1
Q
u
es
ti
o
n
 2
Q
u
es
ti
o
n
 3
Q
u
es
ti
o
n
 4
Su
rr
ey
 a
n
d
 
B
o
rd
er
s 
Pa
rt
n
er
sh
ip
 N
H
S 
Fo
u
n
d
at
io
n
 T
ru
st
W
e 
h
av
e 
n
o
t 
b
an
n
ed
 t
h
e 
u
se
 o
f 
e
-c
ig
ar
et
te
s 
b
u
t 
o
u
r 
p
o
lic
y 
is
 a
b
o
u
t 
b
an
n
in
g
 a
ll 
u
se
 
o
f 
to
b
ac
co
 p
ro
d
u
ct
s 
o
n
 o
u
r 
p
re
m
is
es
. W
e 
ac
tu
al
ly
 p
ro
vi
d
e 
e
-l
it
es
 f
o
r 
fr
ee
 f
o
r 
o
u
r 
in
p
at
ie
n
ts
 a
s 
p
ar
t 
o
f 
th
e 
ce
ss
at
io
n
 p
ro
ce
ss
.
N
/A
Y
es
 t
h
is
 is
 w
as
 f
u
lly
 c
o
n
si
d
er
ed
 w
h
en
 
d
es
ig
n
in
g
 o
u
r 
C
ar
e 
2q
u
it
 p
ro
g
ra
m
m
e 
an
d
 
d
ec
id
ed
 t
o
 n
o
t 
b
an
 e
-c
ig
ar
et
te
s,
 b
u
t 
to
 f
o
cu
s 
o
n
 t
h
e 
b
an
n
in
g
 o
f 
to
b
ac
co
 p
ro
d
u
ct
s 
an
d
 
th
ei
r 
u
se
 o
n
 o
u
r 
p
re
m
is
es
. W
e 
al
so
 e
n
su
re
d
 
th
at
 p
eo
p
le
 h
ad
 s
u
ffi
ci
en
t 
ac
ce
ss
 t
o
 N
R
T 
an
d
 
fu
ll 
sc
re
en
in
g
 w
as
 t
ak
in
g
 p
la
ce
 o
n
 a
d
m
is
si
o
n
 
to
 e
n
su
re
 t
h
at
 a
ll 
p
eo
p
le
 w
h
o
 s
m
o
ke
 r
ec
ei
ve
 
b
ri
ef
 a
d
vi
ce
 o
n
 q
u
it
ti
n
g
 a
n
d
 s
u
p
p
o
rt
 w
h
er
e 
re
q
u
ir
ed
.
Y
es
 w
e 
re
vi
ew
ed
 t
h
is
 a
n
d
 t
h
e 
an
xi
et
ie
s 
ab
o
u
t 
p
o
ss
ib
le
 u
n
kn
o
w
n
 r
is
k
s 
to
 b
o
th
 
st
af
f 
an
d
 p
eo
p
le
 u
si
n
g
 s
er
vi
ce
s 
an
d
 a
s 
a 
re
su
lt
 w
e 
b
an
n
ed
 t
h
e 
u
se
 o
f 
e
-c
ig
ar
et
te
s 
in
 c
o
m
m
u
n
al
 a
re
as
 o
r 
in
 w
ar
d
 s
le
ep
in
g
 
b
ay
s.
 P
eo
p
le
 a
re
 o
n
ly
 p
er
m
it
te
d
 t
o
 u
se
 
th
es
e 
in
 t
h
ei
r 
si
n
g
le
 b
ed
ro
o
m
s 
an
d
/o
r 
g
ar
d
en
s.
 W
e 
al
so
 c
o
n
si
d
er
ed
 t
h
e 
ri
sk
 o
f 
th
e 
va
p
in
g
 s
m
o
ke
 a
ct
iv
at
in
g
 fi
re
 a
la
rm
s 
an
d
 w
e 
to
o
k 
st
ep
s 
to
 m
it
ig
at
e 
th
es
e
W
es
t 
Lo
n
d
o
n
 
M
en
ta
l H
ea
lt
h
 
N
H
S 
Tr
u
st
N
o
. H
o
w
ev
er
, w
e 
h
av
e 
b
an
n
ed
 e
le
ct
ro
n
ic
 
ci
g
ar
et
te
s 
p
u
rc
h
as
ed
 o
u
ts
id
e 
o
f 
th
e 
u
n
it
 
d
u
e 
to
 p
o
te
n
ti
al
 fi
re
 r
is
k
s 
an
d
 t
h
e 
in
ab
ili
ty
 
to
 m
o
n
it
o
r 
th
e 
co
n
te
n
ts
 o
f 
th
em
. W
e 
se
ll 
a 
b
ra
n
d
 o
f 
el
ec
tr
o
n
ic
 c
ig
ar
et
te
 t
h
at
 h
as
 b
ee
n
 
ac
ce
p
te
d
 a
s 
‘s
af
e’
. I
n
 t
w
o
 s
it
es
 t
h
es
e 
ar
e 
so
ld
 
fr
o
m
 a
 v
en
d
in
g
 m
ac
h
in
e,
 in
 o
n
e 
fu
rt
h
er
 s
it
e 
th
ey
 a
re
 s
o
ld
 d
ir
ec
tl
y 
fr
o
m
 t
h
e 
w
ar
d
s.
W
e 
cu
rr
en
tl
y 
h
av
e 
n
o
 p
la
n
s 
to
 b
an
 o
r 
re
st
ri
ct
 
th
e 
u
se
 o
f 
ap
p
ro
ve
d
 E
-c
ig
ar
et
te
s 
so
ld
 o
n
-
si
te
. T
h
e 
EC
ig
s 
w
e 
se
ll 
o
n
 s
it
e 
ar
e 
so
ld
 f
o
r 
£3
 
w
h
ic
h
 is
 c
o
n
si
d
er
ab
ly
 c
h
ea
p
er
 t
h
an
 r
et
ai
l 
sh
o
p
s 
o
n
 t
h
e 
h
ig
h
 s
tr
ee
t.
 C
u
rr
en
tl
y 
w
e 
d
o
 
n
o
t 
h
av
e 
an
y 
p
la
n
s 
to
 a
llo
w
 o
th
er
 E
ci
g
s 
d
u
e 
to
 t
h
e 
p
o
te
n
ti
al
 fi
re
 r
is
k
s 
an
d
 t
h
e 
in
ab
ili
ty
 t
o
 
m
o
n
it
o
r 
th
e 
co
n
te
n
ts
 o
f 
th
em
.
Y
es
 w
e 
d
id
. H
en
ce
, t
h
e 
ac
ti
ve
 p
ro
m
o
ti
o
n
 o
f 
EC
ig
s 
in
 a
d
d
it
io
n
 t
o
 a
 r
an
g
e 
o
f 
N
R
T 
p
ro
d
u
ct
s 
w
h
en
 t
h
e 
Tr
u
st
 im
p
le
m
en
te
d
 t
h
e 
sm
o
ke
-f
re
e 
p
o
lic
y 
in
 J
an
u
ar
y 
20
16
. P
ri
o
r 
to
 in
tr
o
d
u
ci
n
g
 
a 
tr
u
st
 w
id
e 
b
an
 o
n
 s
m
o
ki
n
g
 w
e 
m
ad
e 
th
e 
d
ec
is
io
n
 t
o
 a
llo
w
 t
h
e 
u
se
 o
f 
el
ec
tr
o
n
ic
 
ci
g
ar
et
te
s 
(n
o
t 
in
 w
ar
d
s 
co
m
m
u
n
al
 a
re
as
) 
as
 
a 
h
ar
m
 r
ed
u
ct
io
n
 in
te
rv
en
ti
o
n
. I
n
 a
d
d
it
io
n
 
w
e 
p
u
t 
in
 p
la
ce
 a
 c
o
m
p
re
h
en
si
ve
 s
m
o
ki
n
g
 
ce
ss
at
io
n
 s
tr
at
eg
y 
an
d
 in
te
rv
en
ti
o
n
s.
R
es
ea
rc
h
 h
as
 s
o
 f
ar
 s
h
o
w
n
 t
h
e 
p
o
te
n
ti
al
 
se
co
n
d
 h
an
d
 h
ar
m
 is
 m
in
im
al
. H
o
w
ev
er
, 
w
e 
en
co
u
ra
g
e 
th
es
e 
to
 o
n
ly
 b
e 
u
se
d
 in
 
th
e 
p
at
ie
n
t’
s 
o
w
n
 b
ed
ro
o
m
 t
o
 m
in
im
is
e 
an
y 
d
is
co
m
fo
rt
 o
r 
h
ar
m
 t
o
 o
th
er
 p
at
ie
n
ts
, 
st
af
f 
an
d
 v
is
it
o
rs
. G
iv
en
 c
u
rr
en
t 
ev
id
en
ce
 
an
d
 t
h
e 
fa
ct
 t
h
at
 e
le
ct
ro
n
ic
 c
ig
ar
et
te
s 
ca
n
n
o
t 
b
e 
u
se
d
 in
 c
o
m
m
u
n
al
 a
re
as
 w
e 
d
o
 n
o
t 
h
av
e 
an
y 
si
g
n
ifi
ca
n
t 
co
n
ce
rn
s 
re
g
ar
d
in
g
 s
ec
o
n
d
-h
an
d
 h
ar
m
 c
au
se
d
 b
y 
el
ec
tr
o
n
ic
 c
ig
ar
et
te
s.
C
o
rn
w
al
l 
Pa
rt
n
er
sh
ip
 N
H
S 
Fo
u
n
d
at
io
n
 T
ru
st
Y
es
W
e 
ar
e 
cu
rr
en
tl
y 
re
vi
ew
in
g
 o
u
r 
p
o
lic
y
Y
es
Y
es
B
ar
n
et
, E
n
fi
el
d
 
an
d
 H
ar
in
g
ey
 
M
en
ta
l H
ea
lt
h
 
N
H
S 
Tr
u
st
N
o
, w
e 
h
av
e 
ac
ti
ve
ly
 e
n
co
u
ra
g
ed
 t
h
em
 a
s 
p
ar
t 
o
f 
su
p
p
o
rt
in
g
 o
u
r 
sm
o
ke
fr
ee
 p
o
lic
y 
si
n
ce
 1
7.
1.
17
 (
an
d
 s
in
ce
 2
01
5 
in
 o
u
r 
fo
re
n
si
c 
u
n
it
) 
an
d
 h
av
e 
p
ro
vi
d
ed
 t
h
em
 t
o
 s
er
vi
ce
 
u
se
rs
 o
u
rs
el
ve
s 
in
 e
m
er
g
en
cy
 (
in
 a
d
d
it
io
n
 t
o
 
p
ro
vi
d
in
g
 N
R
T 
in
 a
 r
an
g
e 
o
f 
fo
rm
s)
; i
n
 o
th
er
 
ci
rc
u
m
st
an
ce
s 
w
e 
m
ak
e 
it
 p
o
ss
ib
le
 f
o
r 
th
em
 
to
 p
u
rc
h
as
e 
e
-c
ig
ar
et
te
s 
o
n
 h
o
sp
it
al
 p
re
m
is
es
 
o
r 
en
co
u
ra
g
e 
re
la
ti
ve
s 
to
 b
ri
n
g
 t
h
em
 in
. 
W
e 
al
so
 e
n
co
u
ra
g
e 
th
e 
u
se
 o
f 
va
p
es
 o
n
 o
u
r 
p
re
m
is
es
, n
o
ti
n
g
 t
h
at
 d
is
p
o
sa
b
le
 e
-c
ig
ar
et
te
s 
ar
e 
n
o
t 
su
ffi
ci
en
t 
fo
r 
al
l s
er
vi
ce
 u
se
rs
 t
o
 h
el
p
 
th
em
 t
o
 m
an
ag
e 
w
it
h
o
u
t 
ci
g
ar
et
te
s.
 P
ro
to
co
l 
at
ta
ch
ed
. W
e 
h
av
e 
n
o
te
d
 t
h
o
u
g
h
 t
h
at
 v
ap
es
 
ca
n
 s
et
 o
ff
 s
m
o
ke
 a
la
rm
s 
in
 c
o
n
fi
n
ed
 s
p
ac
es
 
o
r 
w
h
en
 u
se
d
 d
el
ib
er
at
el
y 
to
 d
o
 s
o
, s
o
 w
e 
h
av
e 
h
ad
 t
o
 li
m
it
 t
h
ei
r 
u
se
 in
 c
er
ta
in
 w
ar
d
 
ar
ea
s.
N
/A
Y
es
 a
s 
ab
o
ve
N
o
t 
re
al
ly
. A
 f
ew
 p
eo
p
le
 h
av
e 
ra
is
ed
 it
, 
b
o
th
 o
n
 h
ea
lt
h
 a
n
d
 n
u
is
an
ce
 g
ro
u
n
d
s 
b
u
t 
m
ai
n
ly
 d
u
e 
to
 t
h
e 
fi
re
 a
la
rm
 is
su
e.
 B
u
t 
w
e 
su
p
p
o
rt
 w
ar
d
 m
an
ag
er
s 
to
 li
m
it
 v
ap
e 
u
se
 in
 a
re
as
 w
h
er
e 
it
 c
au
se
s 
a 
n
u
is
an
ce
. 
Th
is
 h
as
 n
o
t 
p
re
ve
n
te
d
 w
id
es
p
re
ad
 u
se
 o
f 
e
-c
ig
ar
et
te
s.
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N
H
S 
Tr
u
st
Q
u
es
ti
o
n
 1
Q
u
es
ti
o
n
 2
Q
u
es
ti
o
n
 3
Q
u
es
ti
o
n
 4
A
vo
n
 a
n
d
 
W
ilt
sh
ir
e 
M
en
ta
l H
ea
lt
h
 
Pa
rt
n
er
sh
ip
 N
H
S 
Tr
u
st
W
e 
h
av
e 
im
p
le
m
en
te
d
 a
 s
m
o
ke
 f
re
e 
p
o
lic
y.
 
Pa
ti
en
ts
 a
n
d
 s
ta
ff
 a
re
 n
o
t 
p
er
m
it
te
d
 t
o
 
sm
o
ke
 in
si
d
e 
th
e 
b
u
ild
in
g
s.
 S
er
vi
ce
 u
se
rs
 
ca
n
 u
se
 a
p
p
ro
ve
d
 e
B
u
rn
s 
an
d
 V
ap
es
 in
 t
h
e 
g
ro
u
n
d
s 
aw
ay
 f
ro
m
 t
h
e 
w
ar
d
.
Th
e 
Tr
u
st
 c
o
n
ti
n
u
al
ly
 r
ev
ie
w
s 
im
p
le
m
en
ta
ti
o
n
 o
f 
th
e 
p
o
lic
y 
in
cl
u
d
in
g
 t
h
e 
re
ce
n
t 
ad
vi
ce
 f
ro
m
 P
H
E.
 W
e 
al
so
 n
ee
d
 t
o
 
co
n
si
d
er
 o
th
er
 f
ac
to
rs
 w
h
ic
h
 w
o
u
ld
 r
eq
u
ir
e 
th
e 
re
p
la
ce
m
en
t 
o
f 
o
u
r 
cu
rr
en
t 
fi
re
 d
et
ec
ti
o
n
 
sy
st
em
s 
if
 e
B
u
rn
 a
n
d
 V
ap
in
g
 w
er
e 
to
 b
e 
p
er
m
it
te
d
 in
si
d
e.
Th
e 
ri
sk
 a
n
d
 b
en
efi
ts
 w
er
e 
co
n
si
d
er
ed
 in
 
p
re
p
ar
in
g
 t
h
e 
cu
rr
en
t 
p
o
lic
y
Th
e 
Tr
u
st
 is
 c
o
n
ce
rn
ed
 r
eg
ar
d
in
g
 
se
co
n
d
-h
an
d
 h
ar
m
 in
cl
u
d
in
g
 t
h
e 
n
ee
d
s 
o
f 
n
o
n
-s
m
o
ke
rs
 in
 r
el
at
io
n
 t
o
 t
h
e 
sm
o
ke
 
fr
o
m
 v
ap
es
. W
e 
w
ill
 c
o
n
ti
n
u
e 
to
 m
o
n
it
o
r 
th
e 
em
er
g
in
g
 e
vi
d
en
ce
 r
eg
ar
d
in
g
 t
h
e 
u
se
 
o
f 
th
es
e 
d
ev
ic
es
 a
n
d
 a
d
o
p
t 
b
es
t 
p
ra
ct
ic
e 
w
h
er
ev
er
 p
o
ss
ib
le
.
N
o
rt
h
 W
es
t 
B
o
ro
u
g
h
s 
H
ea
lt
h
ca
re
 N
H
S 
Fo
u
n
d
at
io
n
 T
ru
st
W
h
en
 t
h
e 
Tr
u
st
 o
ri
g
in
al
ly
 c
o
m
m
it
te
d
 t
o
 
b
ec
o
m
in
g
 s
m
o
ke
fr
ee
 in
 t
h
e 
su
m
m
er
 o
f 
20
16
, a
 d
ec
is
io
n
 w
as
 m
ad
e 
to
 n
o
t 
al
lo
w
 
el
ec
tr
o
n
ic
 c
ig
ar
et
te
s 
w
it
h
in
 o
u
r 
m
en
ta
l 
h
ea
lt
h
 in
p
at
ie
n
t 
u
n
it
s.
 A
t 
th
e 
ti
m
e,
 t
h
er
e 
w
er
e 
co
n
ce
rn
s 
re
g
ar
d
in
g
 t
h
e 
sa
fe
ty
 o
f 
th
es
e 
d
ev
ic
es
 a
n
d
 t
h
e 
p
o
te
n
ti
al
 a
ss
o
ci
at
ed
 r
is
k
s 
fo
r 
p
at
ie
n
ts
 a
n
d
 s
ta
ff
. T
h
er
ef
o
re
 a
t 
th
is
 
p
o
in
t,
 t
h
ey
 w
er
e 
n
o
t 
in
cl
u
d
ed
 w
it
h
in
 t
h
e 
p
o
lic
y 
as
 a
 t
re
at
m
en
t 
o
p
ti
o
n
. H
o
w
ev
er
 a
 
fu
rt
h
er
 r
ev
ie
w
 w
as
 u
n
d
er
ta
ke
n
 1
2 
m
o
n
th
s 
la
te
r 
as
 lo
ca
l i
n
te
lli
g
en
ce
 a
n
d
 p
at
ie
n
t/
ca
re
r 
fe
ed
b
ac
k 
su
g
g
es
te
d
 a
 d
em
an
d
 f
o
r 
th
es
e 
p
ro
d
u
ct
s,
 a
s 
m
an
y 
p
at
ie
n
ts
 h
as
 u
se
d
 t
h
em
 
b
ef
o
re
 a
d
m
is
si
o
n
. T
h
e 
lic
en
se
d
 N
ic
o
ti
n
e 
R
ep
la
ce
m
en
t 
Th
er
ap
y 
p
ro
d
u
ct
s 
w
er
e 
n
o
t 
ac
ce
p
te
d
 b
y 
al
l p
at
ie
n
ts
, s
o
 w
e 
lo
o
ke
d
 a
t 
th
e 
le
as
t 
re
st
ri
ct
iv
e 
p
ra
ct
ic
e 
in
 r
el
at
io
n
 t
o
 
p
ro
vi
si
o
n
 o
f 
n
ic
o
ti
n
e 
re
p
la
ci
n
g
 p
ro
d
u
ct
s 
fo
r 
m
en
ta
l h
ea
lt
h
 in
-p
at
ie
n
ts
 w
it
h
in
 t
h
e 
Tr
u
st
. 
W
it
h
 t
h
e 
b
en
efi
t 
o
f 
sh
ar
ed
 e
xp
er
ie
n
ce
s 
fr
o
m
 
o
th
er
 T
ru
st
s 
an
d
 t
ak
in
g
 in
to
 c
o
n
si
d
er
at
io
n
 
th
e 
ev
id
en
ce
 r
ev
ie
w
 (
M
cN
ei
ll 
et
 a
l, 
20
15
) 
co
m
m
is
si
o
n
ed
 b
y 
Pu
b
lic
 H
ea
lt
h
 E
n
g
la
n
d
, 
a 
d
ec
is
io
n
 w
as
 t
ak
en
 t
o
 a
llo
w
 o
n
e 
sp
ec
ifi
c 
b
ra
n
d
 o
f 
d
is
p
o
sa
b
le
 e
-c
ig
ar
et
te
s 
as
 a
 
n
ic
o
ti
n
e 
d
ep
en
d
en
cy
 t
re
at
m
en
t 
o
p
ti
o
n
. 
W
e 
co
m
m
en
ce
d
 p
ro
vi
d
in
g
 t
h
e 
ch
o
ic
e 
o
f 
N
ic
o
ti
n
e 
R
ep
la
ce
m
en
t 
Th
er
ap
y 
o
r 
d
is
p
o
sa
b
le
 
e
-c
ig
ar
et
te
s 
in
 D
ec
em
b
er
 2
01
7.
W
e 
d
o
 a
llo
w
 t
h
e 
u
se
 o
f 
e
-c
ig
ar
et
te
s 
as
 
o
u
tl
in
ed
 in
 q
u
es
ti
o
n
 1
 a
n
d
 h
av
e 
se
en
 
in
cr
ea
se
d
 c
o
m
p
lia
n
ce
 w
it
h
 o
u
r 
sm
o
ke
 f
re
e 
p
o
lic
y 
as
 a
 r
es
u
lt
.
Y
es
. W
e 
al
so
 t
o
o
k 
in
to
 c
o
n
si
d
er
at
io
n
 t
h
e 
re
vi
ew
 o
f 
u
n
d
er
p
in
n
in
g
 e
vi
d
en
ce
 (
M
cN
ei
ll 
et
 a
l, 
20
15
) 
co
m
m
is
si
o
n
ed
 b
y 
Pu
b
lic
 H
ea
lt
h
 
En
g
la
n
d
.
Y
es
. W
e 
w
ill
 c
o
n
ti
n
u
e 
to
 m
o
n
it
o
r 
th
is
 a
n
d
 
en
su
re
 w
e 
d
el
iv
er
 o
u
r 
se
rv
ic
es
 in
 li
n
e 
w
it
h
 
n
at
io
n
al
 e
vi
d
en
ce
 b
as
e 
an
d
 b
es
t 
p
ra
ct
ic
e.
49 E-cigarettes 
N
H
S 
Tr
u
st
Q
u
es
ti
o
n
 1
Q
u
es
ti
o
n
 2
Q
u
es
ti
o
n
 3
Q
u
es
ti
o
n
 4
K
en
t 
an
d
 M
ed
w
ay
 
N
H
S 
an
d
 S
o
ci
al
 
C
ar
e 
Pa
rt
n
er
sh
ip
 
Tr
u
st
(E
xt
ra
ct
s 
fr
o
m
 
th
ei
r 
sm
o
ke
fr
ee
 
p
o
lic
y)
O
n
ly
 d
is
p
o
sa
b
le
 d
ev
ic
es
 w
it
h
 p
re
fi
lle
d
 
ca
rt
ri
d
g
es
 m
ay
 b
e 
u
se
d
 (
se
e 
A
p
p
en
d
ix
 B
).
 
R
ec
h
ar
g
ea
b
le
 d
ev
ic
es
 o
f 
th
is
 t
yp
e 
ar
e 
n
o
t 
p
er
m
it
te
d
 d
u
e 
to
 t
h
e 
ri
sk
s 
as
so
ci
at
ed
 w
it
h
 
ch
ar
g
in
g
. E
-c
ig
ar
et
te
 u
se
 is
 o
n
ly
 p
er
m
it
te
d
 
fo
r 
p
at
ie
n
ts
, v
is
it
o
rs
 a
n
d
 c
o
n
tr
ac
to
rs
 in
 
d
es
ig
n
at
ed
 a
re
as
 e
.g
. h
o
sp
it
al
 g
ro
u
n
d
s 
an
d
 
co
u
rt
ya
rd
s,
 b
u
t 
n
o
t 
in
 c
o
m
m
u
n
al
 in
d
o
o
r 
ar
ea
s 
o
r 
b
ed
ro
o
m
s.
N
/A
E-
ci
g
ar
et
te
s 
ar
e 
b
at
te
ry
 p
o
w
er
ed
 d
ev
ic
es
 
th
at
 d
el
iv
er
 n
ic
o
ti
n
e 
vi
a 
in
h
al
ed
 v
ap
o
r.
 
Si
n
ce
 e
- 
ci
g
ar
et
te
s 
d
o
 n
o
t 
co
n
ta
in
 t
o
b
ac
co
 
an
d
 a
re
 n
o
t 
b
u
rn
t,
 t
h
ey
 d
o
 n
o
t 
re
su
lt
 in
 
th
e 
in
h
al
at
io
n
 o
f 
ci
g
ar
et
te
 s
m
o
ke
 t
h
ey
 a
re
 
th
er
ef
o
re
 r
eg
ar
d
ed
 b
y 
m
o
st
 e
xp
er
ts
 a
s 
m
u
ch
 
sa
fe
r 
d
el
iv
er
y 
d
ev
ic
es
 f
o
r 
n
ic
o
ti
n
e.
 T
h
is
 d
o
es
 
n
o
t 
m
ea
n
 t
h
at
 t
h
ey
 a
re
 c
o
m
p
le
te
ly
 s
af
e,
 b
u
t 
th
ey
 a
re
 e
n
vi
sa
g
ed
 t
o
 b
e 
m
u
ch
 le
ss
 h
ar
m
fu
l 
th
an
 c
ig
ar
et
te
s.
E-
ci
g
ar
et
te
 u
se
 s
h
o
u
ld
 o
n
ly
 b
e 
p
er
m
it
te
d
 
in
 d
is
cr
et
e 
p
la
ce
s 
an
d
 n
ev
er
 b
e 
p
er
m
it
te
d
 
in
 a
re
as
 w
h
er
e 
p
at
ie
n
ts
 a
n
d
 s
ta
ff
 
co
n
g
re
g
at
e.
M
er
se
y 
C
ar
e 
N
H
S 
Fo
u
n
d
at
io
n
 T
ru
st
W
e 
h
av
e 
n
o
t 
b
an
n
ed
 t
h
e 
u
se
 o
f 
e
-c
ig
ar
et
te
s 
an
d
 a
re
 f
o
llo
w
in
g
 t
h
e 
ad
vi
ce
 f
ro
m
 P
H
E 
an
d
 
th
e 
C
Q
C
 a
b
o
u
t 
th
ei
r 
b
en
efi
ts
 t
o
 s
u
p
p
o
rt
 
se
rv
ic
e 
u
se
rs
 w
h
o
 a
re
 d
ep
en
d
en
t 
o
n
 n
ic
o
ti
n
e.
 
E-
ci
g
ar
et
te
s 
ar
e 
in
 t
h
e 
re
p
er
to
ir
e 
o
f 
N
ic
o
ti
n
e 
R
ep
la
ce
m
en
t 
Th
er
ap
ie
s 
w
e 
su
p
p
o
rt
 f
o
r 
th
e 
p
eo
p
le
 w
h
o
 u
se
 o
u
r 
se
rv
ic
es
.
W
e 
h
av
e 
cu
rr
en
tl
y 
b
an
n
ed
 t
h
e 
u
se
 o
f 
e
-c
ig
ar
et
te
s 
in
 o
u
r 
H
ig
h
 S
ec
u
re
 S
er
vi
ce
, 
w
h
ic
h
 is
 c
o
n
si
st
en
t 
w
it
h
 t
h
e 
o
th
er
 t
w
o
 H
SS
 
Tr
u
st
s.
 H
o
w
ev
er
, w
e 
ar
e 
m
ee
ti
n
g
 t
o
 r
ev
ie
w
 
th
is
 d
ec
is
io
n
 t
o
 c
la
ri
fy
 t
h
e 
cl
in
ic
al
, r
is
k 
an
d
/o
r 
se
cu
ri
ty
 g
ro
u
n
d
s 
w
h
ic
h
 in
fo
rm
 t
h
is
 d
ec
is
io
n
. 
W
e 
m
ay
 a
ls
o
 r
ev
ie
w
 t
h
e 
d
ec
is
io
n
 in
 t
h
e 
lig
h
t 
o
f 
se
rv
ic
e 
u
se
rs
’ e
xp
er
ie
n
ce
 in
 u
si
n
g
 
e
-c
ig
ar
et
te
s 
in
 o
u
r 
m
ed
iu
m
 a
n
d
 lo
w
 s
ec
u
re
 
se
rv
ic
es
 o
r 
if
 o
th
er
 a
p
p
ro
p
ri
at
e 
p
ro
d
u
ct
s 
b
ec
o
m
e 
av
ai
la
b
le
.
Th
e 
Tr
u
st
 c
o
n
si
d
er
ed
, a
n
d
 is
 s
u
p
p
o
rt
iv
e 
o
f,
 
th
e 
h
ar
m
 r
ed
u
ci
n
g
 p
o
te
n
ti
al
 o
f 
e
-c
ig
ar
et
te
s 
an
d
 r
ec
o
g
n
is
es
 t
h
ey
 m
ay
 b
e 
o
f 
as
si
st
an
ce
 t
o
 
en
ab
le
 s
o
m
e 
sm
o
ke
rs
 t
o
 m
o
ve
 a
w
ay
 f
ro
m
 
u
si
n
g
 h
ar
m
fu
l b
u
rn
t 
to
b
ac
co
 t
o
w
ar
d
s 
a 
cl
ea
n
er
 f
o
rm
 o
f 
n
ic
o
ti
n
e 
d
el
iv
er
y,
 a
n
d
 m
ay
 
u
lt
im
at
el
y 
h
el
p
 t
h
em
 t
o
 g
iv
e 
u
p
 s
m
o
ki
n
g
 in
 
th
e 
lo
n
g
er
 t
er
m
 if
 t
h
ey
 m
ak
e 
th
is
 d
ec
is
io
n
. 
In
 a
d
d
it
io
n
, t
h
e 
Tr
u
st
 s
tr
o
n
g
ly
 s
u
p
p
o
rt
s 
se
rv
ic
e 
u
se
rs
’ c
h
o
ic
e 
an
d
 p
re
fe
re
n
ce
s 
in
 t
h
ei
r 
re
co
ve
ry
, a
n
d
 o
u
r 
se
rv
ic
e 
u
se
rs
 in
fo
rm
ed
 
u
s 
th
at
 h
av
in
g
 e
-c
ig
ar
et
te
s 
as
 a
n
 a
va
ila
b
le
 
o
p
ti
o
n
 w
o
u
ld
 a
llo
w
 t
h
em
 t
o
 m
ak
e 
p
o
si
ti
ve
 
im
p
ro
ve
m
en
ts
 in
 b
o
th
 t
h
ei
r 
p
h
ys
ic
al
 a
n
d
 
p
sy
ch
o
lo
g
ic
al
 w
el
l-
b
ei
n
g
. W
e 
co
n
si
d
er
 
co
lla
b
o
ra
ti
o
n
 a
n
d
 c
h
o
ic
e 
to
 b
e 
an
 e
ss
en
ti
al
 
co
m
p
o
n
en
t 
o
f 
o
u
r 
le
as
t 
re
st
ri
ct
iv
e 
an
d
 c
o
-
p
ro
d
u
ce
d
 a
p
p
ro
ac
h
 t
o
 c
ar
e 
w
it
h
in
 t
h
e 
Tr
u
st
.
Th
e 
Tr
u
st
 w
ill
 c
o
n
ti
n
u
e 
to
 r
ev
ie
w
 it
s 
p
o
si
ti
o
n
 o
n
 e
-c
ig
ar
et
te
s,
 in
cl
u
d
in
g
 if
 
an
y 
ri
sk
s 
ar
e 
id
en
ti
fi
ed
 in
 f
u
tu
re
 a
s 
n
ew
 
ev
id
en
ce
 a
n
d
 g
u
id
an
ce
 e
m
er
g
es
. T
h
is
 
w
ill
 in
cl
u
d
e 
re
g
u
la
r 
re
vi
ew
s,
 a
s 
it
 w
o
u
ld
 
an
y 
o
th
er
 n
ew
 a
sp
ec
t 
o
f 
p
ra
ct
ic
e 
an
d
 
ca
re
, t
o
 e
n
su
re
 t
h
e 
Tr
u
st
, i
ts
 s
ta
ff
 a
n
d
 t
h
e 
p
eo
p
le
 w
e 
se
rv
e 
ar
e 
ke
p
t 
fu
lly
 in
fo
rm
ed
 
b
y 
co
n
te
m
p
o
ra
ry
 fi
n
d
in
g
s 
an
d
 s
af
et
y 
in
fo
rm
at
io
n
 s
o
 t
h
at
 w
e 
co
n
ti
n
u
e 
to
 
su
p
p
o
rt
 b
es
t 
p
ra
ct
ic
e 
an
d
 s
af
e 
ca
re
 in
 t
h
is
 
d
ev
el
o
p
in
g
 a
re
a.
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N
H
S 
Tr
u
st
Q
u
es
ti
o
n
 1
Q
u
es
ti
o
n
 2
Q
u
es
ti
o
n
 3
Q
u
es
ti
o
n
 4
D
o
rs
et
 H
ea
lt
h
ca
re
 
U
n
iv
er
si
ty
 N
H
S 
Fo
u
n
d
at
io
n
 T
ru
st
N
o
N
/A
Y
es
W
e 
b
el
ie
ve
 t
h
e 
p
o
te
n
ti
al
 f
o
r 
h
ar
m
 
re
d
u
ct
io
n
 t
h
ro
u
g
h
 s
u
p
p
o
rt
in
g
 t
h
e 
u
se
 o
f 
e
-c
ig
ar
et
te
s 
to
 f
ar
 o
u
tw
ei
g
h
 a
n
y 
co
n
ce
rn
s 
re
g
ar
d
in
g
 e
xp
o
su
re
 t
o
 s
ec
o
n
d
h
an
d
 
va
p
o
u
r.
 T
h
e 
N
C
SC
T’
s 
El
ec
tr
o
n
ic
 c
ig
ar
et
te
s 
b
ri
efi
n
g
 in
d
ic
at
es
 t
h
at
 “
so
m
e 
st
u
d
ie
s 
h
av
e 
fo
u
n
d
 t
ra
ce
s 
o
f 
to
xi
ca
n
ts
 in
 
se
co
n
d
h
an
d
 v
ap
o
u
r,
 b
u
t 
at
 s
u
ch
 lo
w
 
le
ve
ls
 t
h
at
 t
h
ey
 d
o
 n
o
t 
p
o
se
 a
 h
ea
lt
h
 
ri
sk
 t
o
 b
ys
ta
n
d
er
s.
 T
h
er
e 
is
 n
o
 e
vi
d
en
ce
 
th
at
 s
ec
o
n
d
h
an
d
 v
ap
o
u
r 
is
 d
an
g
er
o
u
s 
to
 
o
th
er
s;
 h
o
w
ev
er
, i
t 
h
el
p
s 
to
 b
e 
re
sp
ec
tf
u
l 
w
h
en
 u
si
n
g
 e
-c
ig
ar
et
te
s 
ar
o
u
n
d
 o
th
er
s,
 
es
p
ec
ia
lly
 n
o
n
-s
m
o
ke
rs
.”
 W
e 
h
av
e 
ta
ke
n
 
th
is
 e
vi
d
en
ce
 in
to
 c
o
n
si
d
er
at
io
n
 in
 o
u
r 
sm
o
ke
fr
ee
 p
o
lic
y.
 W
e 
d
o
 a
sk
 o
u
r 
p
at
ie
n
ts
 
an
d
 s
ta
ff
 n
o
t 
to
 u
se
 e
-c
ig
ar
et
te
s 
in
 
co
m
m
u
n
al
 s
p
ac
es
 li
m
it
in
g
 s
u
ch
 e
xp
o
su
re
 
an
d
 n
o
rm
al
is
at
io
n
 o
f 
th
ei
r 
u
se
.
So
u
th
er
n
 H
ea
lt
h
 
N
H
S 
Fo
u
n
d
at
io
n
 
Tr
u
st
N
o
, w
e 
en
co
u
ra
g
e 
th
ei
r 
u
se
.
W
e 
o
n
ly
 r
es
tr
ic
t 
th
e 
u
se
 o
f 
so
m
e 
m
o
d
el
s 
o
f 
e
-c
ig
ar
et
te
 f
o
r 
re
as
o
n
s 
o
f 
fi
re
 s
af
et
y.
Y
es
, b
as
ed
 o
n
 s
tr
o
n
g
 r
es
ea
rc
h
 e
vi
d
en
ce
 o
f 
h
ar
m
 r
ed
u
ct
io
n
.
N
o
, b
u
t 
w
e 
d
is
co
u
ra
g
e 
u
se
 in
 s
h
ar
ed
 a
re
as
 
so
 a
s 
to
 n
o
t 
af
fe
ct
 o
th
er
s 
at
 a
ll.
Ta
vi
st
o
ck
 a
n
d
 
Po
rt
m
an
 N
H
S 
Fo
u
n
d
at
io
n
 T
ru
st
Y
es
 w
e 
h
av
e 
b
an
n
ed
 t
h
e 
u
se
 o
f 
el
ec
tr
o
n
ic
 
ci
g
ar
et
te
s 
in
 o
u
r 
fa
ci
lit
ie
s 
af
te
r 
ca
re
fu
l 
co
n
si
d
er
at
io
n
. W
e 
ar
e 
an
 o
u
t 
-p
at
ie
n
t 
fa
ci
lit
y 
an
d
 t
h
e 
m
aj
o
ri
ty
 o
f 
o
u
r 
p
at
ie
n
ts
 a
re
 c
h
ild
re
n
, 
yo
u
n
g
 p
eo
p
le
 a
n
d
 f
am
ili
es
. O
u
r 
p
at
ie
n
ts
 a
re
 
o
n
 o
u
r 
p
re
m
is
es
 f
o
r 
sh
o
rt
 p
er
io
d
s 
to
 a
tt
en
d
 
o
u
t 
-p
at
ie
n
t 
ap
p
o
in
tm
en
ts
. W
e 
b
an
n
ed
 t
h
e 
u
se
 o
f 
el
ec
tr
o
n
ic
 c
ig
ar
et
te
s 
as
 w
e 
d
id
 n
o
t 
w
is
h
 o
u
r 
yo
u
n
g
 p
at
ie
n
ts
 a
n
d
 f
am
ili
es
 t
o
 s
ee
 
p
at
ie
n
ts
, s
ta
ff
 o
r 
vi
si
to
rs
 u
si
n
g
 a
n
y 
fo
rm
 o
f 
ci
g
ar
et
te
 w
h
ic
h
 m
ig
h
t 
im
p
ly
 o
u
r 
co
n
d
o
n
in
g
 
th
is
 b
eh
av
io
u
r
Y
es
, o
u
r 
sm
o
ke
 f
re
e 
p
o
lic
y 
(M
ay
 2
01
7)
 w
ill
 
b
e 
re
vi
ew
ed
 in
 M
ay
 2
01
8 
o
n
 t
h
e 
b
as
is
 o
f 
an
 u
p
d
at
ed
 r
ev
ie
w
 o
f 
cu
rr
en
t 
ev
id
en
ce
 
in
cl
u
d
in
g
 P
H
E 
ad
vi
ce
.
Y
es
, w
e 
d
id
 a
n
d
 w
e 
en
co
u
ra
g
e 
an
d
 s
u
p
p
o
rt
 
st
af
f 
an
d
 p
at
ie
n
ts
 t
o
 t
ak
e 
u
p
 in
te
rv
en
ti
o
n
s 
to
 s
to
p
 o
r 
re
d
u
ce
 s
m
o
ki
n
g
 t
o
b
ac
co
 t
h
ro
u
g
h
 
ap
p
ro
p
ri
at
e 
m
ea
n
s 
in
cl
u
d
in
g
 s
w
it
ch
in
g
 t
o
 
el
ec
tr
o
n
ic
 c
ig
ar
et
te
s 
as
 a
 s
u
b
st
an
ti
al
ly
 s
af
er
 
al
te
rn
at
iv
e 
fo
r 
w
h
en
 t
h
ey
 a
re
 n
o
t 
o
n
 T
ru
st
 
p
re
m
is
es
.
Y
es
.
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N
H
S 
Tr
u
st
Q
u
es
ti
o
n
 1
Q
u
es
ti
o
n
 2
Q
u
es
ti
o
n
 3
Q
u
es
ti
o
n
 4
N
o
tt
in
g
h
am
sh
ir
e 
H
ea
lt
h
ca
re
 N
H
S 
Fo
u
n
d
at
io
n
 T
ru
st
St
af
f 
an
d
 v
is
it
o
rs
–y
es
.
Pa
ti
en
ts
–Y
es
 in
 t
h
e 
Tr
u
st
’s
 F
o
re
n
si
c 
Se
rv
ic
e 
D
iv
is
io
n
N
o
 in
 t
h
e 
Tr
u
st
’s
 L
o
ca
l P
ar
tn
er
sh
ip
 D
iv
is
io
n
 
(i
n
-p
at
ie
n
t 
m
en
ta
l h
ea
lt
h
 u
n
it
s]
. U
se
 is
 
re
st
ri
ct
ed
 t
o
 ju
st
 o
n
e 
ty
p
e 
o
f 
d
is
p
o
sa
b
le
 
e
-c
ig
ar
et
te
 c
al
le
d
 E
-b
u
rn
 d
u
e 
to
 u
n
iq
u
e 
sa
fe
ty
 f
ea
tu
re
s 
an
d
 t
h
e 
fa
ct
 t
h
at
 n
u
m
er
o
u
s 
o
th
er
 T
ru
st
s 
an
d
 s
o
m
e 
p
ri
so
n
s 
ar
e 
al
lo
w
in
g
 
th
ei
r 
u
se
.
Y
es
 o
u
r 
p
o
si
ti
o
n
 w
ill
 b
e 
u
n
d
er
 c
o
n
st
an
t 
re
vi
ew
 a
n
d
 d
ec
is
io
n
s 
w
ill
 b
e 
m
ad
e 
ac
co
rd
in
g
 
to
 g
u
id
an
ce
 a
n
d
 t
h
e 
em
er
g
in
g
 e
vi
d
en
ce
-
b
as
e.
Y
es
W
e 
ar
e 
g
u
id
ed
 b
y 
PH
E 
ad
vi
ce
, 2
01
6 
“t
h
e 
co
n
st
it
u
en
ts
 o
f 
ci
g
ar
et
te
 s
m
o
ke
 t
h
at
 
h
ar
m
 h
ea
lt
h
–i
n
cl
u
d
in
g
 c
ar
ci
n
o
g
en
s–
ar
e 
ei
th
er
 a
b
se
n
t 
in
 e
-c
ig
ar
et
te
 v
ap
o
u
r 
o
r,
 if
 
p
re
se
n
t,
 t
h
ey
 a
re
 m
o
st
ly
 a
t 
le
ve
ls
 m
u
ch
 
lo
w
er
 t
h
an
 5
%
 o
f 
sm
o
ki
n
g
 d
o
se
 (
m
o
st
ly
 
b
el
o
w
 1
%
 a
n
d
 f
ar
 b
el
o
w
 s
af
et
y 
lim
it
s 
fo
r 
o
cc
u
p
at
io
n
al
 e
xp
o
su
re
)”
C
am
b
ri
d
g
es
h
ir
e 
an
d
 P
et
er
b
o
ro
u
g
h
 
N
H
S 
Fo
u
n
d
at
io
n
 
Tr
u
st
In
 o
u
r 
fa
ci
lit
ie
s 
w
e 
d
o
 n
o
t 
p
er
m
it
 t
h
e 
u
se
 o
f 
el
ec
tr
o
n
ic
 c
ig
ar
et
te
s 
in
d
o
o
rs
. W
e 
d
o
 a
llo
w
 
th
e 
u
se
 o
f 
el
ec
tr
o
n
ic
 c
ig
ar
et
te
s 
am
o
n
g
 
se
rv
ic
e 
u
se
rs
 in
 w
ar
d
 g
ar
d
en
s 
an
d
 a
llo
w
 
st
af
f 
m
em
b
er
s 
to
 u
se
 e
le
ct
ro
n
ic
 c
ig
ar
et
te
s 
o
u
td
o
o
rs
 d
u
ri
n
g
 b
re
ak
 t
im
es
.
O
n
 1
 O
ct
o
b
er
 2
01
7 
C
PF
T 
b
an
n
ed
 s
m
o
ki
n
g
 
an
d
 t
h
e 
u
se
 o
f 
al
l e
le
ct
ro
n
ic
 c
ig
ar
et
te
s 
an
d
 
va
p
o
ri
se
rs
 o
n
 o
u
r 
p
re
m
is
es
. T
h
is
 p
o
lic
y 
w
as
 
am
en
d
ed
 in
 D
ec
em
b
er
 2
01
7 
to
 a
llo
w
 f
o
r 
th
e 
u
se
 o
f 
el
ec
tr
o
n
ic
 c
ig
ar
et
te
s 
an
d
 v
ap
o
ri
se
rs
 
in
 o
u
td
o
o
r 
ar
ea
s 
in
 li
g
h
t 
o
f 
fe
ed
b
ac
k 
fr
o
m
 
st
af
f 
o
n
 o
u
r 
w
ar
d
s.
 T
h
e 
d
ec
is
io
n
 t
o
 a
llo
w
 t
h
e 
u
se
 o
f 
el
ec
tr
o
n
ic
 c
ig
ar
et
te
s 
an
d
 v
ap
o
ri
se
rs
 in
 
o
u
td
o
o
r 
ar
ea
s 
w
as
 r
efl
ec
ti
ve
 o
f 
th
e 
ev
id
en
ce
 
an
d
 r
ec
o
m
m
en
d
at
io
n
s 
p
re
se
n
tl
y 
av
ai
la
b
le
 
fr
o
m
 P
u
b
lic
 H
ea
lt
h
 E
n
g
la
n
d
. T
h
e 
C
PF
T 
Sm
o
ke
 
Fr
ee
 p
o
lic
y 
w
ill
 b
e 
m
o
n
it
o
re
d
 a
n
d
 a
m
en
d
ed
 
as
 a
d
d
it
io
n
al
 e
vi
d
en
ce
 b
ec
o
m
es
 a
va
ila
b
le
.
Th
e 
h
ar
m
 r
ed
u
ct
io
n
 p
o
te
n
ti
al
 o
f 
el
ec
tr
o
n
ic
 
ci
g
ar
et
te
s 
w
as
 a
 f
ac
to
r 
in
 o
u
r 
d
ec
is
io
n
 t
o
 
al
lo
w
 e
le
ct
ro
n
ic
 c
ig
ar
et
te
s 
an
d
 v
ap
o
ri
se
rs
 o
n
 
o
u
r 
g
ro
u
n
d
s.
 A
s 
n
o
te
d
 a
b
o
ve
, t
h
e 
Tr
u
st
 w
ill
 
co
n
ti
n
u
al
ly
 m
o
n
it
o
r 
o
u
r 
Sm
o
ke
 F
re
e 
Po
lic
y 
as
 
ad
d
it
io
n
al
 e
vi
d
en
ce
 b
ec
o
m
es
 a
va
ila
b
le
 f
ro
m
 
Pu
b
lic
 H
ea
lt
h
 E
n
g
la
n
d
 a
ro
u
n
d
 t
h
e 
ri
sk
s 
an
d
 
b
en
efi
ts
 o
f 
el
ec
tr
o
n
ic
 c
ig
ar
et
te
 u
se
.
A
t 
th
e 
m
o
m
en
t 
th
er
e 
is
 n
o
 e
vi
d
en
ce
 t
o
 
su
g
g
es
t 
th
at
 e
le
ct
ro
n
ic
 c
ig
ar
et
te
s 
o
r 
va
p
o
ri
se
rs
 c
au
se
 h
ar
m
 t
o
 n
o
n
-u
se
rs
. A
s 
w
e 
h
av
e 
re
st
ri
ct
ed
 t
h
e 
u
se
 o
f 
el
ec
tr
o
n
ic
 
ci
g
ar
et
te
s 
an
d
 v
ap
o
ri
se
rs
 t
o
 o
u
td
o
o
r 
ar
ea
s 
o
n
ly
 w
e 
d
o
 n
o
t 
cu
rr
en
tl
y 
h
av
e 
an
y 
co
n
ce
rn
s 
ar
o
u
n
d
 t
h
e 
p
o
te
n
ti
al
 f
o
r 
se
co
n
d
ar
y 
h
ar
m
 t
o
 s
er
vi
ce
 u
se
rs
 o
r 
st
af
f.
 
W
e 
w
el
co
m
e 
u
p
d
at
es
 f
ro
m
 P
u
b
lic
 H
ea
lt
h
 
En
g
la
n
d
 a
ro
u
n
d
 t
h
e 
se
co
n
d
-h
an
d
 r
is
k
s 
o
f 
el
ec
tr
o
n
ic
 c
ig
ar
et
te
s 
as
 r
es
ea
rc
h
 in
 t
h
is
 
fi
el
d
 p
ro
g
re
ss
es
.
So
u
th
 W
es
t 
Lo
n
d
o
n
 a
n
d
 S
t 
G
eo
rg
e’
s 
M
en
ta
l 
H
ea
lt
h
 N
H
S 
Tr
u
st
SW
LS
TG
 N
H
S 
Tr
u
st
 h
as
 a
d
o
p
te
d
 a
n
 in
te
ri
m
 
E-
ci
g
ar
et
te
 P
ro
to
co
l t
o
 s
u
p
p
o
rt
 p
at
ie
n
ts
 
to
 m
an
ag
e 
th
ei
r 
n
ic
o
ti
n
e 
d
ep
en
d
en
ce
 
w
h
ils
t 
h
o
sp
it
al
is
ed
. P
at
ie
n
ts
 w
is
h
in
g
 t
o
 
u
se
 e
-c
ig
ar
et
te
s 
as
 p
ar
t 
o
f 
th
ei
r 
n
ic
o
ti
n
e 
m
an
ag
em
en
t 
p
ro
g
ra
m
m
e 
ca
n
 b
ri
n
g
/p
u
rc
h
as
e 
th
e 
b
ra
n
d
 o
f 
th
ei
r 
ch
o
ic
e 
as
 lo
n
g
 a
s 
th
o
se
 a
re
 
d
is
p
o
sa
b
le
 a
n
d
 n
o
n
-r
ec
h
ar
g
ea
b
le
 e
-c
ig
ar
et
te
 
d
ev
ic
es
. P
at
ie
n
ts
 a
re
 a
llo
w
ed
 t
o
 u
se
 
e
-c
ig
ar
et
te
s 
in
 d
es
ig
n
at
ed
 a
re
as
 o
f 
th
e 
w
ar
d
s 
i.e
. t
h
ei
r 
in
d
iv
id
u
al
 b
ed
ro
o
m
s 
an
d
 c
o
u
rt
ya
rd
s 
b
u
t 
sh
o
u
ld
 r
ef
ra
in
 f
ro
m
 v
ap
in
g
 a
t 
in
d
o
o
r 
co
m
m
u
n
al
 a
re
as
. T
h
e 
p
ro
to
co
l p
ro
h
ib
it
s 
th
e 
u
se
 o
f 
e
-c
ig
ar
et
te
s 
in
 a
n
y 
o
th
er
 a
re
as
 o
f 
th
e 
Tr
u
st
 g
ro
u
n
d
s 
an
d
/o
r 
b
u
ild
in
g
s.
 E
-c
ig
ar
et
te
s 
u
se
 b
y 
o
u
tp
at
ie
n
ts
, s
ta
ff
 a
n
d
 v
is
it
o
rs
 is
 
cu
rr
en
tl
y 
p
ro
h
ib
it
ed
 a
cr
o
ss
 T
ru
st
 p
re
m
is
es
.
W
e 
ar
e 
cu
rr
en
tl
y 
re
vi
ew
in
g
 o
u
r 
ex
is
ti
n
g
 
e
-c
ig
ar
et
te
 p
ro
to
co
l t
o
 e
n
su
re
 t
h
at
 it
 
is
 in
 li
n
e 
w
it
h
 t
h
e 
n
ew
 P
H
E 
an
d
 N
IC
E 
re
co
m
m
en
d
at
io
n
s.
 H
o
w
ev
er
, w
e 
al
so
 t
ak
e 
in
to
 c
o
n
si
d
er
at
io
n
 t
h
e 
n
ee
d
s 
an
d
 v
ie
w
s 
o
f 
o
u
r 
se
rv
ic
e 
u
se
rs
, c
ar
er
s 
an
d
 s
ta
ff
.
D
es
p
it
e 
th
e 
lim
it
ed
 e
vi
d
en
ce
 o
n
 t
h
e 
lo
n
g
 
te
rm
 h
ea
lt
h
 e
ff
ec
ts
 o
f 
e
-c
ig
ar
et
te
s,
 t
h
er
e’
s 
b
ee
n
 s
o
m
e 
ev
id
en
ce
 t
h
at
 v
ap
in
g
 is
 9
5%
 le
ss
 
h
ar
m
fu
l t
h
an
 s
m
o
ki
n
g
. O
u
r 
in
p
at
ie
n
ts
 a
re
 
b
ei
n
g
 p
ro
fe
ss
io
n
al
ly
 s
u
p
p
o
rt
ed
 t
o
 m
an
ag
e 
th
ei
r 
n
ic
o
ti
n
e 
d
ep
en
d
en
ce
 w
it
h
 t
h
e 
m
et
h
o
d
 
o
f 
th
ei
r 
ch
o
ic
e 
w
h
et
h
er
 t
h
is
 is
 N
R
T 
o
r 
d
is
p
o
sa
b
le
 e
-c
ig
ar
et
te
s.
 W
e 
co
m
b
in
e 
ei
th
er
 
m
et
h
o
d
 w
it
h
 b
eh
av
io
u
ra
l s
u
p
p
o
rt
.
W
e 
h
av
e 
co
n
si
d
er
ed
 t
h
e 
ve
ry
 f
ew
 
ev
id
en
ce
 o
f 
th
e 
ef
fe
ct
s 
o
f 
se
co
n
d
-h
an
d
 
va
p
in
g
 o
n
 b
ys
ta
n
d
er
s 
w
h
ic
h
 d
o
es
 n
o
t 
su
p
p
o
rt
 t
h
is
 p
o
ss
ib
ili
ty
 b
u
t 
al
so
 d
o
es
 n
o
t 
en
ti
re
ly
 d
is
m
is
s 
th
e 
p
o
te
n
ti
al
 e
ff
ec
ts
. 
H
en
ce
, o
u
r 
b
al
an
ce
d
 d
ec
is
io
n
 t
o
 a
llo
w
 t
h
e 
u
se
 o
f 
e
-c
ig
ar
et
te
s 
in
 o
p
en
-a
ir
 a
re
as
 i.
e.
 
co
u
rt
ya
rd
s 
b
u
t 
n
o
t 
in
 c
o
m
m
u
n
al
 in
d
o
o
r 
ro
o
m
s.
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N
H
S 
Tr
u
st
Q
u
es
ti
o
n
 1
Q
u
es
ti
o
n
 2
Q
u
es
ti
o
n
 3
Q
u
es
ti
o
n
 4
B
ir
m
in
g
h
am
 a
n
d
 
So
ilh
u
ll 
M
en
ta
l 
H
ea
lt
h
 N
H
S 
Fo
u
n
d
at
io
n
 T
ru
st
E-
ci
g
ar
et
te
s 
u
se
 o
r 
‘v
ap
in
g
’ m
u
st
 o
cc
u
r 
o
n
ly
 
o
u
ts
id
e,
 a
t 
n
o
 t
im
e 
in
si
d
e 
an
y 
b
u
ild
in
g
s.
Th
is
 [
e
-c
ig
ar
et
te
 p
o
lic
y]
 is
 c
u
rr
en
tl
y 
u
n
d
er
 a
 
re
vi
ew
 w
it
h
 o
u
r 
Sm
o
ki
n
g
 S
te
er
in
g
 G
ro
u
p
.
Th
e 
e
-c
ig
ar
et
te
 s
ec
ti
o
n
 is
 p
ar
t 
o
f 
th
at
 r
ev
ie
w
 
an
d
 in
 p
ar
ti
cu
la
r 
th
e 
d
is
p
o
sa
b
le
 a
n
d
 r
e
-
ch
ar
g
ea
b
le
 it
em
s.
Y
es
Y
es
Li
n
co
ln
sh
ir
e 
Pa
rt
n
er
sh
ip
 N
H
S 
Fo
u
n
d
at
io
n
 T
ru
st
In
 li
n
e 
w
it
h
 L
in
co
ln
sh
ir
e 
Pa
rt
n
er
sh
ip
 N
H
S 
Fo
u
n
d
at
io
n
 T
ru
st
 (
LP
FT
) 
Sm
o
ke
 F
re
e 
Pr
em
is
es
 
Po
lic
y 
(a
tt
ac
h
ed
),
 w
e 
ad
h
er
e 
to
 t
h
e 
fo
llo
w
in
g
 
g
u
id
an
ce
:
R
es
tr
ic
ti
o
n
s 
o
n
 u
sa
g
e 
o
f 
e
-c
ig
ar
et
te
s 
o
n
 L
PF
T 
Tr
u
st
 P
re
m
is
es
• 
E-
ci
g
ar
et
te
s 
ca
n
 o
n
ly
 b
e 
u
se
d
 in
 o
u
ts
id
e 
ar
ea
s 
aw
ay
 f
ro
m
 e
xi
ts
 a
n
d
 e
n
tr
an
ce
s.
 T
h
ey
 
sh
o
u
ld
 n
o
t 
b
e 
u
se
d
 in
 p
ro
xi
m
it
y 
to
 o
th
er
 
p
eo
p
le
 w
h
o
 c
h
o
o
se
 n
o
t 
to
 u
se
 t
h
em
.
• 
E-
ci
g
ar
et
te
s 
sh
o
u
ld
 o
n
ly
 b
e 
re
ch
ar
g
ed
 u
si
n
g
 
ap
p
ro
ve
d
 d
ev
ic
es
 a
n
d
 m
et
h
o
d
s.
 R
ec
h
ar
g
in
g
 
sh
o
u
ld
 b
e 
u
n
d
er
 t
h
e 
su
p
er
vi
si
o
n
 o
f 
st
af
f 
w
it
h
in
 a
 s
p
ec
ifi
c 
d
es
ig
n
at
ed
 s
af
e 
ch
ar
g
in
g
 
ar
ea
 a
w
ay
 f
ro
m
 s
o
u
rc
es
 o
f 
ig
n
it
io
n
 a
n
d
 
ac
ce
le
ra
n
ts
 s
u
ch
 a
s 
o
xy
g
en
 s
u
p
p
lie
s.
 O
n
ce
 
re
ch
ar
g
in
g
 is
 c
o
m
p
le
te
 t
h
e 
d
ev
ic
e 
sh
o
u
ld
 b
e 
p
ro
m
p
tl
y 
d
is
co
n
n
ec
te
d
 a
n
d
 r
et
u
rn
ed
 t
o
 s
af
e 
st
o
ra
g
e.
• 
St
af
f 
sh
o
u
ld
 b
e 
aw
ar
e 
th
at
 fi
re
 r
is
k
s 
w
h
ils
t 
re
ch
ar
g
in
g
 e
-c
ig
ar
et
te
s 
re
la
te
 la
rg
el
y 
to
:-
- 
U
se
 o
f 
in
co
rr
ec
t 
o
r 
m
al
fu
n
ct
io
n
in
g
 c
h
ar
g
er
- 
B
at
te
ry
 d
ef
ec
ts
 o
r 
o
ve
rt
ig
h
te
n
in
g
 o
f 
th
e 
b
at
te
ry
- 
O
ve
rc
h
ar
g
in
g
 o
f 
th
e 
p
ro
d
u
ct
.
• 
E-
ci
g
ar
et
te
s 
co
n
ta
in
 b
at
te
ri
es
 a
n
d
 m
u
st
 b
e 
d
is
p
o
se
d
 o
f 
in
 a
 d
es
ig
n
at
ed
 b
in
 a
s 
el
ec
tr
o
n
ic
 
w
as
te
.
LP
FT
 h
as
 n
o
t 
b
an
n
ed
 E
-c
ig
ar
et
te
s.
 O
u
r 
cu
rr
en
t 
LP
FT
 S
m
o
ke
 F
re
e 
Pr
em
is
es
 P
o
lic
y 
is
 s
ch
ed
u
le
d
 f
o
r 
re
vi
ew
 in
 J
u
n
e
/J
u
ly
 2
01
8.
 
W
e 
w
ill
 r
ea
p
p
ra
is
e 
o
u
r 
p
o
si
ti
o
n
 a
t 
th
is
 
ti
m
e,
 t
ak
in
g
 in
to
 a
cc
o
u
n
t 
PH
E 
g
u
id
an
ce
 
an
d
 w
e 
w
ill
 c
o
n
ti
n
u
e 
to
 w
o
rk
 c
lo
se
ly
 w
it
h
 
o
u
r 
ex
p
er
ts
 b
y 
ex
p
er
ie
n
ce
, c
ar
er
s 
an
d
 s
ta
ff
 
to
 e
n
su
re
 o
u
r 
p
o
lic
ie
s 
ar
e 
ev
id
en
ce
 b
as
ed
, 
ro
b
u
st
 a
n
d
 u
sa
b
le
.
O
u
r 
vi
si
o
n
 a
t 
LP
FT
 is
 t
o
 m
ak
e 
a 
d
if
fe
re
n
ce
 
to
 t
h
e 
liv
es
 o
f 
p
eo
p
le
 w
it
h
 m
en
ta
l h
ea
lt
h
 
an
d
 le
ar
n
in
g
 d
is
ab
ili
ti
es
. T
o
 p
ro
m
o
te
 
re
co
ve
ry
 a
n
d
 q
u
al
it
y 
o
f 
lif
e 
th
ro
u
g
h
 
ef
fe
ct
iv
e,
 in
n
o
va
ti
ve
 a
n
d
 c
ar
in
g
 s
er
vi
ce
s.
 
W
e 
en
co
u
ra
g
e 
sm
o
ki
n
g
 c
es
sa
ti
o
n
 a
n
d
 h
ar
m
 
re
d
u
ct
io
n
 t
h
ro
u
g
h
 t
h
e 
u
se
 a
n
d
 a
va
ila
b
ili
ty
 
o
f 
n
ic
o
ti
n
e 
re
p
la
ce
m
en
t 
th
er
ap
y.
 W
e 
su
p
p
o
rt
 t
h
e 
u
se
 o
f 
E-
ci
g
ar
et
te
s 
ra
th
er
 t
h
an
 
co
n
ve
n
ti
o
n
al
 c
ig
ar
et
te
s.
Th
e 
ev
id
en
ce
 b
as
e 
is
 s
ti
ll 
lim
it
ed
 a
n
d
 
p
ro
d
u
ct
s 
ar
e 
ch
an
g
in
g
 r
ap
id
ly
. A
t 
LP
FT
 w
e 
su
p
p
o
rt
 t
h
e 
b
el
ie
f 
th
at
 E
-c
ig
ar
et
te
s 
ar
e 
le
ss
 h
ar
m
fu
l t
h
an
 c
o
n
ve
n
ti
o
n
al
 c
ig
ar
et
te
s 
an
d
 w
e 
w
ill
 s
u
p
p
o
rt
 o
u
r 
p
at
ie
n
ts
 a
t 
ev
er
y 
st
ag
e 
o
f 
th
ei
r 
sm
o
ki
n
g
 c
es
sa
ti
o
n
 jo
u
rn
ey
.
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N
H
S 
Tr
u
st
Q
u
es
ti
o
n
 1
Q
u
es
ti
o
n
 2
Q
u
es
ti
o
n
 3
Q
u
es
ti
o
n
 4
O
xf
o
rd
 H
ea
lt
h
 
N
H
S 
Fo
u
n
d
at
io
n
 
Tr
u
st
W
e 
h
av
e 
b
an
n
ed
 t
h
em
 o
n
 o
u
r 
in
p
at
ie
n
t 
w
ar
d
s 
at
 t
h
e 
m
o
m
en
t.
W
e 
h
av
e 
re
vi
ew
ed
 t
h
is
 d
ec
is
io
n
–i
n
 li
g
h
t 
o
f 
th
e 
ad
vi
ce
 a
n
d
 n
ew
 p
ro
d
u
ct
s 
th
at
 a
re
 n
o
w
 
av
ai
la
b
le
. P
la
n
 is
 t
h
at
 w
e 
w
ill
 p
ilo
t 
u
se
 w
it
h
 
a 
p
ar
ti
cu
la
r 
b
ra
n
d
 o
f 
e 
ci
g
ar
et
te
s.
 W
e 
ar
e 
w
o
rk
in
g
 w
it
h
 p
at
ie
n
ts
 o
n
 t
h
is
 p
ilo
t.
 T
h
e 
Pi
lo
t 
w
ill
 b
e 
ac
ti
ve
 w
it
h
in
 t
h
e 
n
ex
t 
co
u
p
le
 o
f 
m
o
n
th
s 
w
it
h
 s
h
o
rt
 c
yc
le
 b
ef
o
re
 r
o
lli
n
g
 o
u
t 
ac
ro
ss
 a
ll 
in
p
at
ie
n
t 
ar
ea
s.
W
h
en
 t
h
e 
in
it
ia
l d
ec
is
io
n
 w
as
 m
ad
e 
to
 b
an
 
e
-c
ig
ar
et
te
s 
th
er
e 
w
as
 n
o
 g
u
id
an
ce
 a
va
ila
b
le
. 
A
t 
th
e 
ti
m
e 
th
er
e 
w
as
 c
o
n
ce
rn
 a
b
o
u
t 
sa
fe
ty
 
o
f 
th
e 
m
o
d
el
s 
av
ai
la
b
le
.
H
o
w
ev
er
 w
it
h
 t
h
e 
in
tr
o
d
u
ct
io
n
 o
f 
sa
fe
 
m
o
d
el
s 
to
 u
se
 o
n
 w
ar
d
s,
 t
h
e 
ad
vi
ce
 f
ro
m
 
p
u
b
lic
 h
ea
lt
h
 a
n
d
 t
h
e 
fa
ct
 t
h
at
 o
u
r 
p
at
ie
n
ts
 
ar
e 
as
ki
n
g
 f
o
r 
th
em
 h
as
 m
ea
n
t 
th
at
 w
e 
h
av
e 
re
vi
si
te
d
 o
u
r 
d
ec
is
io
n
 a
n
d
 a
re
 a
b
o
u
t 
to
 
em
b
ar
k 
o
n
 a
 s
h
o
rt
 p
ilo
t 
in
 o
n
e 
o
f 
o
u
r 
lo
w
 
se
cu
re
 w
ar
d
s 
w
it
h
 t
h
e 
ai
m
 t
o
 r
o
ll 
o
u
t 
ac
ro
ss
 
al
l s
er
vi
ce
s.
Sm
o
ki
n
g
 c
es
sa
ti
o
n
—
en
co
u
ra
g
in
g
 t
h
ei
r 
u
se
 a
s 
a 
p
ro
ve
n
 a
id
 t
o
 s
to
p
 s
m
o
ki
n
g
.
W
e 
d
o
 n
o
t 
b
el
ie
ve
 t
h
at
 t
h
er
e 
w
ill
 b
e 
an
 
in
cr
ea
si
n
g
 r
is
k 
o
f 
se
co
n
d
 h
an
d
 h
ar
m
 t
o
 
p
at
ie
n
ts
 b
y 
u
se
 o
f 
e
-c
ig
ar
et
te
s.
Th
ey
 a
re
 h
az
ar
d
o
u
s 
w
as
te
 a
n
d
 n
ee
d
 t
o
 b
e 
d
is
p
o
se
d
 o
f 
sa
fe
ly
 b
u
t 
w
e 
h
av
e 
p
la
n
s 
in
 
p
la
ce
 t
o
 e
n
su
re
 t
h
at
 t
h
is
 h
ap
p
en
s.
 E-cigarettes 54
N
H
S 
Tr
u
st
Q
u
es
ti
o
n
 1
Q
u
es
ti
o
n
 2
Q
u
es
ti
o
n
 3
Q
u
es
ti
o
n
 4
Pe
n
n
in
e 
C
ar
e 
N
H
S 
Fo
u
n
d
at
io
n
 T
ru
st
Th
e 
Tr
u
st
 d
o
es
 n
o
t 
h
av
e 
a 
b
an
 o
n
 t
h
e 
u
se
 
o
f 
el
ec
tr
o
n
ic
 c
ig
ar
et
te
s,
 t
h
ey
 a
re
 h
o
w
ev
er
 
re
st
ri
ct
ed
. T
h
ey
 c
an
n
o
t 
cu
rr
en
tl
y 
b
e 
u
se
d
 
in
si
d
e 
Tr
u
st
 B
u
ild
in
g
s.
 T
h
is
 in
cl
u
d
es
 In
p
at
ie
n
t 
w
ar
d
s.
Th
e 
Tr
u
st
 is
 c
u
rr
en
tl
y 
co
n
si
d
er
in
g
 it
s 
p
o
si
ti
o
n
 
o
n
 t
h
e 
u
se
 o
f 
e
-c
ig
ar
et
te
s,
 p
ar
ti
cu
la
rl
y 
w
it
h
 
re
g
ar
d
 t
o
 t
h
e 
im
p
le
m
en
ta
ti
o
n
 o
f 
Sm
o
ke
 
Fr
ee
 N
H
S.
 T
h
is
 is
 b
o
th
 in
 t
h
e 
lig
h
t 
o
f 
th
e 
ad
vi
ce
 p
ro
vi
d
ed
 f
ro
m
 P
H
E 
an
d
 a
ls
o
 a
s 
a 
re
su
lt
 
o
f 
th
e 
sh
ar
ed
 le
ar
n
in
g
 f
ro
m
 a
 n
u
m
b
er
 o
f 
Tr
u
st
s 
w
h
o
 a
re
 s
u
cc
es
sf
u
lly
 m
an
ag
in
g
 t
h
e 
u
se
 o
f 
e
-c
ig
ar
et
te
s.
 A
d
d
it
io
n
al
ly
, t
h
e 
Tr
u
st
 
h
as
 s
ec
u
re
d
 s
u
p
p
o
rt
 f
ro
m
 t
h
es
e 
Tr
u
st
s 
in
 
th
e 
re
vi
ew
in
g
 o
f 
o
u
r 
p
o
si
ti
o
n
. T
h
is
 in
cl
u
d
es
 
Tr
u
st
s 
w
h
o
 h
av
e 
su
cc
es
sf
u
lly
 m
an
ag
ed
 t
h
is
 
fo
r 
m
en
ta
l h
ea
lt
h
 in
p
at
ie
n
t 
fa
ci
lit
ie
s.
 T
h
e 
ad
vi
ce
 a
n
d
 in
fo
rm
at
io
n
 f
ro
m
 P
H
E 
to
g
et
h
er
 
w
it
h
 t
h
e 
sh
ar
ed
 le
ar
n
in
g
 f
ro
m
 t
h
es
e 
ex
am
p
le
s 
o
f 
su
cc
es
sf
u
l i
m
p
le
m
en
ta
ti
o
n
 
w
ill
 c
o
n
tr
ib
u
te
 t
o
 t
h
e 
Tr
u
st
’s
 r
ev
ie
w
 o
f 
it
’s
 
p
o
si
ti
o
n
 w
it
h
 r
eg
ar
d
 t
o
 e
-c
ig
ar
et
te
s.
 T
h
e 
co
lla
ti
o
n
 o
f 
th
is
 in
fo
rm
at
io
n
 f
o
r 
B
o
ar
d
 le
ve
l 
d
is
cu
ss
io
n
s 
w
it
h
 r
eg
ar
d
 t
o
 t
h
e 
w
ay
 f
o
rw
ar
d
 is
 
cu
rr
en
tl
y 
b
ei
n
g
 p
re
p
ar
ed
.
Th
e 
Tr
u
st
 c
o
n
si
d
er
ed
 t
h
is
 in
 f
o
rm
u
la
ti
n
g
 
o
u
r 
in
it
ia
l d
ec
is
io
n
s,
 h
o
w
ev
er
 a
t 
th
at
 t
im
e 
th
e 
p
ic
tu
re
 w
it
h
 r
eg
ar
d
 t
o
 a
 w
id
er
 v
ar
ie
ty
 
o
f 
as
so
ci
at
ed
 r
is
k
s 
w
as
 s
ig
n
ifi
ca
n
tl
y 
le
ss
 
cl
ea
r 
th
an
 it
 n
o
w
 is
. G
en
u
in
e 
co
n
si
d
er
at
io
n
s 
su
ch
 a
s 
fi
re
/c
h
ar
g
er
 s
af
et
y 
an
d
 u
n
re
g
u
la
te
d
 
p
ro
d
u
ct
s 
w
er
e 
al
so
 c
o
n
si
d
er
ed
 t
o
g
et
h
er
 w
it
h
 
th
e 
u
n
kn
o
w
n
 lo
n
g
er
-t
er
m
 r
is
k
s 
o
f 
e
-c
ig
ar
et
te
 
u
se
. A
s 
n
ew
 a
n
d
 r
el
ia
b
le
 in
fo
rm
at
io
n
 a
n
d
 
ex
p
er
ie
n
ce
 h
as
 n
o
w
 b
ee
n
 m
ad
e 
av
ai
la
b
le
, 
th
e 
Tr
u
st
 is
 in
 a
 g
o
o
d
 p
o
si
ti
o
n
 t
o
 c
o
n
si
d
er
 o
u
r 
cu
rr
en
t 
ap
p
ro
ac
h
. T
h
e 
h
ea
lt
h
 h
ar
m
 r
ed
u
ct
io
n
 
b
en
efi
ts
 o
f 
e
-c
ig
ar
et
te
s 
fo
r 
in
d
iv
id
u
al
s 
o
ve
r 
to
b
ac
co
 c
ig
ar
et
te
s 
ar
e 
n
o
w
 e
xp
lic
it
ly
 c
le
ar
. 
Th
e 
PH
E 
ad
vi
ce
 a
n
d
 in
fo
rm
at
io
n
 w
it
h
 r
eg
ar
d
 
to
 t
h
is
 h
as
 b
ee
n
 v
er
y 
h
el
p
fu
l. 
A
d
d
it
io
n
al
ly
, 
m
an
y 
o
f 
th
e 
o
th
er
 p
o
te
n
ti
al
 r
is
k
s 
ar
e 
fa
r 
b
et
te
r 
u
n
d
er
st
o
o
d
 n
o
w
. T
h
e 
Tr
u
st
 f
ee
ls
 t
h
is
 
g
iv
es
 u
s 
an
 e
xc
el
le
n
t 
b
as
e 
fr
o
m
 w
h
ic
h
 t
o
 
co
n
si
d
er
 a
n
d
 u
p
d
at
e 
o
u
r 
ap
p
ro
ac
h
 w
h
er
e 
ap
p
ro
p
ri
at
e.
Th
e 
Tr
u
st
 c
o
n
si
d
er
ed
 a
n
y 
an
d
 a
ll 
p
o
te
n
ti
al
 
ri
sk
s 
w
h
en
 d
ev
el
o
p
in
g
 it
’s
 o
ri
g
in
al
 
p
o
si
ti
o
n
 w
it
h
 r
eg
ar
d
 t
o
 t
h
e 
u
se
 o
f 
e
-c
ig
ar
et
te
s.
 T
h
is
 in
cl
u
d
ed
 a
n
y 
p
o
te
n
ti
al
 
se
co
n
d
-h
an
d
 h
ar
m
 a
n
d
 t
an
g
en
ti
al
 
co
n
se
q
u
en
ce
s 
(n
o
t 
o
n
ly
 h
ea
lt
h
 r
el
at
ed
).
 
Th
e 
Tr
u
st
 w
ill
 in
cl
u
d
e 
an
y 
u
p
d
at
ed
 
kn
o
w
le
d
g
e 
an
d
 in
fo
rm
at
io
n
 r
eg
ar
d
in
g
 
th
es
e 
co
n
si
d
er
at
io
n
s 
as
 p
ar
t 
o
f 
th
e 
re
vi
ew
 
o
f 
o
u
r 
p
o
si
ti
o
n
.
O
u
r 
u
n
d
er
st
an
d
in
g
 o
f 
th
e 
cu
rr
en
t 
in
fo
rm
at
io
n
 a
n
d
 k
n
o
w
le
d
g
e 
av
ai
la
b
le
 
is
 t
h
at
 t
h
er
e 
is
 n
o
t 
st
ro
n
g
 e
vi
d
en
ce
 o
f 
si
g
n
ifi
ca
n
t 
h
ea
lt
h
 h
ar
m
s 
fr
o
m
 s
ec
o
n
d
ar
y 
‘s
m
o
ke
’ a
s 
it
 is
 v
ap
o
u
r 
an
d
 is
 n
o
t 
p
ro
d
u
ce
d
 f
ro
m
 a
 t
o
b
ac
co
 p
ro
d
u
ct
, n
o
r 
is
 
it
 ig
n
it
ed
 a
s 
su
ch
.
W
e 
ar
e 
aw
ar
e 
h
o
w
ev
er
 o
f 
is
su
es
 s
u
ch
 a
s 
la
rg
e 
cl
o
u
d
s 
o
f 
st
ro
n
g
 s
m
el
lin
g
 v
ap
o
u
r 
b
ei
n
g
 u
n
p
le
as
an
t 
fo
r 
so
m
e 
p
eo
p
le
 a
n
d
 
p
o
ss
ib
ly
 d
is
tr
es
si
n
g
 t
o
 s
o
m
e 
p
eo
p
le
 u
n
d
er
 
so
m
e 
ci
rc
u
m
st
an
ce
s.
W
e 
ar
e 
al
so
 a
w
ar
e 
o
f 
th
e 
p
o
te
n
ti
al
 
em
er
g
en
ce
 o
f 
se
co
n
d
ar
y 
m
ar
ke
ts
 
as
so
ci
at
ed
 w
it
h
 e
-c
ig
ar
et
te
s 
(a
s 
th
er
e 
is
 w
it
h
 t
o
b
ac
co
 c
ig
ar
et
te
s)
. T
h
e 
Tr
u
st
 
w
ill
 r
em
ai
n
 v
ig
ila
n
t 
w
it
h
 r
eg
ar
d
 t
o
 t
h
is
, 
p
ar
ti
cu
la
rl
y 
w
it
h
 o
u
r 
m
o
re
 v
u
ln
er
ab
le
 
p
o
p
u
la
ti
o
n
s.
W
e 
al
so
 r
em
ai
n
 v
ig
ila
n
t 
ab
o
u
t 
th
e 
p
o
ss
ib
ili
ty
 o
f 
e
-c
ig
ar
et
te
s 
b
ei
n
g
 
im
p
lic
at
ed
 in
 fi
re
 s
et
ti
n
g
 (
d
el
ib
er
at
e 
o
r 
ac
ci
d
en
ta
l)
 a
n
d
 t
h
e 
ve
ry
 o
b
vi
o
u
s 
se
co
n
d
-h
an
d
 h
ar
m
 t
h
at
 c
o
u
ld
 b
ri
n
g
. W
e 
ar
e 
aw
ar
e 
h
o
w
ev
er
 o
f 
th
e 
si
g
n
ifi
ca
n
tl
y 
in
cr
ea
se
d
 s
af
et
y 
p
ro
fi
le
 o
f 
th
es
e 
d
ev
ic
es
 
n
o
w
 o
ve
r 
ea
rl
ie
r,
 u
n
re
g
u
la
te
d
 m
o
d
el
s.
Sh
ef
fi
el
d
 H
ea
lt
h
 
an
d
 S
o
ci
al
 C
ar
e 
N
H
S 
Fo
u
n
d
at
io
n
 
Tr
u
st
N
o
, w
e 
p
er
m
it
 t
h
es
e 
w
it
h
in
 o
u
r 
sm
o
ke
-f
re
e 
p
o
lic
y
N
/A
Y
es
, t
h
is
 is
 w
h
y 
w
e 
al
lo
w
 t
h
em
W
e 
o
n
ly
 a
llo
w
 o
u
td
o
o
r 
u
se
; a
n
y 
se
co
n
d
 
h
an
d
 h
ar
m
 is
 li
ke
ly
 t
o
 b
e 
sm
al
l b
y 
co
m
p
ar
is
o
n
 w
it
h
 e
it
h
er
 t
h
e 
d
ir
ec
t 
o
r 
se
co
n
d
 h
an
d
 e
ff
ec
ts
 o
f 
ac
tu
al
 s
m
o
ke
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N
H
S 
Tr
u
st
Q
u
es
ti
o
n
 1
Q
u
es
ti
o
n
 2
Q
u
es
ti
o
n
 3
Q
u
es
ti
o
n
 4
N
o
rt
h
u
m
b
er
la
n
d
, 
Ty
n
e 
an
d
 W
ea
r 
N
H
S 
Fo
u
n
d
at
io
n
 
Tr
u
st
N
o
, s
el
ec
te
d
 e
 c
ig
ar
et
te
s 
ar
e 
al
lo
w
ed
N
T
W
 h
as
 a
lr
ea
d
y 
ag
re
ed
 t
o
 s
u
p
p
ly
 a
 li
m
it
ed
 
n
u
m
b
er
 o
f 
e
-c
ig
ar
et
te
s 
o
n
 a
d
m
is
si
o
n
 a
n
d
 
al
lo
w
 p
u
rc
h
as
e 
in
 h
o
sp
it
al
 s
h
o
p
s 
th
er
ea
ft
er
. 
W
e 
ar
e 
m
o
d
if
yi
n
g
 o
u
r 
p
o
lic
y 
an
d
 p
ro
ce
d
u
re
s 
ac
co
rd
in
g
ly
.
Y
es
W
e 
w
is
h
 t
o
 a
vo
id
 n
o
n
-s
m
o
ke
rs
 b
ei
n
g
 
ex
p
o
se
d
 t
o
 n
ic
o
ti
n
e 
va
p
o
u
r 
so
 w
ill
 r
es
tr
ic
t 
va
p
in
g
 in
 c
o
m
m
u
n
al
 a
re
as
. W
e 
h
av
e 
co
n
ce
rn
s 
ab
o
u
t 
p
o
ss
ib
le
 lo
n
g
 t
er
m
 e
ff
ec
ts
 
o
f 
ex
p
o
su
re
 t
o
 n
ic
o
ti
n
e 
an
d
/o
r 
ex
ci
p
ie
n
ts
.
O
xl
ea
s 
N
H
S 
Fo
u
n
d
at
io
n
 T
ru
st
N
o
Y
es
 a
s 
p
er
 p
o
lic
y
Y
es
M
o
n
it
o
ri
n
g
 p
le
as
e 
se
e 
p
o
lic
y 
ab
o
u
t 
th
is
D
u
d
le
y 
an
d
 
W
al
sa
ll 
M
en
ta
l 
H
ea
lt
h
 P
ar
tn
er
sh
ip
 
N
H
S 
Tr
u
st
Th
e 
Tr
u
st
 c
u
rr
en
tl
y 
h
as
 n
o
 b
an
 in
 p
la
ce
. 
Th
e 
d
ra
ft
 s
m
o
ke
 f
re
e 
p
o
lic
y 
w
h
ic
h
 is
 in
 
d
ev
el
o
p
m
en
t 
d
o
es
 n
o
t 
ex
cl
u
d
e 
th
e 
u
se
 o
f 
el
ec
tr
o
n
ic
 c
ig
ar
et
te
s,
 t
h
e 
p
o
lic
y 
st
ip
u
la
te
s 
th
at
 t
h
e 
d
ev
is
e 
m
u
st
 b
e 
a 
se
al
ed
 u
n
it
 
id
en
ti
fi
ed
 b
y 
th
e 
Tr
u
st
.
C
u
rr
en
tl
y 
w
e 
d
o
 n
o
t 
h
av
e 
a 
b
an
.
Y
es
 t
h
is
 is
 u
n
d
er
 c
o
n
si
d
er
at
io
n
 b
y 
th
e 
sm
o
ke
 
fr
ee
 s
te
er
in
g
 g
ro
u
p
.
Y
es
 t
h
is
 is
 u
n
d
er
 c
o
n
si
d
er
at
io
n
 b
y 
th
e 
sm
o
ke
 f
re
e 
st
ee
ri
n
g
 g
ro
u
p
.
W
o
rc
es
te
rs
h
ir
e 
H
ea
lt
h
 a
n
d
 C
ar
e 
N
H
S 
Tr
u
st
O
n
 r
ev
ie
w
 o
f 
th
e 
Tr
u
st
’s
 s
m
o
ke
 f
re
e 
p
o
lic
y 
it
 c
le
ar
ly
 s
ta
te
s 
th
at
 w
e 
ar
e 
m
in
d
fu
l o
f 
co
m
m
o
n
 la
w
 a
n
d
 s
ta
tu
to
ry
 d
u
ti
es
 t
o
 p
ro
te
ct
 
th
e 
h
ea
lt
h
 a
n
d
 s
af
et
y 
o
f 
al
l o
u
r 
em
p
lo
ye
es
 
an
d
 t
h
er
ef
o
re
 w
e 
d
o
 n
o
t 
su
p
p
o
rt
 t
h
e 
u
se
 o
f 
e
-c
ig
ar
et
te
s 
in
 t
h
e 
w
o
rk
p
la
ce
. I
t 
is
 e
xp
ec
te
d
 
th
at
 s
ta
ff
 t
re
at
 e
-c
ig
ar
et
te
s 
in
 t
h
e 
sa
m
e 
w
ay
 a
s 
o
th
er
 t
yp
es
 o
f 
sm
o
ki
n
g
. H
o
w
ev
er
, 
th
er
e 
ar
e 
ex
p
ec
ta
ti
o
n
s 
to
 t
h
is
 in
 r
eg
ar
d
 t
o
 
p
at
ie
n
ts
 a
s 
to
 w
h
et
h
er
 s
p
ec
ia
l a
rr
an
g
em
en
ts
 
n
ee
d
 t
o
 b
e 
m
ad
e 
so
 t
h
at
 t
h
e 
p
er
so
n
 m
ay
 
b
e 
p
er
m
it
te
d
 t
o
 s
m
o
ke
 o
n
 a
 t
ru
st
 s
it
e.
 I 
am
 
aw
ar
e 
th
at
 f
o
r 
in
p
at
ie
n
ts
 t
h
e 
w
ar
d
s 
h
av
e 
n
o
 b
an
 in
 p
la
ce
 in
 r
eg
ar
d
 t
o
 t
h
e 
u
se
 o
f 
e
-c
ig
ar
et
te
s 
o
r 
va
p
es
 a
n
d
 t
h
is
 is
 e
n
co
u
ra
g
ed
 
fo
r 
th
o
se
 in
d
iv
id
u
al
s 
w
h
o
 w
is
h
 t
o
 g
iv
e 
u
p
 
sm
o
ki
n
g
. T
h
e 
w
ar
d
 e
n
vi
ro
n
m
en
ts
 t
re
at
 
e
-c
ig
ar
et
te
s 
th
e 
sa
m
e 
as
 n
o
rm
al
 c
ig
ar
et
te
 
an
d
 r
eq
u
es
ts
 t
h
at
 p
at
ie
n
ts
 u
se
 t
h
e 
o
u
ts
id
e 
ar
ea
s 
to
 u
se
 t
h
es
e.
 It
 is
 e
xp
ec
te
d
 t
h
at
 
p
at
ie
n
ts
 c
o
m
p
ly
 w
it
h
 t
h
is
 f
o
r 
th
e 
co
m
fo
rt
 o
f 
o
th
er
 p
at
ie
n
ts
. H
o
w
ev
er
 t
h
e 
u
se
 o
f 
el
ec
tr
o
n
ic
 
ci
g
ar
et
te
s 
w
it
h
in
 o
u
r 
fa
ci
lit
ie
s 
is
 b
an
n
ed
 f
o
r 
st
af
f.
A
t 
th
e 
p
re
se
n
t 
ti
m
e 
th
er
e 
ar
e 
n
o
 p
la
n
s 
to
 
re
vi
ew
 t
h
is
 p
o
si
ti
o
n
 a
s 
o
u
r 
p
o
lic
y 
h
as
 b
ee
n
 
re
ce
n
tl
y 
u
p
d
at
ed
, h
o
w
ev
er
 t
h
is
 w
ill
 b
e 
ke
p
t 
u
n
d
er
 r
ev
ie
w
 t
o
 e
n
su
re
 a
n
y 
n
at
io
n
al
 
g
u
id
an
ce
 is
 r
efl
ec
te
d
.
Ph
ys
ic
al
 h
ea
lt
h
 m
o
n
it
o
ri
n
g
 a
n
d
 p
ro
m
o
ti
o
n
 
o
f 
p
o
si
ti
ve
 p
h
ys
ic
al
 h
ea
lt
h
 f
o
rm
s 
an
 
im
p
o
rt
an
t 
as
p
ec
t 
o
f 
th
e 
w
o
rk
 u
n
d
er
ta
ke
n
 
b
y 
o
u
r 
in
p
at
ie
n
t 
st
af
f 
in
 s
u
p
p
o
rt
in
g
 a
n
d
 
p
ro
m
o
ti
n
g
 t
h
e 
p
h
ys
ic
al
 h
ea
lt
h
 a
n
d
 w
el
lb
ei
n
g
 
o
f 
o
u
r 
in
p
at
ie
n
ts
. A
s 
p
ar
t 
o
f 
th
is
 t
h
e 
u
se
 o
f 
e
-c
ig
ar
et
te
s 
o
r 
va
p
es
 is
 s
u
p
p
o
rt
ed
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o
r 
th
o
se
 
m
en
ta
l h
ea
lt
h
 p
at
ie
n
ts
 w
h
o
 w
is
h
 t
o
 g
iv
e 
u
p
 
sm
o
ki
n
g
, a
lo
n
g
si
d
e 
th
e 
u
se
 o
f 
o
th
er
 n
ic
o
ti
n
e 
re
p
la
ce
m
en
t 
p
ro
d
u
ct
s.
Th
er
e 
d
o
es
 n
o
t 
ap
p
ea
r 
to
 b
e 
ev
id
en
ce
 
th
at
 s
ec
o
n
d
 h
an
d
 d
am
ag
e 
sh
o
u
ld
 b
e 
le
ss
 
o
f 
th
at
 t
h
an
 o
th
er
 t
yp
es
 o
f 
sm
o
ki
n
g
 a
s 
th
e 
lik
el
ih
o
o
d
 o
f 
in
d
iv
id
u
al
 h
ar
m
 is
 r
ed
u
ce
d
. 
H
o
w
ev
er
, w
it
h
in
 t
h
e 
cl
in
ic
al
 e
n
vi
ro
n
m
en
t 
th
er
e 
m
ay
 b
e 
co
n
ce
rn
 o
f 
d
if
fe
re
n
t 
ri
sk
s 
u
n
re
la
te
d
 t
o
 t
h
e 
va
p
o
u
r 
th
at
 is
 e
xp
el
le
d
.
N
o
rt
h
 
St
af
fo
rd
sh
ir
e 
C
o
m
b
in
ed
 
H
ea
lt
h
ca
re
N
o
, w
e 
al
lo
w
 t
h
e 
u
se
 o
f 
e 
ci
g
ar
et
te
s 
in
 
o
u
td
o
o
r 
sp
ac
es
 f
o
llo
w
in
g
 o
u
r 
jo
u
rn
ey
 t
o
 
“T
o
b
ac
co
 S
m
o
ke
 F
re
e”
 in
 A
p
ri
l 2
01
8.
N
/A
Y
es
, i
n
 c
o
lla
b
o
ra
ti
o
n
 w
it
h
 o
u
r 
PH
 c
o
lle
ag
u
es
 
an
d
 s
u
p
p
o
rt
in
g
 e
vi
d
en
ce
.
W
e 
o
n
ly
 a
llo
w
 t
h
e 
u
se
 o
f 
e
- 
ci
g
ar
et
te
s 
in
 
o
u
td
o
o
r 
sp
ac
es
.
So
le
n
t 
N
H
S 
Tr
u
st
So
le
n
t 
N
H
S 
Tr
u
st
 a
llo
w
s 
th
e 
u
se
 o
f 
d
is
p
o
sa
b
le
 
e
-c
ig
ar
et
te
s,
 b
u
t 
n
o
t 
re
ch
ar
g
ea
b
le
 v
ap
es
.
W
e 
d
id
 c
o
n
si
d
er
 t
h
e 
h
ar
m
 o
f 
e
-c
ig
ar
et
te
s,
 
b
u
t 
co
m
p
ar
ed
 it
 t
o
 t
h
e 
h
ar
m
 o
f 
n
o
rm
al
 
to
b
ac
co
 a
n
d
 t
h
e 
im
p
lic
at
io
n
s 
o
n
 o
u
r 
p
at
ie
n
ts
.
In
 r
el
at
io
n
 t
o
 s
ec
o
n
d
 h
an
d
 h
ar
m
 o
f 
e
-c
ig
ar
et
te
s,
 t
h
is
 is
 m
in
im
is
ed
 b
y 
o
n
ly
 
al
lo
w
in
g
 t
h
ei
r 
u
se
 in
 o
u
r 
o
p
en
 g
ar
d
en
s.
H
u
m
b
er
 N
H
S 
Fo
u
n
d
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n
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ru
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N
o
N
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Y
es
N
o
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p
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n
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y
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Formal minutes
Monday 16 July 2018
Members present:
Norman Lamb in the Chair
Bill Grant
Liz Kendall
Stephen Metcalfe
Carol Monaghan
Draft Report (E-cigarettes), proposed by the Chair, brought up and read.
Ordered, That the draft Report be read a second time, paragraph by paragraph.
Paragraphs 1 to 83 read and agreed to.
Summary agreed to.
A Paper was appended to the Report as Appendix 1.
Resolved, That the Report be the Seventh Report of the Committee to the House.
Ordered, That the Chair make the Report to the House.
Ordered, That embargoed copies of the Report be made available (Standing Order No. 134).
[Adjourned till Tuesday 17 July 9.00am.
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Witnesses
The following witnesses gave evidence. Transcripts can be viewed on the inquiry publications 
page of the Committee’s website.
Tuesday 9 January 2018 Question number
Professor Peter Hajek, Professor of Clinical Psychology, Queen Mary 
University of London; Professor Mark Conner, Professor of Applied Social 
Psychology, University of Leeds; and Professor Riccardo Polosa, Professor 
of Internal Medicine, University of Catania Q1–72
Dr Lion Shahab, Senior Lecturer in Health Psychology, University College 
London; Dr Jamie Brown, Deputy Director, Tobacco and Alcohol Research 
Group, University College London; and Professor Paul Aveyard, Co-
ordinating Editor, Cochrane Tobacco Addiction Group Q73–132
Tuesday 27 February 2018
Dr Ian Jones, Vice-President, Reduced-Risk Products, Japan Tobacco 
International; Dr Chris Proctor, Chief Scientific Officer, British American 
Tobacco; Dr Moira Gilchrist, Vice-President, Scientific and Public 
Communications, Philip Morris Limited; and Dr Grant O’Connell, 
Regulatory and Scientific Affairs, Fontem Ventures Q133–183
Professor David Harrison, Chair of the UK Committee on Carcinogenicity 
of Chemicals in Food, Consumer Products and the Environment (COC); and 
Dr Lynne Dawkins, Associate Professor, Centre for Addictive Behaviours 
Research, London South Bank University Q184–216
Tuesday 27 March 2018
Michelle Jarman-Howe, Executive Director, Public Sector Prisons South; 
and Heather Thomson, Smoke-free Lead, Nottinghamshire Healthcare NHS 
Foundation Trust Q217–291
Deborah Arnott, Chief Executive, Action on Smoking and Health; and 
Hazel Cheeseman, Director of Policy, Action on Smoking and Health Q292–354
Tuesday 24 April 2018
Rob Morrison, Senior Regulatory Policy Executive, Advertising Standards 
Authority; Professor John Newton, Director of Health Improvement, 
Public Health England; Professor Gillian Leng, Deputy Chief Executive, 
National Institute for Health and Care Excellence; and Dr Ian Hudson, Chief 
Executive, Medicines and Healthcare products Regulatory Agency Q355–439
Steve Brine MP, Parliamentary Under-Secretary of State for Public 
Health and Primary Care; and Dr Tim Baxter, Deputy Director of Healthy 
Behaviours, Department of Health and Social Care Q440–495
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Wednesday 9 May 2018
John Dunne, Director, UK Vaping Industry Association; Fraser Cropper, 
Chair, Independent British Vape Trade Association; and Sarah Jakes, Chair, 
New Nicotine Alliance Q496–559
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Published written evidence
The following written evidence was received and can be viewed on the inquiry publications 
page of the Committee’s website.
ECG numbers are generated by the evidence processing system and so may not be complete.
1 Action on Smoking and Health (ECG0071) (ECG0107)
2 Advertising Standards Authority (ECG0015)
3 Ariff Patel (ECG0012)
4 ASH Scotland (ECG0011)
5 ASH Wales (ECG0066)
6 Association for Young People’s Health (ECG0093)
7 Association of Convenience Stores (ECG0032)
8 Beckett Associates (ECG0090)
9 Benjamin Smith (ECG0004)
10 Blue Skies China (ECG0086)
11 British American Tobacco UK (ECG0074)
12 British Heart Foundation (ECG0065)
13 British Lung Foundation (ECG0042)
14 British Medical Association (ECG0037)
15 British Psychological Society (ECG0088)
16 BSMW Ltd. (ECG0052)
17 Cancer Research UK (ECG0057)
18 Carole Smith (ECG0001)
19 Centre for Addictive Behaviours Research, LSBU (ECG0018)
20 Charles Hamshaw-Thomas (ECG0083)
21 Chartered Trading Standards Institute (ECG0040)
22 Cheshire and Wirral Partnership NHS Foundation Trust (ECG0072)
23 CiggyJuice Ltd (ECG0043)
24 Clive Bates (ECG0078)
25 CLOSER (ECG0077)
26 David Bareham and Professor Martin McKee (ECG0039) (ECG0094)
27 Department of Health and Social Care (ECG0030) (ECG0095)
28 DISPLAY Study Research Team (ECG0069)
29 Dr Caitlin Notley (ECG0028)
30 Dr Charlotte Smith (ECG0014)
31 Dr Graham Cope (ECG0013)
32 Dr Nicola Gray (ECG0091)
33 Dr Richard Holliday (ECG0036)
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34 Dr Robert Combes and Professor Michael Balls (ECG0080)
35 EL-Science (ECG0038)
36 Imperial Brands (ECG0063)
37 INNCO (ECG0079)
38 Institute of Economic Affairs (ECG0020)
39 JAC Vapour Ltd (ECG0068)
40 Japan Tobacco International (ECG0061)
41 Johnson & Johnson Ltd (ECG0112)
42 Keith Butt (ECG0005)
43 Kind Consumer Limited (ECG0026)
44 Leicester City Council (ECG0022)
45 Lord Brabazon of Tara, Earl Cathcart and Viscount Ridley (ECG0033)
46 Medic Pro Limited (ECG0075)
47 Medicines and Healthcare products Regulatory Agency (ECG0103)
48 Melanie Atwood (ECG0105)
49 Mental Health and Smoking Partnership (ECG0060)
50 Miss Daniele Kerr (ECG0076)
51 Mr Anthony Stuart (ECG0008)
52 Mr Christopher Lukehurst (ECG0021)
53 Mr Clive Bates (ECG0096)
54 Mr Ian Bardrick (ECG0006)
55 Mr Michael Jones (ECG0002)
56 Mr Oliver Kershaw (ECG0059)
57 MRC/CSO Social and Public Health Sciences Unit, University of Glasgow (ECG0055)
58 National Institute for Health and Care Excellence (NICE) (ECG0067)
59 Nerudia (ECG0048)
60 New Nicotine Alliance (UK) (ECG0044)
61 NFRN (ECG0046)
62 NHC NHSFT (ECG0070)
63 NHS England Mental Health Trusts additional replies to Committee (ECG0116)
64 NHS England Mental Health Trusts additional reply to Committee (ECG0117)
65 NHS England Mental Health Trusts replies to Committee question (ECG0102)
66 NHS Providers (ECG0109)
67 NJOY Innovations Ltd (ECG0110)
68 Origin Packaging Ltd (ECG0099)
69 PAGB (Proprietary Association of Great Britain) (ECG0050)
70 Petrol Retailers Association (ECG0104)
71 Pfizer Ltd (ECG0023)
61 E-cigarettes 
72 Philip Morris Limited (ECG0073) (ECG0115)
73 Piers Clifford (ECG0009)
74 Professor Mark Conner (ECG0024)
75 Professor Peter Hajek (ECG0017)
76 Professor Riccardo Polosa (ECG0034) (ECG0106)
77 Protec Fire Detection plc (ECG0010)
78 Public Health England (ECG0108)
79 Public Health England and MHRA (ECG0081)
80 Roger Gross (ECG0003)
81 Royal College of Physicians (ECG0035)
82 Royal College of Physicians of Edinburgh (ECG0025)
83 Royal Society for Public Health (ECG0049)
84 Scottish Grocers Federation (ECG0064)
85 Smoking in Pregnancy Challenge Group (ECG0062)
86 Stephen Roberts (ECG0019)
87 Stoke-on-Trent City Council (ECG0029)
88 Swedish Match (ECG0045)
89 Terry Walker (ECG0007)
90 The Cochrane Tobacco Addiction Group (ECG0041)
91 The Freedom Association (ECG0027)
92 The Independent British Vape Trade Association (ECG0058) (ECG0084) (ECG0114)
93 Tobacco Manufacturers’ Association (ECG0053)
94 UK Centre for Tobacco and Alcohol Studies (ECG0031)
95 UK Committee on Toxicity of Chemicals in Food, Consumer Products and the 
Environment (ECG0082)
96 UK Vaping Industry Association (ECG0054) (ECG0101) (ECG0111)
97 University College London Tobacco and Alcohol Research Group (ECG0047)
98 University of Liverpool (ECG0056)
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